The complete list is available online at
www.karger.com/doi/10.1159/000335520

List of Drugs in Development for Neurodegenerative Diseases: Update October 2011

Vanda Pogačić Kramp

Novartis Pharma AG, Basel, Switzerland

Neurodegenerative diseases are an increasingly important issue in our society. There are, however, still many obstacles on the way to finding methods for the cure. This table is intended to give an overview over neurodegenerative drugs that are currently in research and development, providing the reader with an idea about the complexity of drug discovery in this field. It is intended only as a starting point and my recommendation is to obtain additional information from the internet in order to check for the newest developments.

Note that the drugs that are registered, launched, discontinued, with no development reported, or used for research tools in the previous issues are deleted in this issue.

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
1.	*No development reported (Discovery)	University of South Florida	(-)-epigallocatechin-3-gallate	Neurodegenerative disease; <i>Legionella</i> infection	IL synthesis modulator; Protein kinase C modulator; TACE modulator	Cell cycle inhibitor
2.	*No development reported (Discovery)	Daewoong Pharmaceutical	(-)-phenserine	Alzheimers disease	Acetylcholinesterase inhibitor; Beta amyloid synthesis inhibitor	Nootropic agent
3.	**Phase 1	GlaxoSmithKline plc	2018682	Multiple sclerosis	Sphingosine-1-phosphate receptor-1 agonist	Immuno-modulator
4.	Phase 2	GlaxoSmithKline plc	249320	Stroke	Myelin associated glycoprotein inhibitor; CNS modulator	Monoclonal antibody
5.	Phase 1	GlaxoSmithKline plc/ Neurocrine Biosciences Inc	586529	Anxiety disorder; Major depressive disorder	CRF-1 receptor antagonist	Antidepressant; Anxiolytic
6.	Phase 1	University of Pittsburgh	11C-6-Me-BTA-1	Alzheimers disease	Beta amyloid modulator; PET contrast agent	CNS diagnostic agent

* Changes made from the last issue; ** newly added drug.

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
7.	Phase 1	AstraZeneca plc	11C-AZD-2184	Alzheimers disease	Beta amyloid modulator; PET contrast agent	CNS diagnostic agent
8.	*No development reported (Phase 1)	AstraZeneca plc	11C-AZD-2995	Alzheimers disease	Beta amyloid modulator; PET contrast agent	CNS diagnostic agent
9.	*No development reported (Phase 1)	GlaxoSmithKline plc	11C-GSK-215083	Neurodegenerative disease	5-HT 6 receptor antagonist	PET contrast agent; CNS diagnostic agent
10.	Phase 1	National Institutes of Health	11C-PBR-28	Brain disease	Benzodiazepine receptor modulator	PET contrast agent; Radiodiagnostic; CNS diagnostic agent
11.	*No development reported (Phase 2)	Avid Radiopharmaceuticals Inc	123I-IMPY	Alzheimers disease	SPECT contrast agent	Radiodiagnostic; CNS diagnostic agent
12.	**Phase 1	Institute for Neurodegenerative Disorders	123I-MNI-168	Alzheimers disease		Imaging agent; SPECT contrast agent; CNS diagnostic agent
13.	Phase 1	Molecular Neuroimaging Llc	123I-MNI-330	Alzheimers disease	Imaging agent	CNS diagnostic agent
14.	**Phase 1	Institute for Neurodegenerative Disorders	123I-MNI-420	Huntingtons chorea; Parkinsons disease		Imaging agent; SPECT contrast agent; CNS diagnostic agent
15.	**Discovery	Avid Radiopharmaceuticals Inc	18F-AV-45 dimer	Cerebral amyloid angiopathy	Beta amyloid modulator	Imaging agent; PET contrast agent; Radiodiagnostic; Cardiovascular diagnostic agent; CNS diagnostic agent
16.	*No development reported (Phase 1)	University of California Los Angeles/ Siemens Medical Solutions Molecular Imaging	18F-FDDNP	Alzheimers disease	Beta amyloid modulator; PET contrast agent	Radiodiagnostic; Imaging agent; CNS diagnostic agent
17.	**Phase 1	Bayer Schering Pharma AG	18F-FEDAA-1106	Multiple sclerosis	Translocator protein modulator	PET contrast agent; Radiodiagnostic; CNS diagnostic agent; Autoimmune diagnostic agent
18.	*Pre-registration (Phase 3)	Avid Radiopharmaceuticals Inc	18F-florbetapir; former 18F-AV-45	Alzheimers disease; Dementia; Mild cognitive impairment	Beta amyloid modulator; PET contrast agent	Radiodiagnostic; Imaging agent; CNS diagnostic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
19.	**Clinical	Molecular Neuroimaging Llc/ Institute for Neurodegenerative Disorders	18F-MNI-558	Alzheimers disease	Beta amyloid modulator	PET contrast agent; CNS diagnostic agent
20.	Phase 2	Aposense Ltd	18F-NST-ML-10	Breast tumor; Brain tumor; Head and neck tumor; Lung tumor; Non-Hodgkin lymphoma; Ovary tumor; Small-cell lung cancer; Stroke	PET contrast agent	Radiodiagnostic; Cardiovascular diagnostic agent; CNS diagnostic agent; Endocrine diagnostic agent; Immune diagnostic agent; Neoplasm diagnostic agent
21.	**Clinical	Siemens Medical Solutions Molecular Imaging (Siemens AG)	18F-SMIBR-W372	Alzheimers disease		Imaging agent; PET contrast agent; Radiodiagnostic; CNS diagnostic agent
22.	Phase 2	GlaxoSmithKline plc	249320	Stroke; Nervous system injury	Myelin associated glycoprotein inhibitor	CNS modulator
23.	**Discovery	Genzyme Corp (Sanofi)/Isis Pharmaceuticals Inc	2-MOE phosphorothioate gapmers (myotonic dystrophy)	Myotonic dystrophy	Muscle system agent; DMPK gene inhibitor	Neuroprotectant
24.	**Discovery	Prana Biotechnology Ltd	4E10 (Alzheimer's disease)	Alzheimers disease		Nootropic agent
25.	*No development reported (Phase 1)	Digna Biotech SL	4-PBA (Alzheimers disease)	Alzheimers disease	Histone deacetylase inhibitor	Neuroprotectant
26.	Discovery	Pfizer Inc	5-HT 2c agonists	Obesity; Schizophrenia; Drug dependence; Major depressive disorder	5-HT 2c receptor agonist	Appetite suppressant; Antidepressant; Anxiolytic
27.	Discovery	Pfizer Inc	5-HT 2c agonists (neurological/ psychiatric disease)	Obesity; Neurological disease; Psychiatric disorder; Urinary incontinence	5-HT 2c receptor agonist	Psychomodulator
28.	**Discovery	Suven Life Sciences Ltd	5-HT 4 agonists/ partial agonists (neurogenerative diseases)	Alzheimers disease; Neurodegenerative disease	5-HT 4 receptor partial agonist; Antipsychotic; 5-HT 4 receptor agonist	Nootropic agent
29.	**Discovery	Suven Life Sciences Ltd	5-HT 6 antagonists (cognitive disorder)	Schizophrenia; Neurological disease	5-HT 6 receptor antagonist	Neuroprotectant; Nootropic agent; Antipsychotic
30.	**Discovery	Proximagen Group plc	5-HT 6 antagonists (cognitive disorder/ pain)	Pain; Cognitive disorder	5-HT 6 receptor antagonist	Nootropic agent; Analgesic
31.	**Discovery	Bristol-Myers Squibb Co	5-HT 6 antagonists (obesity, cognitive disorder)	Obesity; Cognitive disorder	5-HT 6 receptor antagonist	Appetite suppressant; Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
32.	*No development reported (Discovery)	Pfizer Inc	5-HT ₆ antagonists (oral, Alzheimer's disease/cognitive impairment)	Cognitive disorder; Neurological disease	5-HT ₆ receptor antagonist	Nootropic agent; Neuroprotectant
33.	Discovery	ChemDiv Inc	5-HT ₆ receptor antagonists (Alzheimer's disease); former CD-0080045	Alzheimers disease	5-HT ₆ receptor antagonist	Neuroprotectant; Nootropic agent
34.	*No development reported (Phase 1)	University of Pennsylvania/GE Healthcare	99m-Tc-tropantol	Parkinsons disease; Brain disease	SPECT contrast agent; Dopamine modulator	CNS diagnostic agent
35.	**Discovery	Heptares Therapeutics Ltd	A2a receptor antagonist (Parkinsons disease)	Parkinsons disease	Adenosine A2a receptor antagonist	Antiparkinsonian
36.	**Discovery	Abbott Laboratories	A-887755	Alzheimers disease	Beta amyloid modulator	Neuroprotectant
37.	**Discovery	Abbott Laboratories	A-992401	Alzheimers disease	Advanced glycosylation product receptor antagonist; ARC gene inhibitor	Neuroprotectant
38.	Discovery	Lundbeck Research USA Inc	AA-29504; former Retigabine analogs (depression)	Major depressive disorder	GABA A receptor agonist	Antidepressant
39.	Discovery	Pfizer Inc/Janssen Alzheimer Immunotherapy	AAB-002	Alzheimers disease	Beta amyloid modulator; Monoclonal antibody	Neuroprotectant
40.	*Phase 1 (Discovery)	GNT Pharma Co Ltd/ AmKor Pharma Inc	AAD-2004	Alzheimers disease; Parkinsons disease; Motor neurone disease	Prostaglandin E synthase-1 inhibitor; Beta amyloid antagonist	Neuroprotectant; Antiparkinsonian; Anti-inflammatory; Antioxidant agent; Nootropic agent
41.	**Discovery	Genzyme Corp (Sanofi)	AAV2/8-CBA-hSMN1	Spinal muscular atrophy	Survival motor neuron protein stimulator; Adeno-associated virus based gene therapy	Neuroprotectant
42.	**Discovery	SYGNIS Bioscience GmbH & Co KG (SYGNIS Pharma AG)	AAV-delivered G-CSF gene therapy (ALS)	Motor neurone disease	CSF3 gene modulator; Adenovirus based gene therapy	Neuroprotectant
43.	Phase 1	Ferrer Internacional SA	Abaperidone	Schizophrenia	Dopamine D3 receptor antagonist; Dopamine D2 antagonist; 5-HT _{2a} antagonist	Antipsychotic
44.	**Discovery	New York University/ Aria Neurosciences	Abeta aggregation inhibitors (Alzheimer's disease)	Alzheimers disease	Amyloid protein deposition inhibitor	Nootropic agent
45.	**Discovery	Novartis AG/ University of Heidelberg	Abeta retrovirus particles (Alzheimer's disease)	Alzheimers disease	Beta amyloid modulator; Amyloid protein deposition inhibitor	Recombinant viral vector vaccine; Therapeutic vaccine; Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
46.	Phase 2	Abiogen Pharma SpA	ABIO-08-01	Anxiety disorder; Panic disorder		Anxiolytic
47.	*Phase 1 (Discovery)	Abiogen Pharma SpA	ABIO 09-01; former Antidepressants	Major depressive disorder		Antidepressant; Anxiolytic
48.	**Discovery	Abiogen Pharma SpA	ABP-102	Alzheimers disease	Amyloid protein deposition inhibitor; Protease modulator	Neuroprotectant
49.	Phase 2	Abbott Laboratories	ABT-126	Alzheimers disease; Schizophrenia	Antipsychotic	Nootropic agent
50.	Phase 2	Abbott Laboratories	ABT-288	Alzheimers disease; Schizophrenia	Histamine H3 receptor antagonist	Nootropic agent; Antipsychotic
51.	**Phase 2	Abbott Laboratories	ABT-384	Alzheimers disease	Unspecified drug target	Nootropic agent
52.	Phase 1	Abbott Laboratories	ABT-560	Cognitive disorder	Nicotinic ACh receptor alpha 4 subunit stimulator; Nicotinic ACh receptor beta 2 subunit stimulator; Nicotinic acetylcholine receptor agonist	Nootropic agent
53.	Discovery	Neura Pharmaceuticals Inc	AC-0523	Huntingtons chorea		Neuroprotectant; Nootropic agent
54.	**Phase 1	Medtronic Inc	AC-105	CNS injury		Neuroprotectant
55.	**Discovery	Dainippon Sumitomo Pharma Co Ltd (Sumitomo Chemical Co Ltd)	AC-4402	Alzheimers disease; Dementia	GABA A receptor inverse agonist	Nootropic agent
56.	Discovery	Neura Pharmaceuticals Inc	AC-8632	Parkinsons disease	Acetyl CoA carboxylase inhibitor	Antiparkinsonian
57.	**Discovery	XenoPort Inc	Acamprosate prodrugs (alcohol dependence/fragile X syndrome/ Parkinsons disease)	Alcoholism; Fragile X syndrome; Parkinsons disease	Glutamate receptor antagonist	
58.	*No development reported (Discovery)	Pfizer Inc/Janssen Alzheimer Immunotherapy	ACC-002	Alzheimers disease	Therapeutic vaccine; Beta amyloid modulator	Neuroprotectant
59.	*No development reported (Discovery)	University of California/Scripps Research Institute/ Siemens Medical Solutions Molecular Imaging	Acetylcholinesterase (AChE) inhibitors	Alzheimers disease	Acetylcholinesterase inhibitor	Nootropic agent
60.	Phase 1	AC Immune SA	ACI-24	Alzheimers disease; Down syndrome	Protein subunit vaccine; Beta amyloid modulator	Therapeutic vaccine; Neuroprotectant
61.	Discovery	AC Immune SA	ACI-518	Alzheimers disease	AMPA receptor agonist	Nootropic agent
62.	Discovery	AC Immune SA	ACI-636	Alzheimers disease	Amyloid protein deposition inhibitor	Neuroprotectant
63.	Phase 2	AC Immune SA	ACI-91	Alzheimers disease; Peripheral neuropathy	Beta secretase 1 modulator	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
64.	**Phase 1	Affiris AG/ GlaxoSmithKline Biologicals	AD-03	Alzheimers disease	Protein subunit vaccine; Therapeutic vaccine; Beta amyloid antagonist	Neuroprotectant
65.	**Discovery	Bioarctic Neuroscience AB	AD-0802	Alzheimers disease	Beta amyloid modulator	Neuroprotectant
66.	**Discovery	PsychoGenics Inc	Adenosine A1/A2 ligands (depression, Parkinson's disease)	Parkinsons disease; Major depressive disorder	Adenosine A2 receptor antagonist; Adenosine A1 receptor antagonist	Antidepressant; Antiparkinsonian
67.	**Discovery	Kyowa Hakko Kirin Co Ltd/H Lundbeck HS	Adenosine A2A antagonist (Parkinson's disease)	Migraine; Parkinsons disease	Adenosine A2a receptor antagonist	Analgesic; Antiparkinsonian
68.	Discovery	Almirall Prodesfarma SA/Neurocrine Biosciences Inc	Adenosine A2a receptor antagonists (Parkinsons)	Parkinsons disease	Adenosine A2a antagonist	Antiparkinsonian
69.	**Discovery	University of California Irvine (University of California)/Ichor Medical Systems Inc/ Institute for Molecular Medicine	ADepVac	Alzheimers disease	Prophylactic vaccine; DNA vaccine	Neuroprotectant
70.	**Discovery	Cephalon Inc/ Mesoblast Ltd	Adult mesenchymal precursor stem cell therapy (CNS disease)	CNS disease	CNS modulator	
71.	Discovery	Addex Pharmaceuticals SA	ADX-63365	Schizophrenia; Cognitive disorder	Metabotropic glutamate receptor 5 modulator	Nootropic agent; Anticancer
72.	*Phase 2 (Phase 1)	Janssen Pharmaceuticals Inc	ADX-71149; former mGluR2 PAMs (CNS disorders)	Psychiatric disorder; Schizophrenia	Metabotropic glutamate receptor 2 modulator	Nootropic agent; Antidepressant; Anxiolytic; Antipsychotic
73.	Phase 2	Aegera Therapeutics Inc	AEG-33773	Neuropathy; Diabetic neuropathy	Apoptosis inhibitor; Hsp 70 family stimulator; Hsp 90 modulator	Neuroprotectant; Analgesic
74.	Discovery	Aeolus Pharmaceuticals Inc	AEOL-11207; former catalytic antioxidants	Parkinsons disease; Epilepsy	Anticancer; Antioxidant agent; Antiparkinsonian	Radioprotectant; Anticonvulsant agent
75.	Phase 2	GlaxoSmithKline Biologicals/Affiris AG	Affitope AD-02	Alzheimers disease	Beta amyloid antagonist	Protein subunit vaccine; Therapeutic vaccine; Neuroprotectant
76.	**Discovery	ArmaGen Technologies Inc	AGT-110	Neurodegenerative disease; Neurological disease; Brain injury	Insulin receptor antagonist; Type II TNF receptor modulator	Neuroprotectant; Antidepressant
77.	Discovery	ArmaGen Technologies Inc	AGT-115; former erythropoietin-human insulin receptor antibody fusion protein	Brain disease	Insulin receptor modulator; Erythropoietin ligand	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
78.	*No development reported (Discovery)	ArmaGen Technologies Inc	AGT-120	Stroke	Unspecified receptor modulator	Neuroprotectant
79.	Discovery	ArmaGen Technologies Inc	AGT-160	Alzheimers disease	Amyloid protein deposition inhibitor; Beta amyloid antagonist; Insulin receptor modulator	Neuroprotectant
80.	**Discovery	ArmaGen Technologies Inc	AGT-185	Poison intoxication; Central nervous system disease	PON1 gene modulator; Phosphatase stimulator; Insulin receptor modulator	Neuroprotectant; Antidote
81.	**Discovery	ArmaGen Technologies Inc	AGT-190	Parkinsons disease; Drug dependence; Stroke	GDNF receptor modulator; Insulin receptor modulator	Neuroprotectant; Antiparkinsonian
82.	**Discovery	ArmaGen Technologies Inc	AGT-2000	Brain tumor	EGFR gene inhibitor; Plasmid based gene therapy; Unspecified non-viral vector based gene therapy	Anticancer
83.	**Discovery	Reata Pharmaceuticals Inc	AIMs (CNS disease/ respiratory disease/ autoimmune disease)	Autoimmune disease; Central nervous system disease; Respiratory disease	NFE2L2 gene stimulator; Nuclear factor kappa B inhibitor	Anti-inflammatory; Antioxidant agent
84.	Discovery	Allon Therapeutics Inc	AL-209	CNS disease; Ocular disease	PARP stimulator; Tubulin binding agent	Neuroprotectant; CNS modulator
85.	Discovery	Allon Therapeutics Inc	AL-309	CNS disease	PARP stimulator	Neuroprotectant; CNS modulator; Analgesic
86.	Discovery	Allon Therapeutics Inc	AL-408	CNS disease	CNS modulator; PARP stimulator; Activity-dependent neuroprotector modulator	Neuroprotectant, Nootropic agent
87.	**Discovery	Allon Therapeutics Inc	AL-508	CNS disease		Neuroprotectant
88.	**Discovery	Zenobia Therapeutics Inc/St Jude Children's Research Hospital	ALK inhibitors (neuroblastoma)	Neuroblastoma	Alk tyrosine kinase receptor inhibitor	Anticancer
89.	**Discovery	Novartis AG	Allosteric GABA B receptor modulators	Anxiety disorder; Drug dependence; Central nervous system disease	GABA B receptor modulator	CNS modulator; Anxiolytic
90.	**Discovery	SAGE Therapeutics	Allosteric GABA receptor modulators (CNS disorders)	CNS disease	GABA receptor modulator	Neuroprotectant
91.	**Discovery	SAGE Therapeutics	Allosteric glutamate receptor modulators (CNS disorders)	CNS disease	Glutamate receptor modulator	Neuroprotectant
92.	**Discovery	Ligand Pharmaceuticals Inc/ SAGE Therapeutics	Allosteric modulators (Captisol, CNS disorders)	CNS disease	Unspecified drug target	CNS modulator
93.	**Discovery	Allosterix Ltd	Allosteric peptide BACE-1 inhibitors (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta secretase 1 inhibitor	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
94.	*Discontinued (Phase 3)	Actelion Ltd/ GlaxoSmithKline plc	Almorexant	Neurological disease; Insomnia; Eating disorder	Orexin 1 receptor antagonist; Orexin 2 receptor antagonist	Appetite modulator; Hypnotic
95.	**Discovery	Alnylam Pharmaceuticals Inc (Alnylam Holding Co)/ Medtronic Inc	ALN-HTT	Huntingtons chorea	HTT gene inhibitor; Huntingtin inhibitor	Neuroprotectant; siRNA agent
96.	**Discovery	ALSP Inc	Aloxistatin (Alzheimer's disease)	Alzheimers disease; Brain injury	Cysteine protease inhibitor; Cathepsin B inhibitor	Neuroprotectant; Nootropic agent
97.	**Discovery	Suven Life Sciences Ltd	Alpha 4 beta 2 nAChR antagonist (neurological disease/schizophrenia/obesity/metabolic disorder/pain)	Pain; Obesity; Schizophrenia; Metabolic disorder; Neurological disease	Nicotinic ACh receptor alpha 4 subunit inhibitor; Nicotinic ACh receptor beta 2 subunit inhibitor; Nicotinic acetylcholine receptor antagonist	Neuroprotectant; Nootropic agent; Antipsychotic; Analgesic
98.	**Discovery	Suven Life Sciences Ltd	Alpha 4 beta 2 nicotinic acetylcholine receptor (nAChR) agonist (Alzheimer's disease)	Alzheimers disease	Nicotinic ACh receptor alpha 4 subunit stimulator; Nicotinic ACh receptor beta 2 subunit stimulator; Nicotinic acetylcholine receptor agonist	Nootropic agent
99.	Discovery	Pfizer Inc	Alpha 6/alpha 4 (alpha-6*) beta 4 and alpha 3 beta 4 nAChR agonists (CNS disorders)	Psychotic disorder; Neurological disease	Nicotinic ACh receptor alpha 3 subunit stimulator; Nicotinic ACh receptor alpha 4 subunit stimulator; Nicotinic ACh receptor alpha 6 subunit stimulator; Nicotinic ACh receptor beta 4 subunit stimulator	
100.	**Discovery	University of California Irvine (University of California)	Alpha7 nAChR modulators (cognitive disorder)	Cognitive disorder	Nicotinic ACh receptor alpha 7 subunit stimulator; Dopamine synthesis stimulant; Noradrenaline release stimulator	Nootropic agent
101.	**Discovery	Novartis AG	Alpha-7 nicotinic acetylcholine receptor agonists (CNS disorders)	CNS disease	Nicotinic ACh receptor alpha 7 subunit stimulator	CNS modulator
102.	**Discovery	Abbott Laboratories	Alpha-7 nicotinic acetylcholine receptor positive allosteric modulators (cognitive disorders)	Cognitive disorder	Nicotinic ACh receptor alpha 7 subunit modulator	Neuroprotectant; Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
103.	**Discovery	Proximagen Group plc	Alpha7 nicotinic acetylcholine receptor positive allosteric modulators (PAMs) (CNS disorders)	Cognitive disorder; CNS disease	Nicotinic ACh receptor alpha 7 subunit stimulator; CNS modulator	Nootropic agent
104.	*No development reported (Discovery)	Roche Bioscience	Alpha 7 nicotinic AChR agonists (Alzheimer's/ Parkinson's)	Alzheimers disease; Parkinsons disease	Nicotinic ACh receptor alpha 7 subunit stimulator; Nicotinic acetylcholine receptor agonist	Nootropic agent
105.	**Discovery	Bristol-Myers Squibb Co	Alpha-7 nicotinic agonist (neuroscience)	Neurological disease	Nicotinic ACh receptor alpha 7 subunit stimulator	Antipsychotic
106.	Discovery	University of Queensland/CCA Therapeutics Pty Ltd	Alpha-conotoxins	Neurological disease; Neuropathic pain	Nicotinic ACh antagonist; Calcium channel inhibitor; GABA B receptor modulator	
107.	**Discovery	Alnylam Pharmaceuticals Inc (Alnylam Holding Co)	Alpha-synuclein gene-silencing siRNAs (Parkinson's disease)	Parkinsons disease	SNCA gene inhibitor	siRNA agent; Antiparkinsonian; Antisense oligonucleotide inhibitor
108.	**Discovery	FoldRx Pharmaceuticals Inc (Pfizer Inc)	Alpha synuclein-modulators (Parkinson's disease)	Parkinsons disease	Synuclein alpha modulator	Antiparkinsonian
109.	**Discovery	Biogen Idec Inc	Alpha-synuclein modulator (Parkinson's disease)	Parkinsons disease	Synuclein alpha modulator	Neuroprotectant; Antiparkinsonian
110.	**Discovery	Neotope Biosciences Ltd (Elan Corp plc)	Alpha-synuclein-targeted antibody therapy (Parkinson's disease)	Parkinsons disease	Synuclein alpha modulator	Antiparkinsonian
111.	Phase 3	Alseres Pharmaceuticals Inc	Altropane	Parkinsons disease; Attention deficit hyperactivity disorder		SPECT contrast agent; Radiodiagnostic; CNS diagnostic agent
112.	Phase 2	Ablynx NV	ALX-0081	Thrombosis; Stroke; Thrombocytopenic purpura	Von Willebrand factor ligand inhibitor	Coagulation inhibitor
113.	**Discovery	Siena Biotech SpA/ Roche Holding AG	Alzheimers disease therapeutics	Alzheimers disease	CNS modulator; Unspecified drug target	Neuroprotectant; Nootropic agent
114.	**Discovery	Acino Holding AG	Alzheimer's disease therapeutic (transdermal formulation)	Alzheimers disease	Unspecified drug target	Neuroprotectant
115.	Discovery	reMYND NV/Roche Holding AG	Alzheimer program (tau-mediated cytotoxicity)	Alzheimers disease	Tau deposition inhibitor	Neuroprotectant
116.	*No development reported (Discovery)	H Lundbeck A/S	Alzheimer's vaccine (AutoVac)	Alzheimers disease	Vaccine; Target not disclosed	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
117.	Discovery	ACADIA Pharmaceuticals Inc/ Meiji Seika Kaisha Ltd	AM-831	Alzheimers disease; Schizophrenia	Muscarinic M1 agonist; Dopamine receptor antagonist; 5-HT receptor antagonist	Nootropic agent; Antipsychotic
118.	**Phase 3	Adamas Pharmaceuticals Inc	Amantadine (extended release formulation, Parkinsons disease/ movement disorder)	Parkinsons disease		Neuroprotectant; Antiparkinsonian
119.	**Phase 1	Amgen Inc	AMG-747	Schizophrenia; Cognitive disorder	Glycine transporter-1 inhibitor	Antipsychotic
120.	**Discovery	Amgen Inc	AMG-889436	Parkinsons disease	Glutamate receptor 4 modulator; Glutamate receptor 4 agonist	Antiparkinsonian
121.	**Discovery	University of Pennsylvania	Aminothieno-pyridazines (neurodegenerative disease)	Neurodegenerative disease	Tau aggregation inhibitor	Neuroprotectant
122.	Discovery	Eli Lilly & Co	AMPA modulators	Cognitive disorder	AMPA receptor modulator	Nootropic agent
123.	**Phase 1	GlaxoSmithKline plc	AMPA receptor positive modulator	CNS disease	AMPA receptor modulator	
124.	Discovery	University of California Davis	Amyloid beta oligomers (imaging agent)	Alzheimers disease		Imaging agent; CNS diagnostic agent
125.	**Discovery	Bristol-Myers Squibb Co	Amyloid beta peptide modulator (Alzheimer's disease)	Alzheimers disease	Beta amyloid modulator	Nootropic agent
126.	Discovery	Buck Institute	Amyloid-beta synthesis inhibitor (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor	
127.	**Discovery	Merz & Co GmbH	Amyloid-derived diffusible ligands (ADDL, Alzheimer's disease)	Alzheimers disease	Beta amyloid modulator	
128.	**Discovery	Ecole Polytechnique Federale de Lausanne	Amyloid precursor protein C-terminal fragment-targeted monoclonal antibodies (Alzheimer's disease)	Alzheimers disease	Amyloid protein deposition inhibitor	Nootropic agent
129.	*Discontinued (Phase 2)	Xytis Inc	Anatibant	Head injury	Bradykinin B2 antagonist	Anti-inflammatory; Neuroprotectant
130.	Discovery	Anavex Life Sciences Corp	ANAVEX-1-41	Alzheimers disease; Major depressive disorder; Stroke	Sodium channel modulator; Chloride channel modulator; Apoptosis inhibitor; Muscarinic M1 receptor agonist; Muscarinic M2 receptor antagonist; Sigma-1 opioid modulator	Nootropic agent; Anticonvulsant agent; Neuroprotectant; Antidepressant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
131.	*Phase 1 (Discovery)	Anavex Life Sciences Corp	ANAVEX-2-73	Epilepsy; Alzheimers disease; Stroke	Sodium channel modulator; NMDA receptor modulator; Opioid receptor sigma modulator 1	Anticonvulsant agent; Nootropic agent; Neuroprotectant
132.	**Discovery	Johns Hopkins University/Mapp Biopharmaceutical Inc	Anti-Abeta monoclonal antibodies (Alzheimer's disease)	Alzheimers disease	Amyloid beta A4 binding protein inhibitor	Neuroprotectant
133.	Discovery	Acumen Pharmaceuticals Inc/ Merck & Co Inc	Anti-ADDL antibodies (Alzheimers disease)	Alzheimers disease	Amyloid protein deposition inhibitor	Biological therapeutic
134.	**Discovery	Kyowa Hakko Kirin Co Ltd	Anti-amyloid beta antibodies (Alzheimers disease)	Alzheimers disease	Beta amyloid antagonist	Nootropic agent
135.	Discovery	Medtronic Inc	Anti-amyloid beta monoclonal antibodies (Alzheimer's disease)	Alzheimers disease	Beta amyloid modulator	Nootropic agent; Neuroprotectant
136.	**Discovery	Neuronex Inc	Anti-epileptic program	Epilepsy	Unspecified drug target	Anticonvulsant agent
137.	**Phase 1	Biogen Idec Inc	Anti-LINGO-1 antibody (multiple sclerosis)	Multiple sclerosis; Demyelinating disease	Nogo receptor modulator	
138.	**Discovery	Acino Holding AG	Antiparkinsonian agent (oral)	Parkinsons disease	Unspecified drug target	Antiparkinsonian
139.	**Discovery	Acino Holding AG	Antiparkinsonian agent (transdermal formulation)	Parkinsons disease	Unspecified drug target	Antiparkinsonian
140.	**Phase 1	Acino Holding AG	Antipsychotics (oral, schizophrenia)	Schizophrenia		Antipsychotic
141.	**Discovery	Genzyme Corp/Isis Pharmaceuticals Inc	Antisense oligonucleotides (Huntington's disease)	Huntingtons chorea	Antisense oligonucleotide inhibitor	Huntingtin inhibitor
142.	**Discovery	TauRx Therapeutics Pte Ltd	Anti-synuclein compounds (Parkinson's disease)	Parkinsons disease	Synuclein inhibitor	Antiparkinsonian
143.	Discovery	Antoxis Ltd	AO-1 antioxidants; former AO-1-530	Stroke	Antioxidant agent; Free radical scavenger	Neuroprotectant
144.	**Discovery	Antoxis Ltd	AO-2 antioxidants	Stroke; Neurological disease; Diabetes mellitus		Neuroprotectant; Hypoglycemic agent; Unspecified drug target; Antioxidant agent; Cardiovascular agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
145.	**Discovery	Antoxis Ltd	AO-3 antioxidants	Stroke; Neurological disease; Diabetes mellitus		Neuroprotectant; Hypoglycemic agent; Unspecified drug target; Antioxidant agent; Cardiovascular agent
146.	**Discovery	Hangzhou Adamerck Phamlabs Inc	Aom-0937	Cerebrovascular disease; Stroke; Neurological disease	Chelating agent; Calcium metabolism modulator; Metalloprotease-2 inhibitor; Metalloprotease-9 inhibitor	Neuroprotectant; Antioxidant agent
147.	*No development reported (Discovery)	AcurePharma AB	AP-267	Alzheimers disease; Acute stress disorder; Opiate dependence	5-HT 2c receptor modulator	Neuroprotectant
148.	Phase 2	Apogenix GmbH	APG-101	Graft versus host disease; Glioblastoma; Cancer	Apoptosis inhibitor; CD95 antagonist	Anticancer; Immuno-suppressant; Cerebro-protectant; Cardiovascular agent
149.	**Phase 2	Ligand Pharmaceuticals Inc	Aplindore	Restless legs syndrome; Parkinsons disease	Dopamine D2 receptor partial agonist	Antipsychotic; Antiparkinsonian
150.	Discovery	Cognosci Inc	Apolipoprotein E agonist series (Alzheimer's/ Parkinsons disease)	Alzheimers disease; Parkinsons disease	Apolipoprotein E modulator	Neuroprotectant; Antiparkinsonian
151.	Phase 2	Novartis AG	AQW-051	Alzheimers disease; Schizophrenia; Mild cognitive impairment	Unspecified drug target	Nootropic agent; Antipsychotic
152.	**Phase 3	Seaside Therapeutics Inc	Arbaclofen	Fragile X syndrome; Autism	GABA B receptor agonist	CNS modulator
153.	Phase 2	Archer Pharmaceuticals	ARC-029; former Nilvadipine (blood-brain-barrier penetrative, Alzheimer's disease)	Alzheimers disease	Amyloid protein deposition inhibitor	Neuroprotectant
154.	*No development reported (Discovery)	Archer Pharmaceuticals	ARC-050	Alzheimers disease	Beta secretase inhibitor	
155.	**Discovery	Archer Pharmaceuticals	ARC-069	Alzheimers disease	Gamma-secretase inhibitor	Neuroprotectant
156.	Phase 3	Orphazyme ApS	Arimoclomol	Motor neurone disease; Stroke; Hypoxia; Neuropathy	Hypoglycemic agent; Chaperonin stimulator	Neuroprotectant
157.	*No development reported (Phase 3)	Ono Pharmaceutical Co Ltd	Arundic acid (injectable formulation)	Alzheimers disease; Motor neurone disease; Parkinsons disease; Cerebral infarction; Stroke	Astrocyte modulator	Neuroprotectant; Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
158.	**Phase 1	Merck Serono SA	ARX-424	Multiple sclerosis	Immunomodulator; Interferon beta ligand	Neuroprotectant
159.	Phase 1	Astellas Pharma Inc	ASP-0777	Alzheimers disease	Unspecified drug target	Neuroprotectant
160.	*Discontinued (Phase 1)	Astellas Pharma Inc	ASP-2905	Alzheimers disease; Schizophrenia	Unspecified drug target	Neuroprotectant; Nootropic agent; Antipsychotic
161.	**Phase 1	Astellas Pharma Inc	ASP-4058	Multiple sclerosis	Unspecified drug target	Immuno-modulator
162.	Phase 1	Novartis AG	ATI-355	Spinal cord injury	NOGO receptor antagonist	Neuroprotectant
163.	**Phase 2	Apitope Technology (Bristol) Ltd/Merck Serono SA	ATX-MS-1467	Multiple sclerosis	Therapeutic vaccine; Immunomodulator; T-lymphocyte stimulator	
164.	**Discovery	Apitope Technology (Bristol) Ltd	ATX-MS-2	Multiple sclerosis	Unspecified drug target	Immuno-modulator
165.	**Discovery	Apitope Technology (Bristol) Ltd	ATX-MS-3	Multiple sclerosis	Unspecified drug target	Immuno-modulator
166.	**Discovery	Daya Drug Discoveries Inc	Atypical antipsychotics (schizophrenia)	Schizophrenia	5-HT receptor modulator	Antipsychotic
167.	Phase 2	RNL Bio Co Ltd	Autologous fat-derived stem cell therapy	Alzheimers disease; Behcets disease; Erectile dysfunction; Osteoarthritis; Peripheral arterial occlusive disease; Reperfusion injury; Rheumatoid arthritis; Spinal cord injury; Thromboangiitis obliterans; Urinary tract injury; Vascular injury; Cancer; Hypersensitivity; Liver disease	Osteoblast modulator; Fibroblast modulator; Anti-inflammatory; Vascular agent	Nootropic agent; Anticancer
168.	*Phase 1 (Discovery)	VistaGen Therapeutics Inc	AV-101; former NMDA receptor antagonists	Epilepsy; Huntingtons chorea; Neurophatic pain; Parkinson disease; Schizophrenia	NMDA receptor antagonist	Cerebro-protectant; Anticonvulsant agent; Analgesic; Antiparkinsonian; Neuroprotectant
169.	Discovery	MediciNova Inc	AV-1013	Nervous system inflammation	Macrophage migration inhibitory factor inhibitor	Neuroprotectant; Analgesic; Anti-inflammatory
170.	*Phase 1 (Phase 2)	Genzyme Corp	AV-201	Parkinsons disease	Dopamine synthesis stimulant; Adeno-associated virus based gene therapy; Tyrosine hydroxylase stimulator; Dopa decarboxylase stimulator	Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
171.	*No development reported (Discovery)	Avigen Inc	AV-333	Neuropathic pain	IL-10 agonist; Adeno-associated virus based gene therapy	Analgesic; Anti-inflammatory
172.	Phase 2	Bristol-Myers Squibb Co	Avagacestat; former BMS-708163	Alzheimers disease; Mild cognitive impairment	Beta amyloid synthesis inhibitor; Gamma-secretase inhibitor	Neuroprotectant
173.	Phase 2	Avineuro Pharmaceuticals Inc/ ChemDiv Inc	AVN-101	Alzheimers disease; Anxiety disorder	5-HT 6 receptor antagonist	Antidepressant; Nootropic agent; Anxiolytic
174.	Phase 2	Avineuro Pharmaceuticals Inc/ ChemDiv Inc	AVN-211	Schizophrenia	5-HT 6 receptor antagonist	Neuroprotectant; Nootropic agent
175.	**Phase 1	Avineuro Pharmaceuticals Inc/ ChemDiv Inc	AVN-322	Alzheimers disease; Cognitive disorder	5-HT 6 receptor antagonist	Neuroprotectant; Nootropic agent
176.	**Discovery	Avineuro Pharmaceuticals Inc	AVN-457	Cognitive disorder	Unspecified drug target	Nootropic agent
177.	**Discovery	Avineuro Pharmaceuticals Inc	AVN-458	Cognitive disorder	Unspecified drug target	Nootropic agent
178.	**Discovery	Avineuro Pharmaceuticals Inc	AVN-492	Cognitive disorder	Unspecified drug target	Nootropic agent
179.	Phase 2	Sygnis Bioscience GmbH & Co KG	AX-200	Motor neurone disease; Spinal cord injury; Parkinsons disease; Peripheral arterial occlusive disease; Stroke	Neuronal growth factor; GCSF receptor agonist	Neuroprotectant; Vascular agent
180.	*Suspended (Discovery)	SYGNIS Bioscience GmbH & Co KG	AX-201	Spinal cord injury; Stroke; Neurodegenerative disease	Unspecified drug target	Neuroprotectant
181.	Discovery	Alseras Pharmaceuticals Inc	Axogenesis Factor-1	Spinal cord injury; Glaucoma; Neurodegenerative disease; Stroke	NGF agonist	Neuroprotectant; Antiglaucoma agent
182.	Phase 2	AstraZeneca plc/ Targacept Inc	AZD-1446	Alzheimers disease; Cognitive disorder	Nicotinic ACh receptor alpha 4 subunit modulator; Nicotinic ACh receptor beta 2 subunit modulator	Nootropic agent
183.	**Discovery	INSERM/AlzProtect/ Universite du Droit et de la Sante de Lille II	AZP-2006	Alzheimers disease		Neuroprotectant
184.	Discovery	Massachusetts General Hospital/ FluoroPharma Inc	AZPET; former Molecular imaging agents (Alzheimer's disease)	Alzheimers disease	PET contrast agent; Amyloid protein deposition inhibitor; Muscarinic receptor agonist; Imaging agent	Imaging agent
185.	**Discovery	Biogen Idec Inc	BIIB-042	Alzheimers disease	Beta amyloid synthesis inhibitor; Gamma-secretase inhibitor	Neuroprotectant
186.	Discovery	Amgen Inc	BACE inhibitors	Alzheimers disease	Beta secretase 1 inhibitor; Amyloid protein deposition inhibitor	

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
187.	Discovery	Pfizer Inc	BACE inhibitors (Alzheimer's disease)	Alzheimers disease	Beta secretase 1 inhibitor; Beta amyloid synthesis inhibitor	Neuroprotectant
188.	Discovery	Evotec AG	BACE inhibitors (Alzheimer's disease)	Alzheimers disease	Beta secretase inhibitor	Nootropic agent
189.	*No development reported (Discovery)	Johnson & Johnson	BACE inhibitor (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta secretase inhibitor	Nootropic agent
190.	Discovery	Astex Therapeutics Ltd/AstraZeneca plc/SuperGen Inc	BACE inhibitors (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta-secretase inhibitor	Nootropic agent
191.	*Discontinued (Discovery)	Medivir AB	BACE1 inhibitors (Alzheimer's disease)	Alzheimers disease	Beta secretase inhibitor; Beta amyloid synthesis inhibitor	Nootropic agent
192.	Discovery	Novartis AG	BACE 1 inhibitors (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor, Beta secretase 1 inhibitor	Neuroprotectant
193.	Discovery	GlaxoSmithKline plc	BACE1 inhibitors	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta secretase 1 inhibitor	Nootropic agent
194.	Phase 1	Merck & Co Inc	BACE-1 inhibitors (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor, Beta secretase 1 inhibitor	Neuroprotectant
195.	**Discovery	Samada Research	BACE-1 inhibitors (Alzheimer's disease)	Alzheimers disease	Beta secretase 1 inhibitor	
196.	Discovery	Bristol-Myers Squibb Co	BACE-1 inhibitors (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta secretase 1 inhibitor	Nootropic agent
197.	**Phase 2	Novartis AG	BAF-312	Multiple sclerosis; Dermatomyositis; Polymyositis	Lysosphingolipid receptor modulator	Immuno-modulator
198.	**Discovery	Biogen Inc	Baminercept	Multiple sclerosis	Lymphotoxin beta receptor modulator; Lymphotoxin beta ligand inhibitor	Anti-inflammatory
199.	Discovery	Bioarctic Neuroscience AB	BAN-2203	Alzheimers disease	Beta amyloid modulator	Neuroprotectant; Immuno-modulator
200.	*Phase 1 (Discovery)	Eisai Co Ltd	BAN-2401	Alzheimers disease	Beta amyloid modulator	Neuroprotectant
201.	Phase 3	Pfizer Inc/Janssen Alzheimer Immunotherapy	Bapineuzumab	Alzheimers disease	Beta amyloid antagonist	Neuroprotectant; Monoclonal antibody
202.	**Phase 2	Janssen Alzheimer Immunotherapy	Bapineuzumab (sc/ humanized mAb, Alzheimer's disease)	Alzheimers disease	Beta amyloid modulator	Neuroprotectant
203.	**Phase 1	Bayer AG	BAY-1006578	Alzheimers disease	Imaging agent; PET contrast agent	CNS diagnostic agent
204.	Phase 1	Bayer AG/INSERM	BAY-85-8102	Brain disease	Imaging agent; Radiodiagnostic; Benzodiazepine receptor agonist	CNS diagnostic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
205.	**Phase 2	Angion Biomedica Corp	BB-3	Myocardial infarction; Liver fibrosis; Kidney transplantation; Stroke; Renal failure	Hepatocyte growth factor agonist	Renal system agent; Cardiac agent
206.	Discovery	NasVax Ltd	BBS-1 BACE inhibitor mAb vaccine (Alzheimer's disease)	Alzheimers disease	Beta secretase inhibitor; Genetically engineered autologous cell vaccine	Neuroprotectant; Nootropic agent
207.	**Phase 1	BrainCells Inc/ Taisho Pharmaceutical Co Ltd	BCI-632	Cognitive disorder; CNS disease; Major depressive disorder	Metabotropic glutamate receptor 2 antagonist; Metabotropic glutamate receptor 3 antagonist; Nootropic agent; CNS modulator	Antidepressant
208.	*Discontinued (Phase 1)	Pfizer Inc	Begacestat	Alzheimers disease	Beta amyloid synthesis inhibitor; Gamma-secretase inhibitor	Nootropic agent
209.	**Discovery	Merck Serono SA	Bentamapimod	CNS disease; Inflammatory disease; Ischemia; Multiple sclerosis; Pulmonary fibrosis	Jun N terminal kinase-1 inhibitor; Jun N terminal kinase-2 inhibitor; Jun N terminal kinase-3 inhibitor	Vasoprotectant; Anti-inflammatory
210.	Discovery	Medisyn Technologies Inc/Mount Sinai School of Medicine	Beta-amyloid aggregation inhibitors (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor; Amyloid protein deposition inhibitor	Neuroprotectant; Nootropic agent
211.	**Discovery	Senexis Ltd	Beta-amyloid aggregation inhibitors (Alzheimer's disease)	Alzheimers disease	Beta amyloid antagonist; Amyloid protein deposition inhibitor	Neuroprotectant
212.	Discovery	Intellect Neuroscience Inc	Beta-amyloid fragment-tetanus toxoid prophylactic vaccine (Alzheimer's disease)	Alzheimers disease	Beta amyloid antagonist	Prophylactic vaccine
213.	Discovery	Star Scientific Inc/ Roskamp Institute	Beta-amyloid inhibitor (Alzheimer's disease)	Alzheimers disease	Beta amyloid antagonist	Neuroprotectant
214.	**Discovery	Icogenex Corp	Beta-amyloid inhibitor (Alzheimer's disease)	Alzheimers disease	Beta amyloid antagonist	Neuroprotectant; Nootropic agent
215.	Discovery	Medisyn Technologies Inc/Mount Sinai School of Medicine	Beta amyloid lowering agents (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor; Amyloid protein deposition inhibitor	Neuroprotectant; Nootropic agent
216.	*No development reported (Discovery)	Senexis Ltd	Beta-amyloid synthesis inhibitors (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor	Nootropic agent
217.	**Discovery	Johns Hopkins University/Nervada Inc	Beta-interferon (intranasal, multiple sclerosis)	Multiple sclerosis	Interferon beta ligand	Immuno-modulator

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
218.	*No development reported (Discovery)	Actelion Ltd	Beta-secretase inhibitors	Alzheimers disease	Beta amyloid modulator; Beta-secretase inhibitor	Nootropic agent
219.	Discovery	Elan Corp plc	Beta-secretase inhibitors	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta secretase inhibitor; Aspartic protease inhibitor	
220.	Discovery	ProMediTech Inc/LG Life Sciences Ltd/Seoul National University	Beta-secretase inhibitors	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta-secretase inhibitor	Neuroprotectant
221.	Discovery	Merck & Co Inc	Beta-secretase inhibitors (Alzheimers)	Alzheimers disease	Beta secretase 1 inhibitor; Beta amyloid synthesis inhibitor	Neuroprotectant
222.	**Discovery	BACE Therapeutics	Beta secretase inhibitors (Alzheimer's disease)	Alzheimers disease	Beta secretase 1 inhibitor; Beta amyloid synthesis inhibitor	Neuroprotectant
223.	Discovery	Vitae Pharmaceuticals Inc/Boehringer Ingelheim Corp	Beta-secretase inhibitors (oral, Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta secretase 1 inhibitor	Nootropic agent
224.	Phase 2	Portola Pharmaceuticals Inc	Betrixaban	Stroke; Embolism and thrombosis	Factor Xa antagonist; Coagulation inhibitor	Neuroprotectant
225.	*Discovery (Phase 1)	QR Pharma Inc	Bisnorcymserine	Alzheimers disease	Beta amyloid synthesis inhibitor; Cholinesterase inhibitor	Nootropic agent
226.	*No development reported (Discovery)	Alseres Pharmaceuticals Inc	BLS-0602; former DAT inhibitors (Parkinson's disease)	Parkinsons disease	Dopamine uptake inhibitor	Antiparkinsonian
227.	Discovery	Bioalvo SA	BLV-0703; former BLV-200703	CNS disease	Tau aggregation inhibitor	CNS modulator
228.	Discovery	Bioalvo SA	BLV-0801	Cancer; Nervous system inflammation	Indoleamine-pyrrole-2,3-dioxygenase inhibitor	CNS modulator; Anticancer; Anti-inflammatory
229.	Discovery	Bristol-Myers Squibb Co	BMS-241027	Alzheimers disease	Tau protein modulator; Microtubule stabilizer	Neuroprotectant
230.	Discovery	Ipsen	BN-82541; former COX inhibitors (Huntington's disease/Parkinson's disease)	Huntingtons chorea; Parkinsons disease	Cyclooxygenase 2 inhibitor; Sodium channel inhibitor; Antioxidant agent; Cyclooxygenase 1 inhibitor	Antiparkinsonian
231.	*No development reported (Discovery)	Aastrom Biosciences Inc	Bone marrow-derived stem cell therapy (neurodegenerative diseases/SCI)	Neurodegenerative disease	Stem cell therapy; Angiogenesis stimulator	Neuroprotectant
232.	**Discovery	Genentech Inc	Brain-targeted BACE1 antibody (Alzheimer's disease)	Alzheimers disease	Transferrin modulator; Beta amyloid synthesis inhibitor; Beta secretase 1 inhibitor	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
233.	Phase 3	UCB Pharma SA	Brivaracetam	Epilepsy	Synaptic vesicle glycoprotein 2A modulator	Analgesic; Anticonvulsant agent
234.	Discovery	Blanchette Rockefeller Neurosciences Institute (BNRI)	Bryostatin-1 (cognitive disorder)	Cognitive disorder; Stroke	Protein kinase C stimulator; Amyloid protein deposition inhibitor	Nootropic agent
235.	**Discovery	Biovista Inc	BVA-201	Multiple sclerosis	Anti-inflammatory	Neuroprotectant
236.	**Discovery	Glenmark Pharmaceuticals Ltd/ Lay Line Genomics Spa	BXL-1H5	Pain	TrkA receptor antagonist	Analgesic
237.	Phase 2	Cytos Biotechnology AG/Novartis AG	CAD-106	Alzheimers disease	Beta amyloid modulator; Therapeutic vaccine	Neuroprotectant; Nootropic agent
238.	Discovery	ACB Blocks Ltd	Caged dimebon analogs (Alzheimer's disease)	Alzheimers disease	Cholinesterase inhibitor; 5-HT 7 receptor modulator; 5-HT 6 receptor modulator	Neuroprotectant; Nootropic agent
239.	**Discovery	Bristol-Myers Squibb Co	Calcium-activated small conductance potassium channel blockers	CNS disease	Potassium channel inhibitor	
240.	Discovery	Abbott Laboratories	Calpain inhibitors (neurological disorders)	Neurological disease	Calpain inhibitor	Neuroprotectant
241.	**Discovery	Axotect Inc	Calpain inhibitors (neuropathy)	Peripheral neuropathy	Smooth muscle cell proliferation inhibitor; Calpain inhibitor	Neuroprotectant; Vasoprotectant
242.	Discovery	Senju Pharmaceutical Co Ltd	Calpain inhibitors (oral, AMD/ retinopathy)	Retinopathy; Age related macular degeneration; Optic neuritis	Ocular antineovascularisation agent; Angiogenesis inhibitor; Calpain inhibitor	Neuroprotectant; Anti-inflammatory;
243.	**Discovery	Abbott Laboratories	Cannabinoid CB1 receptor agonists (multiple sclerosis)	Multiple sclerosis	Cannabinoid CB1 receptor agonist	Neuroprotectant
244.	**Phase 3	IMPAX laboratories Inc/GlaxoSmithKline plc	Carbidopa + levodopa (controlled release, Parkinsons disease)	Parkinsons disease	Dopamine receptor agonist; Dopa decarboxylase inhibitor	Antiparkinsonian
245.	**Discovery	Zenobia Therapeutics Inc	Caspase-6 inhibitors (Huntington's disease)	Huntingtons chorea	Caspase-6 inhibitor	Neuroprotectant
246.	*No development reported (Discovery)	Yungjin Pharmaceutical Co Ltd/Korea Research Institute of Chemical Technology	Caspase inhibitors (neurodegenerative disease)	Neurodegenerative disease	Caspase inhibitor	Neuroprotectant
247.	**Clinical	Johns Hopkins University School of Medicine (Johns Hopkins University)	CB1 antagonists (brain imaging)	Pain; Schizophrenia; Drug dependence	Cannabinoid CB1 receptor antagonist	PET contrast agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
248.	Discovery	Merck & Co Inc	CB1 antagonists (endocrine/ neurological diseases)	Neurological disease; Endocrine disease	Cannabinoid CB1 receptor antagonist	
249.	**Phase 2	Celgene Corp	CC-11006	Myelodysplastic syndrome; Neurodegenerative disease	TNF alpha synthesis inhibitor	Anticancer; Blood system agent; Neuroprotectant; Anti-inflammatory
250.	Discovery	Pfizer Inc	CDK5/p25 inhibitor (neurodegeneration)	Neurodegenerative disease	Cyclin dependent kinase 5 activator 1 inhibitor	Neuroprotectant
251.	Phase 3	Pfizer Inc	Celecoxib	Alzheimers disease	Cyclooxygenase 2 inhibitor; Anticancer	Nootropic agent; Analgesic; Non-steroidal anti-inflammatory
252.	**Phase 2	Celgene Cellular Therapeutics (Celgene Corp)	Cenplacel-L	Sarcoidosis; Multiple sclerosis; Rheumatoid arthritis; Ulcerative colitis; Stroke; Cancer; Crohns disease		Anticancer; Anti-inflammatory
253.	Phase 2	Ceregene Inc	CERE-110	Alzheimers disease	NGFB gene stimulator; Adeno-associated virus based gene therapy	Neuroprotectant; Nootropic agent
254.	Phase 2	Ceregene Inc/Genzyme Corp	CERE-120	Ocular disease; Parkinsons disease; Neurological disease	NTN gene stimulator; Adeno-associated virus based gene therapy; GDNF receptor agonist	Neuroprotectant; Antiparkinsonian
255.	Discovery	Ceregene Inc	CERE-135	Motor neurone disease	Insulin-like growth factor 1 agonist; Adeno-associated virus based gene therapy	Neuroprotectant
256.	**Phase 2	Alseras Pharmaceuticals Inc	Cethrin	CNS disease; Spinal cord injury	Rho associated protein kinase inhibitor; Anticancer protein kinase inhibitor; PARP stimulator	Antiglaucoma agent; Anticancer; Neuroprotectant
257.	*Phase 2 (Phase 1)	Chiesi Farmaceutici SpA	CHF-5074	Alzheimers disease	Gamma secretase subunit inhibitor; Amyloid protein deposition inhibitor	Nootropic agent
258.	**Discovery	Medical College of Georgia (Georgia Health Sciences University)	Choline analogs (neurodegenerative diseases)	Alzheimers disease; Neurological disease	Acetylcholine receptor agonist	Neuroprotectant; Nootropic agent
259.	**Discovery	Acorda Therapeutics Inc	Chondroitinase AC/B	Spinal cord injury	Chondroitin ABC endolyase 1 stimulator	
260.	Discovery	Living Cell Technologies Ltd	Choroid plexus cell therapy (alginate encapsulated)	Neurodegenerative disease; Hearing disorder	Neuroprotectant; Unspecified drug target	Cell therapy
261.	*Phase 2 (Discovery)	Kringle Pharma Inc/ ChronTech Pharma AB	ChronSeal; former Recombinant HGF	Fibrosis; Wound healing; Neurological disease; Varicosis ulcer; Renal failure; Spinal cord injury	Fibrinolysis inhibitor; Hepatocyte growth factor agonist	Vulnerary agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
262.	Phase 3	Insys Therapeutics Inc	Cintredekin besudotox	Glioblastoma	Interleukin 13 ligand; Protein synthesis inhibitor	Anticancer
263.	Discovery	INSERM	Ciproxifan	Epilepsy; Alzheimers disease; Dementia	Histamine H3 antagonist	Anticonvulsant agent; Nootropic agent
264.	Phase 2	Rexahn Pharmaceuticals Inc	Clavulanic acid (extended-release, depression/ Parkinson's disease)	Anxiety disorder; Major depressive disorder; CNS disease; Parkinsons disease	5-HT receptor agonist; Dopamine receptor agonist; PDE 5 inhibitor; Antiparkinsonian	Antidepressant; Anxiolytic; Neuroprotectant
265.	*Suspended (Phase 3)	Actelion Ltd/Handok Pharmaceuticals	Clazosentan	Intracranial vasospasm	Endothelin ET-A antagonist	Vasoprotectant
266.	**Discovery	The Salk Institute for Biological Studies	CNB-001	Stroke; Brain injury		Neuroprotectant; Nootropic agent; Cerebroprotectant
267.	**Phase 2	Johnson & Johnson Pharmaceutical Research & Development LLC	CNTO-0007	Stroke		Cerebro-protectant
268.	Discovery	Cognosci Inc	COG-112	Alzheimers disease; Colitis; Multiple sclerosis; Cancer	Apolipoprotein E agonist; Anti-inflammatory	Neuroprotectant; Anticancer
269.	Discovery	Cognosci Inc	COG-133	Brain injury; Neurodegenerative disease; Vascular injury; Vasculitis	Apolipoprotein E modulator; Anti-inflammatory; Amyloid protein deposition inhibitor; Tau deposition inhibitor	Neuroprotectant
270.	*Discontinued (Phase 2)	Mitsubishi Tanabe Pharma Corp	Coleneuramide	Diabetic neuropathy	NGF receptor agonist	
271.	Discovery	ReGen Therapeutics plc	Colostrinin-derived peptides (neurodegenerative disease/obesity)	Neurodegenerative disease; Obesity	Immunomodulator	Antioxidant agent; Neuroprotectant; Nootropic agent
272.	Phase 2	BrainCells Inc	Coluracetam	Anxiety disorder; Major depressive disorder	Choline uptake enhancer; AMPA receptor agonist	Neuroprotectant; Nootropic agent; Antidepressant; Anxiolytic; Antipsychotic
273.	**Discovery	Pharming NV	Conestat alfa	Stroke	Mannan-binding lectin serine protease inhibitor; Complement C1s subcomponent inhibitor	Fibrinolysis modulator; Kallikrein modulator; Coagulation modulator
274.	**Discovery	Flamel Technologies SA	Controlled-release agent (oral/ Micropump, CNS disorders)	CNS disease	Unspecified drug target	CNS modulator
275.	**Discovery	BTG plc/MS Therapeutics Ltd	Core 2 O-GlcNAc transferase inhibitor (multiple sclerosis)	Multiple sclerosis	N-acetylgalactosaminyltransferase 2 inhibitor	Anti-inflammatory

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
276.	Clinical	Pfizer Inc	CP-810123	Cognitive disorder	Nicotinic ACh agonist; Nicotinic Ach receptor alpha 7 subunit stimulator	Nootropic agent; Anxiolytic; Antipsychotic
277.	*Discovery (Phase 1)	Chase Pharmaceuticals Corp	CPC-001	Alzheimers disease	Unspecified drug target	Neuroprotectant
278.	**Phase 1	Crimson Pharmaceutical (Hong Kong) Ltd	CPH-106	CNS disease	Unspecified drug target	CNS modulator;
279.	Discovery	Catalyst Pharmaceutical Partners Inc	CPP-115; former Vigabatrin derivatives (oral)	Epilepsy; Neuropathic pain; Drug dependence	GABA transaminase inhibitor	Antipsychotic; Analgesic; Anti-convulsant agent
280.	**Discovery	Abiogen Pharma SpA	CRAM 1-2	CNS disease	Unspecified drug target	Neuroprotectant; Antioxidant agent
281.	**Discovery	Helicon Therapeutics Inc	CREB modulators	Cognitive disorder	cAMP responsive element binding protein modulator	Nootropic agent
282.	*Phase 2 (Phase 1)	AC Immune SA/ Genentech Inc/Roche	Crenezumab; former MABT-5102A	Alzheimers disease	Beta amyloid antagonist	Neuroprotectant
283.	*No development reported (Discovery)	CSL Behring	CSL-111	Atherosclerosis; Stroke	HDL cholesterol enhancer	Neuroprotectant
284.	Discovery	British Canadian Biosciences Corp	CTCE-0501	Stroke	Unspecified chemokine modulator	Neuroprotectant
285.	**Discovery	F Hoffmann-La Roche Ltd (Roche Holding AG)	CTEP	Fragile X syndrome; Parkinsons disease; Major depressive disorder	Metabotropic glutamate receptor 5 antagonist	Nootropic agent; Antidepressant; Antiparkinsonian
286.	*No development reported (Phase 1)	CoMentis Inc/Astellas Pharma Inc	CTS-21166	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta secretase 1 inhibitor	Neuroprotectant
287.	Phase 2	M's Science Corp	Cutamesine	Alzheimers disease; Stroke; Major depressive disorder; Multiple sclerosis; Brain injury; Cognitive disorder; Spinal cord injury	Opioid receptor sigma agonist 1	Neuroprotectant; Antidepressant; Nootropic agent
288.	Clinical	CardioVascular BioTherapeutics Inc	CVBT-141D	Ischemia	FGF-1 ligand	Angiogenesis stimulator
289.	*No development reported (Discovery)	CardioVascular BioTherapeutics Inc	CVBT-141F	Stroke	FGF-1 ligand	Neuroprotectant
290.	**Discovery	JW Pharmaceutical Corp	CWF-0804	Alzheimers disease	Unspecified drug target	Nootropic agent
291.	Phase 2	Cortex Pharmaceuticals Inc	CX-1739	Sleep apnea; Attention deficit hyperactivity disorder	CNS modulator; AMPA receptor modulator	
292.	*No development reported (Discovery)	Cortex Pharmaceuticals Inc	CX-1796	Alzheimers disease; Attention deficit hyperactivity disorder; Respiratory disorder	AMPA receptor modulator; CNS modulator	Respiratory system agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
293.	*No development reported (Discovery)	Cortex Pharmaceuticals Inc	CX-1837	Fragile X syndrome; Huntingtons chorea; Rett syndrome; Parkinsons disease; Alzheimers disease	AMPA receptor modulator; Brain derived neurotrophic factor ligand modulator	Neuroprotectant; Nootropic agent; Antiparkinsonian
294.	**Discovery	Cortex Pharmaceuticals Inc	CX-1846	Parkinsons disease	AMPA receptor modulator	Antiparkinsonian
295.	Discovery	Cortex Pharmaceuticals Inc/ Biovail Laboratories International Srl	CX-1942	Sleep apnea; Respiratory disorder	AMPA receptor modulator	Respiratory system agent
296.	Discovery	Cortex Pharmaceuticals Inc	CX-2007	Alzheimers disease; Attention deficit hyperactivity disorder	AMPA receptor modulator	CNS modulator
297.	Phase 2	Cortex Pharmaceuticals Inc	CX-717	Alzheimers disease; Attention deficit hyperactivity disorder; Respiratory disorder	AMPA receptor modulator	Neuroprotectant; Nootropic agent; Antidepressant; Antipsychotic
298.	**Clinical	Cortex Pharmaceuticals Inc	CX-717 (iv)	Alzheimers disease; Attention deficit hyperactivity disorder; Respiratory disorder	AMPA receptor modulator	Neuroprotectant; Respiratory system agent
299.	*No development reported (Discovery)	Cortex Pharmaceuticals Inc	CX-929	Fragile X syndrome; Huntingtons chorea; Rett syndrome	AMPA receptor modulator	
300.	Discovery	Isotechnika Pharma Inc	Cyclosporine analogs (HCV infection/ neurological disease)	Hepatitis C virus infection; Neurological disease	Peptidylprolyl isomerase inhibitor	Neuroprotectant; Antiviral
301.	Discovery	Maas BiolAB LLC	Cyclosporin A (neuroprotectant)	Alzheimers disease; Huntingtons chorea; Motor neurone disease; Parkinsons disease	Calcineurin modulator; Cytokine synthesis inhibitor	Neuroprotectant; Antiparkinsonian
302.	**Discovery	New York University	Cystatin C (Alzheimer's disease)	Alzheimers disease	Cysteine protease inhibitor	Neuroprotectant
303.	**Discovery	Promentis Pharmaceuticals Inc/ University of Wisconsin-Milwaukee/ Marquette University	Cystine analogs (schizophrenia/CNS disease)	Schizophrenia; CNS disease	Neurotransmitter modulator	Antipsychotic
304.	**Phase 3	Abbott Laboratories/ Biogen Idec Inc	Daclizumab (subcutaneous, multiple sclerosis)	Multiple sclerosis	IL-2 antagonist; IL-2 receptor alpha subunit inhibitor	Immuno-suppressant
305.	Phase 2	Allon Therapeutics Inc	Davunetide (iv/sc Alzheimer's disease)	Alzheimers disease; Schizophrenia; Parkinsons disease; Dementia	Tau deposition inhibitor; Microtubule stabilizer; Amyloid protein deposition inhibitor; PARP stimulator; Glycogen synthase kinase-3 inhibitor	Neuroprotectant; Nootropic agent; Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
306.	*Phase 3 (Phase 2)	Allon Therapeutics Inc	Davunetide (intranasal spray)	Alzheimers disease; Frontotemporal dementia; Schizophrenia; Cognitive disorder; Progressive supranuclear palsy; Parkinsons disease	Tau deposition inhibitor; Amyloid protein deposition inhibitor; PARP stimulator; Microtubule stabilizer; Glycogen synthase kinase-3 inhibitor	Neuroprotectant; Nootropic agent; Antiparkinsonian
307.	**Phase 2	Allon Therapeutics Inc	Davunetide (iv/sc, Alzheimer's disease)	Alzheimers disease; Schizophrenia; Parkinsons disease; Dementia	Tau deposition inhibitor; Amyloid protein deposition inhibitor; PARP stimulator; Microtubule stabilizer; Glycogen synthase kinase-3 inhibitor	Neuroprotectant; Nootropic agent; Antiparkinsonian
308.	Discovery	Roche Holding AG	DBT-066	Alzheimers disease	Advanced glycosylation product receptor modulator	Nootropic agent
309.	Discovery	Daewoong Pharmaceuticals Co Ltd/Medifron DBT Co Ltd	DBT-1339	Alzheimers disease	Amyloid protein deposition inhibitor	Nootropic agent
310.	Phase 2	Undisclosed	DCB-AD1	Alzheimers disease	Natural product	Neuroprotectant; Nootropic
311.	Discovery	DiverDrugs SL	DD-20207	Alzheimers disease; Parkinsons disease; Neuropathic pain	NMDA receptor antagonist	Analgesic; Antiparkinsonian; Neuroprotectant
312.	**Discovery	ENKAM Pharmaceuticals A/S	Dekafin-1	Huntingtons chorea	Protein tyrosine kinase modulator; FGF receptor agonist	Neuroprotectant; Nootropic agent
313.	**Discovery	Sanomune Inc	Deferoxamine	Alzheimers disease	Iron chelator	Neuroprotectant; Nootropic agent
314.	Phase 3	PAION AG/H Lundbeck A/S	Desmoteplase	Stroke	Fibrinolysis stimulator; Plasminogen activator stimulator; Plasmin stimulator	Neuroprotectant
315.	**Phase 3	Biogen Idec Inc/Knopp Neurosciences Inc	Dexpramipexole	Alzheimers disease; Motor neurone disease	Unspecified drug target	Neuroprotectant
316.	**Phase 2	SK biopharmaceuticals/ Neuronex Inc	Diazepam (intranasal/spray/ microemulsion, epilepsy)	Epilepsy	Benzodiazepine receptor agonist	Anticonvulsant agent
317.	**Phase 3	Taro Pharmaceutical Industries Ltd	Diclofenamide (periodic paralyses)	Paralysis	Carbonic anhydrase inhibitor	
318.	**Phase 3	Biogen Idec Inc	Dimethyl fumarate	Multiple sclerosis	NFE2L2 gene stimulator; Anti-inflammatory; KEAP1 gene modulator	Immuno-modulator; Neuroprotectant
319.	**Phase 2	Addex Pharmaceuticals SA	Dipraglurant-IR	Gastroesophageal reflux; Parkinsons disease; Movement disorder; Dystonia; Central nervous system disease; Major depressive disorder	Gastrointestinal system agent; Metabotropic glutamate receptor 5 modulator	Antidepressant; Anxiolytic; Analgesic; Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
320.	**Discovery	Biogen Idec Inc	Disease specific epitope-targeting monoclonal antibodies (amyotrophic lateral sclerosis)	Motor neurone disease	Superoxide dismutase modulator	Neuroprotectant
321.	**Discovery	DiaMedica Inc	DM-199	Autoimmune disease; Neurological disease; Insulin dependent diabetes; Non-insulin dependent diabetes		Neuroprotectant; Insulin sensitizer; Nootropic agent; Immuno-suppressant; Hypoglycemic agent
322.	Discovery	DiaMedica Inc	DM-204; former anti-GSK-3beta monoclonal antibodies	Central nervous system disease; Diabetes mellitus; Cancer; <i>Francisella tularensis</i> infection; Hypertension; Influenza virus infection	Hypoglycemic agent; Glycogen synthase kinase-3 beta inhibitor; Anticancer monoclonal antibody; Anticancer protein kinase inhibitor	Antibacterial; Antihypertensive; Hypoglycemic agent; Antiviral
323.	Discovery	Ikerchem	DMNT inhibitors (cancer, neurological disorders), former DNA methyltransferase 1 inhibitors (cancer/neurological disorders)	Cancer; Neurological disease	Anticancer; DNA cytosine-5 methyltransferase 1 inhibitor	Neuroprotectant
324.	*Pre-registration (Phase 2)	Eisai Co Ltd/Teikoku Pharma USA Inc	Donepezil (once weekly transdermal formulation)	Alzheimers disease	Acetylcholinesterase inhibitor	Neuroprotectant; Nootropic agent
325.	**Discovery	Proximagen Group plc	Dopamine D1 agonist (Parkinson's disease)	Parkinsons disease	Dopamine D1 receptor agonist	Antiparkinsonian
326.	**Discovery	Proximagen Group plc	Dopamine D1 receptor positive allosteric modulators (PAMs) (neurological conditions)	Neurological disease	Dopamine D1 receptor agonist; CNS modulator	Antiparkinsonian
327.	*Discovery (No development reported)	Organix Inc	Dopamine transporter modulator	Parkinsons disease; Schizophrenia; Cocaine addiction; Drug dependence	Dopamine transporter modulator	Antipsychotic; Antiparkinsonian
328.	*No development reported (Discovery)	Purdue University	Doxanthrine	Parkinsons disease; Schizophrenia	Dopamine D1 agonist	Antipsychotic; Antiparkinsonian
329.	**Phase 2	to-BBB technologies BV/Netherlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Doxorubicin (PEGylated liposomal, G-technology)	Brain tumor	DNA polymerase inhibitor; Topoisomerase II inhibitor	Anticancer; DNA intercalator; Glutathione modulator

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
330.	Discovery	D-Pharm Ltd	DP-109	Alzheimers disease; Neurodegenerative disease; Parkinsons disease	Chelating agent; Apoptosis modulator; Calcium metabolism modulator	Neuroprotectant
331.	Discovery	D-Pharm Ltd	DP-460	Alzheimers disease; Motor neurone disease	Chelating agent	Neuroprotectant
332.	Phase 3	D-Pharm Ltd/Yungjin Pharmaceutical Co Ltd/Wanbang Biopharma	DP-b99	Stroke; Brain injury; Neurodegenerative disease	Chelating agent; Calcium metabolism modulator; Apoptosis modulator; Metalloprotease-2 inhibitor; Metalloprotease-9 inhibitor	Neuroprotectant; Anti-inflammatory; Anticonvulsant agent; Antioxidant agent
333.	Phase 2	D-Pharm Ltd/Jiangsu Nhwa Pharmaceutical Group Co Ltd	DP-VPA	Epilepsy; Bipolar disorder; Migraine	Derivative of valproic acid; GABA modulator; GABA receptor modulator	Anticonvulsant agent; Antidepressant
334.	**Discovery	Biogen Idec Inc	DR6 antagonist antibodies (multiple sclerosis)	Multiple sclerosis	TNF receptor 21 antagonist	Immuno-modulator
335.	**Phase 1	Dainippon Sumitomo Pharma Co Ltd	DSP-8658	Alzheimers disease; Non-insulin dependent diabetes; Diabetes mellitus	Insulin sensitizer; PPAR gamma agonist; PPAR alpha agonist; Hypoglycemic agent; Beta amyloid antagonist	
336.	**Discovery	Domain Therapeutics SA	DT-1133	Parkinsons disease	Adenosine A2a receptor antagonist	Antiparkinsonian
337.	**Discovery	Domain Therapeutics SA/Merck Serono SA	DT-1687	Parkinsons disease; Schizophrenia; Neurological disease	Metabotropic glutamate receptor 4 modulator	Anxiolytic; Antipsychotic; Analgesic; Antiparkinsonian
338.	**Discovery	Domain Therapeutics SA	DT-2228	Alzheimers disease; Major depressive disorder	Metabotropic glutamate receptor 2 modulator	Nootropic agent; Antidepressant
339.	*No development reported (Discovery)	Prestwick Pharmaceuticals Inc	D-serine (schizophrenia/ Alzheimers disease/ autism)	Schizophrenia; Autism; Alzheimers disease	NMDA receptor agonist	Antipsychotic; Neuroprotectant
340.	**Discovery	Korea Research Institute of Chemical Technology	Dual 5-HT _{2C} /5-HT ₆ receptor antagonists (cognitive dysfunction)	Cognitive disorder	5 HT _{2c} receptor antagonist; 5-HT ₆ receptor antagonist	Nootropic agent
341.	**Discovery	Johnson & Johnson	Dual A _{2A} /A ₁ antagonists	Parkinsons disease	Adenosine A ₁ receptor antagonist; Adenosine A _{2a} receptor antagonist	
342.	Discovery	Solvay Pharmaceuticals BV	Dual AChE inhibitors/CB ₁ antagonists (Alzheimer's disease)	Alzheimers disease	Acetylcholinesterase inhibitor; Cannabinoid CB ₁ receptor antagonist	Neuroprotectant; Nootropic agent
343.	Discovery	Critical Outcome Technologies Inc	Dual beta secretase and gamma secretase inhibitors (Alzheimer's disease)	Alzheimers disease	Beta secretase inhibitor; Gamma-secretase inhibitor	

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
344.	**Discovery	F Hoffmann-La Roche Ltd (Roche Holding AG)	Dual gamma-secretase/PPAR gamma modulators (Alzheimer's disease)	Alzheimers disease	PPAR gamma modulator; Gamma-secretase modulator	Nootropic agent
345.	Discovery	Universite Denis Diderot/Shanghai Jiao Tong University	Dual PAF/AChE inhibitors (Alzheimer's disease)	Alzheimers disease	Acetylcholinesterase inhibitor; Platelet activating factor receptor antagonist; Amyloid protein deposition inhibitor	Nootropic agent
346.	Discovery	Zalicus Inc	Dual voltage-gated sodium and calcium channel modulators (pain)	Neuropathic pain; Pain	Calcium channel modulator; Voltage gated sodium channel modulator	Analgesic
347.	Discovery	Daewoong Pharmaceuticals Co Ltd	DWJ-209	Alzheimers disease	Unspecified drug target	Nootropic agent
348.	Discovery	Daewoong Pharmaceuticals Co Ltd	DWP-09031	Alzheimers disease	Amyloid protein deposition inhibitor; Beta amyloid antagonist	Nootropic agent
349.	*Discontinued (Phase 1)	Eisai Co Ltd	E-2012	Alzheimers disease	Beta amyloid modulator; Gamma-secretase modulator	
350.	*Phase 1 (Discovery)	Eisai Co Ltd	E-2212	Alzheimers disease	Beta amyloid synthesis inhibitor; Gamma-secretase modulator	Neuroprotectant
351.	**Phase 1	Eisai Co Ltd	E-2609	Alzheimers disease	Beta secretase inhibitor	Nootropic agent
352.	**Discovery	Eisai Co Ltd	E-3210	Parkinsons disease	Adenosine A2a receptor antagonist; Adenosine A2b receptor antagonist	Antiparkinsonian; Hypoglycemic agent;
353.	*No development reported (Phase 2)	Eli Lilly & Co	Eglumetad	Epilepsy; Neurodegenerative disease; Nicotine dependence; Anxiety disorder; Schizophrenia; Drug dependence	Metabotropic glutamate receptor 2 agonist; Metabotropic glutamate receptor 3 agonist	Anxiolytic; Anticonvulsant agent
354.	*Discontinued (Discovery)	Exonhit	EHT-1864	Alzheimers disease; Cancer	RAC1 GTPase inhibitor; Beta amyloid synthesis inhibitor; Gamma-secretase modulator	Anticancer; Neuroprotectant; Nootropic agent
355.	**Discovery	Bristol-Myers Squibb Co	EHT/AGN-0002	Pain; Neurodegenerative disease; Ocular disease		Ophthalmological agent; Neuroprotectant; Analgesic
356.	**Discovery	Exonhit/Allergan Inc	EHT/AGN-0003	Neurodegenerative disease; Ocular disease	Unspecified enzyme modulator	Ophthalmological agent; Neuroprotectant
357.	**Phase 2	Elan Corp plc	ELND-002	Multiple sclerosis; Autoimmune disease	CD49d antagonist	Immuno-modulator

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
358.	**Phase 2	Elan Corp plc	ELND-002 (PEGylated subcutaneous formulation, hematological malignancies/ multiple sclerosis)	Hematological neoplasm; Multiple sclerosis	Integrin alpha-4/beta-1 antagonist	Anticancer; Anti-inflammatory
359.	Phase 2	Elan Corp plc	ELND-005	Alzheimers disease	Amyloid protein deposition inhibitor	Nootropic agent
360.	*Discontinued (Phase 1)	Elan Pharmaceuticals Inc	ELND-007; former ELND-006	Alzheimers disease	Gamma-secretase inhibitor; Beta amyloid synthesis inhibitor	Nootropic agent
361.	**Phase 2	PsychoGenics Inc/ ReqMed Co Ltd	Eloprazine	Schizophrenia; Attention deficit hyperactivity disorder; Movement disorder	5 HT 2c receptor antagonist; 5-HT 1a receptor agonist; 5-HT 1b receptor agonist	Antihypertensive; Antipsychotic; Antiparkinsonian
362.	Discovery	EndogenX Inc	ENDG-5020 + non-opioid analgesic (stroke/brain trauma)	Brain injury; Stroke	Endothelin antagonist	Analgesic
363.	Discovery	EndogenX Inc	ENDG-6010	Alzheimers disease; Dementia	Endothelin antagonist	
364.	**Discovery	EndogenX Inc	ENDG-8010	Epilepsy	Unspecified drug target	Anticonvulsant agent
365.	Phase 2	PAION AG	Enecadin	Stroke	Sodium channel blocker; Calcium channel blocker	Neuroprotectant
366.	Discovery	ACADIA Pharmaceuticals Inc	Estrogen receptor beta agonists	Parkinsons disease; Pain	Estrogen receptor beta agonist	Analgesic; Anti-inflammatory; Antiparkinsonian
367.	Phase 2	Exonhit	Etazolate	Alzheimers disease	GABA A receptor modulator; PDE 4 inhibitor; APP gene stimulator; Alpha-secretase stimulator	Neuroprotectant; Nootropic agent
368.	*No development reported (Discovery)	e-Therapeutics Ltd	ETX-6765	Alzheimers disease		
369.	Discovery	Eustralis Pharmaceuticals Ltd	EU-C-002	Brain hemorrhage; Reperfusion injury	Unspecified drug target	
370.	Phase 1	EnVivo Pharmaceuticals Inc	EVP-0334	Neurodegenerative disease; Alzheimers disease	Histone deacetylase inhibitor	Nootropic agent
371.	*Phase 1 (Discovery)	EnVivo Pharmaceuticals Inc	EVP-0962	Alzheimers disease	Gamma-secretase modulator; Beta amyloid synthesis inhibitor	Neuroprotectant
372.	Phase 2	EnVivo Pharmaceuticals Inc/ Mitsubishi Tanabe Pharma Corp	EVP-6124	Alzheimers disease; Schizophrenia	Nicotinic ACh receptor alpha 7 subunit stimulator	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
373.	*No development reported (Phase 1)	Evotec AG	EVT-101	Neuropathic pain; Alzheimers disease; Major depressive disorder	NMDA receptor epsilon 2 subunit inhibitor	Neuroprotectant; Nootropic agent; Analgesic; Antidepressant
374.	Phase 1	Evotec Neurosciences GmbH	EVT-103	Major depressive disorder	NMDA receptor epsilon 2 subunit inhibitor	Antidepressant
375.	*Discovery (Discontinued)	Roche Holding AG	EVT-302	Alzheimers disease; Nicotine dependence; Parkinsons disease	MAO B inhibitor	Neuroprotectant; Antiparkinsonian; Nootropic agent
376.	Discovery	Evotec AG	EVT-501; former H3 antagonists	Sleep disorder; Cognitive disorder	Histamine H3 antagonist	Nootropic agent; Hypnotic
377.	Phase 1	ProteoTech Inc/Tasly Pharmaceuticals Ltd	Exebryl-1	Alzheimers disease	Amyloid protein deposition inhibitor	Neuroprotectant
378.	*No development reported (Discovery)	NeuroNova AB	Exenatide (neuronal proliferation stimulator)	Central nervous system disease	Glucagon-like peptide 1 agonist; Exendin 4 ligand	Neuroprotectant
379.	**Discovery	University of Queensland	FC29 peptide (neurodegenerative disease)	Neurodegenerative disease	Trk tyrosine kinase receptor modulator; Type II TNF receptor modulator	Neuroprotectant
380.	**Discovery	Buck Institute	FGF-2 agonist (Huntington's disease)	Huntingtons chorea	FGF-2 ligand	Neuroprotectant
381.	Phase 1	Enkam Pharmaceuticals A/S	FGLL	Alzheimers disease	Beta amyloid modulator; FGF receptor modulator; CNS modulator	Neuroprotectant
382.	Phase 2	Santhera Pharmaceuticals AG/Ipsen	Fipamezole	Movement disorder	Alpha 2 adrenoceptor antagonist	Antiparkinsonian
383.	**Phase 2	GlaxoSmithKline plc	Firategrast	Multiple sclerosis	Integrin alpha-4/beta-1 antagonist; Integrin alpha-4/beta-7 antagonist	Anti-inflammatory
384.	*No development reported (Discovery)	Astellas Pharma Inc	FK-1706	Neurological disease	NGF agonist; MAP kinase stimulator	Neuroprotectant
385.	Phase 2	Avid Radiopharmaceuticals Inc	Florbenazine F 18; former 18F-AV-133	Alzheimers disease; Parkinsons disease; Lewy body dementia; Diabetes mellitus	Synaptic vesicular amine transporter modulator	PET contrast agent; Radiodiagnostic
386.	Phase 3	Bayer AG	Florbetaben (18F)	Alzheimers disease; Mild cognitive impairment	Beta amyloid modulator; PET contrast agent	Radiodiagnostic; Imaging agent; CNS diagnostic agent
387.	Phase 1	Alseres Pharmaceuticals Inc	Fluoratec	Parkinsons disease; Attention deficit hyperactivity disorder	Dopamine uptake modulator	SPECT contrast agent; CNS diagnostic agent
388.	**Discovery	Johnson & Johnson	Fluorine-18-based PET imaging agents (neuropsychiatric disorders)	CNS disease	PDE 10 inhibitor	PET contrast agent; CNS diagnostic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
389.	*No development reported (Discovery)	Avid Radiopharmaceuticals Inc	Fluoropeglylated indolylphenyl-acetylenes (Alzheimer's disease)	Alzheimers disease	Beta amyloid modulator; PET contrast agent	Radiodiagnostic; CNS diagnostic agent
390.	Discovery	Kyungpook National University	Fluorovinyl-oxyacetamide anti-inflammatory drugs (neuroinflammation/neurodegeneration)	Nervous system inflammation; Neurodegenerative disease	Unspecified drug target; Anti-inflammatory	Neuroprotectant
391.	Phase 3	University of Pittsburgh/Uppsala Imanet AB	Flutemetamol (18F)	Alzheimers disease	Beta amyloid modulator; PET contrast agent	Radiodiagnostic; CNS diagnostic agent
392.	**Discovery	Zenobia Therapeutics Inc/Johns Hopkins University	G-2019S LRRK2 program (Parkinson's disease)	Parkinsons disease	Leucine rich serine threonine kinase 2 inhibitor	Neuroprotectant; Antiparkinsonian
393.	**Discovery	AgeneBio Inc	GABA-A $\alpha 5$ agonists (amnesic mild cognitive impairment)	Cognitive disorder	GABA A receptor alpha-5 subunit stimulator	Nootropic agent
394.	**Discovery	F Hoffmann-La Roche Ltd	GABA-A alpha-5 inverse agonists (cognitive impairment)	Cognitive disorder	GABA A receptor inverse agonist	Nootropic agent
395.	**Discovery	Kyowa Hakko Kirin Co Ltd	GABA A alpha 5 receptor inverse agonists (cognitive disorders)	Alzheimers disease; Cognitive disorder	GABA A receptor alpha-5 subunit modulator; GABA A receptor inverse agonist	Nootropic agent
396.	Discovery	University of Wisconsin-Milwaukee	GABA-A antagonists (anxiety/alcoholism/amnesia)	Anxiety disorder; Alcoholism; Amnesia	GABA-A receptor antagonist	Anxiolytic; Nootropic agent
397.	Discovery	Umeocrine AB	GABA A receptor antagonists (Alzheimer's disease)	Alzheimers disease	GABA A receptor antagonist	Nootropic agent
398.	Pre-registration	XenoPort Inc/Astellas Pharma Inc/ GlaxoSmithKline plc	Gabapentin enacarbil	Neuralgia; Postherpetic neuralgia; Neuropathic pain; Restless legs syndrome; Migraine	GABA modulator; CACNA2D3 calcium channel subunit modulator	Analgesic; Anticonvulsant agent; Anti-inflammatory
399.	**Discovery	ProteoTech Inc	GAG/carbohydrate compounds (oligosaccharide, Alzheimers disease)	Alzheimers disease	Glycosaminoglycan modulator	Neuroprotectant
400.	Discovery	Gaia BioPharma Ltd	GAI-122	Neurological disease; Liver disease	Apoptosis inhibitor	Neuroprotectant; Anti-inflammatory; ATP modulator
401.	Phase 2	Sanochemia Pharmazeutika AG	Galantamine (liposomal)	Neuropathic pain	Acetylcholinesterase inhibitor	Analgesic
402.	Discovery	Merck & Co Inc	Gamma-secretase inhibitors (Alzheimers)	Alzheimers disease	Amyloid protein deposition inhibitor; Gamma-secretase inhibitor	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
403.	**Discovery	F Hoffmann-La Roche Ltd	Gamma secretase modulators (Alzheimer's disease)	Alzheimers disease	Gamma-secretase modulator	Nootropic agent
404.	Discovery	Janssen Pharmaceuticals Inc	Gamma secretase modulators (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor; Gamma-secretase modulator	Neuroprotectant
405.	*Phase 2 (Phase 1)	Roche Holding AG/ Chugai Pharmaceutical Co Ltd/MorphoSys AG	Gantenerumab	Alzheimers disease	Monoclonal antibody; Beta amyloid antagonist	Neuroprotectant
406.	**Discovery	Medtronic Inc	Gene therapy (Huntington's disease)	Huntingtons chorea	Adenovirus based gene therapy	Neuroprotectant
407.	Phase 2	PN Gerolymatos SA	Gero-46	Alzheimers disease	Chelating agent; Beta amyloid modulator	
408.	*Phase 1 (Discovery)	Acorda Therapeutics Inc	GGF-2 (cardiac failure/ neurodegenerative disorders)	Neurodegenerative disease; Cardiac failure	EGFR family tyrosine kinase receptor modulator; Neuregulin-1 ligand	Neuroprotectant; Cardiac agent
409.	Discovery	GenKyoTex SA	GKT-03 program	Neurological disease	NADPH oxidase 2 inhibitor; Antihypertensive	Neuroprotectant
410.	**Discovery	MedGenesis Therapeutix Inc/ Amgen Inc	Glial cell line-derived neurotrophic factor protein (CNS disease)	CNS disease	Glial cell neurotrophic factor ligand	Neuroprotectant
411.	*Phase 2 (Discovery)	Remedy Pharmaceuticals Inc	Glibenclamide (iv, stroke/TBI/spinal cord injury)	Brain injury; Spinal cord injury; Stroke	Sulfonylurea receptor-1 modulator	Cerebro-protectant
412.	Discovery	Galantos Pharma GmbH	GLN-1062; former Memogain	Alzheimers disease	Nicotinic Ach receptor modulator; Acetylcholinesterase inhibitor	Nootropic agent
413.	Phase 2	CellMed AG/Eisai Co Ltd	GLP-1-expressing stem cell therapy (drug eluting bead, neurological trauma/ neurodegeneration)	Stroke; Metabolic disorder	Glucagon-like peptide 1 agonist	Neuroprotectant
414.	*No development reported (Discovery)	Eisai Co Ltd	Glutamate carboxypeptidase II inhibitors	Neuropathy	Glutamate carboxypeptidase II inhibitor	Anticancer; Neuroprotectant; Anticonvulsant agent
415.	*No development reported (Phase 2)	Eli Lilly & Co	Glutamate receptor 5 antagonists; former LY-498582	Pain; CNS disease	Glutamate receptor 5 antagonist	Neuroprotectant; Analgesic; Anticonvulsant
416.	*No development reported (Discovery)	Eli Lilly & Co	Glycine transporter inhibitors (schizophrenia)	Schizophrenia	Glycine transport inhibitor	Antipsychotic
417.	**Discovery	Jeil Pharmaceutical Co Ltd	Glycogen synthase inhibitor (neurodegenerative disease)	Neurodegenerative disease	Glycogen synthase kinase inhibitor	CNS modulator

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
418.	**Discovery	Helicon Therapeutics Inc	GlyT1 inhibitors (cognitive disorder)	Cognitive disorder	Glycine transporter-1 inhibitor	Nootropic agent
419.	**Discovery	Stem Cell Therapeutics Corp	GM-CSF (white matter disorders)	Neurological disease	GM-CSF ligand	Neuroprotectant
420.	Discovery	Siena Biotech SpA	GPCR antagonists (Alzheimer's disease/ Huntington's disease)	Alzheimers disease; Huntingtons chorea	Unspecified GPCR antagonist	Neuroprotectant; Nootropic agent
421.	**Discovery	Heptares Therapeutics Ltd/AstraZeneca plc	GPCR modulators (central nervous system/pain/ cardiovascular/ metabolic/ inflammatory diseases)	Inflammatory disease; Cardiovascular disease; Central nervous system disease; Metabolic disorder	Unspecified GPCR modulator;	Anticancer; CNS modulator; Anti-inflammatory; Cardiovascular agent
422.	**Discovery	Heptares Therapeutics Ltd/Takeda Pharmaceutical Co Ltd	GPCR modulators (CNS disorders)	CNS disease	Unspecified GPCR modulator	CNS modulator
423.	*Phase 1 (Discovery)	Geron Corp	GRNOPC-1	Spinal cord injury; Parkinsons disease; Stroke; Alzheimers disease; Multiple sclerosis; Canavan disease	Embryonic stem cell therapy	Neuroprotectant; Antiparkinsonian; Nootropic agent
424.	*Phase 1 (Discovery)	Merck & Co Inc	GSI-1; former gamma-secretase inhibitors (Alzheimers)	Alzheimers disease	Beta amyloid synthesis inhibitor; Amyloid protein deposition inhibitor; Gamma-secretase inhibitor; Notch antagonist	Nootropic agent
425.	**Phase 1	GlaxoSmithKline plc	GSK-1034702	Psychotic disorder; Dementia	Muscarinic M1 receptor agonist	Neuroprotectant; Nootropic agent; Antipsychotic
426.	**Phase 1	GlaxoSmithKline plc	GSK-1223249	Motor neurone disease; Multiple sclerosis	Immunomodulator; Reticulon 4 inhibitor	Neuroprotectant
427.	Phase 2	GlaxoSmithKline plc	GSK-239512	Alzheimers disease; Schizophrenia; Dementia	Histamine H3 receptor antagonist	Nootropic agent; Antipsychotic
428.	*No development reported (Discovery)	AstraZeneca AB	GSK-3 inhibitors	Alzheimers disease	Glycogen synthase kinase inhibitor	Nootropic agent
429.	**Discovery	Takeda Pharmaceutical Co Ltd	GSK-3 inhibitors (Alzheimer's disease)	Alzheimers disease	Tau aggregation inhibitor; Glycogen synthase kinase-3 alpha inhibitor; Glycogen synthase kinase-3 beta inhibitor	Neuroprotectant; Nootropic agent
430.	Discovery	Crystalgenomics Inc	GSK-3 inhibitor (cancer/ schizophrenia/ Alzheimers disease)	Alzheimers disease; Cancer; Schizophrenia	Glycogen synthase kinase-3 inhibitor; Anticancer protein kinase inhibitor	Neuroprotectant; Antipsychotic
431.	*Phase 2 (Phase 1)	GlaxoSmithKline plc	GSK-933776A	Alzheimers disease; Age related macular degeneration	Monoclonal antibody; Unspecified drug target	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
432.	Phase 2	CoMentis Inc	GTS-21	Alzheimers disease; Attention deficit hyperactivity disorder; Cognitive disorder	Nicotinic ACh receptor alpha 7 subunit stimulator; Nicotinic ACh receptor agonist	Nootropic agent; Antipsychotic
433.	Discovery	Bioprojet, Societe Civile de Recherche / Berlin Free University/ INSERM/University College London	H3 antagonists	Neurological disease; Psychiatric disorder	Histamine H3 receptor antagonist	Antipsychotic; Hypnotic; Anticonvulsant agent
434.	Discovery	GlaxoSmithKline plc	H3 antagonists (cognitive disorder)	Cognitive disorder	Histamine H3 receptor antagonist	Nootropic agent
435.	**Discovery	UCB SA	H3 antagonists (cognitive disorder)	Cognitive disorder	Histamine H3 receptor antagonist	Nootropic agent
436.	**Discovery	Johnson & Johnson	H3 histamine antagonists	Narcolepsy; Schizophrenia; Cognitive disorder	Histamine H3 receptor antagonist	Nootropic agent; CNS modulator; Antipsychotic
437.	**Discovery	F Hoffmann-La Roche Ltd (Roche Holding AG)	H3 receptor inverse agonists (CNS disorders, obesity)	Obesity; Central nervous system disease	CNS modulator; Histamine H3 receptor inverse agonist	
438.	Discovery	Hibernaid Inc	HBN-1	Neurological disease	Unspecified drug target	Neuroprotectant
439.	Discovery	Hibernaid Inc	HBN-2	Neurological disease	Neurotensin receptor agonist	Neuroprotectant
440.	**Discovery	Handok Pharmaceuticals Co Ltd	HD-0801	Parkinsons disease	Unspecified drug target	Antiparkinsonian
441.	**Discovery	CHDI Foundation Inc (CHDI Inc)/BioFocus DPI	HDAC4 inhibitors (Huntington's disease)	Huntingtons chorea	Histone deacetylase-4 inhibitor	Nootropic agent
442.	**Discovery	Repligen Corp	HDAC inhibitors (oral, Friedreich's ataxia/neurological disorders)	Parkinsons disease; Friedreich ataxia; Neurological disease	FXN gene stimulator; Histone deacetylase-1 inhibitor; Histone deacetylase-3 inhibitor; Histone deacetylase-4 inhibitor	Neuroprotectant; Antiparkinsonian;
443.	**Discovery	H Lundbeck A/S	Heat shock protein 90 inhibitors (Alzheimer's disease)	Alzheimers disease	Hsp 90 inhibitor	Nootropic agent
444.	Phase 2	Newron Pharmaceuticals SpA	HF-0220	Alzheimers disease; Inflammatory disease; Ischemia; Rheumatoid arthritis	Prostaglandin D synthase stimulator; Steroidal anti-inflammatory; Anti-inflammatory	Neuroprotectant; Cardioprotectant; Nootropic agent
445.	Discovery	Loyola University of Chicago	HF-0420	Alzheimers disease; Dementia	Heparin modulator	Neuroprotectant; Nootropic agent
446.	**Discovery	Human genome Sciences Inc	HG-1000	Immune disorder; Inflammatory disease; Cancer; Neurological disease	ADAM-10 modulator	Anticancer; Neuroprotectant; Anti-inflammatory
447.	**Discovery	Human genome Sciences Inc	HG-1007	Cancer; Neurological disease	Caspase-3 modulator	Anticancer; Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
448.	**Discovery	Human genome Sciences Inc	HG-1015	Neurological disease	Acetylcholine transferase modulator; Carnitine O-acetyltransferase modulator	Neuroprotectant
449.	**Discovery	Human genome Sciences Inc	HG-1027	Cancer; Neurological disease	Brain fatty acid binding protein modulator	Anticancer; Neuroprotectant
450.	**Discovery	Human genome Sciences Inc	HG-1029	Neurological disease	FGF-11 ligand modulator; FGF-14 ligand modulator	Neuroprotectant
451.	**Discovery	Human genome Sciences Inc	HG-1031	Neurological disease	FGF-11 ligand modulator; FGF-13 ligand modulator	Neuroprotectant
452.	**Discovery	Human genome Sciences Inc	HG-1032	Cardiovascular disease; Neurological disease	FGF-14 ligand modulator; FGF-15 ligand modulator	Neuroprotectant; Cardiovascular agent
453.	**Discovery	Human genome Sciences Inc	HG-1033	Neurological disease	GABA A receptor subunit modulator	Neuroprotectant
454.	**Discovery	Human genome Sciences Inc	HG-1034	Neurological disease	GABA A receptor pi subunit modulator	Neuroprotectant
455.	**Discovery	Human genome Sciences Inc	HG-1035	Neurological disease	UDP glucose 4-epimerase modulator	Neuroprotectant
456.	**Discovery	Human genome Sciences Inc	HG-1042	Neurological disease	Endothelin receptor modulator; Bombesin receptor modulator	Neuroprotectant
457.	**Discovery	Human genome Sciences Inc	HG-1044	Neurological disease	Orexin 1 receptor modulator	Neuroprotectant
458.	**Discovery	Human genome Sciences Inc	HG-1045	Cancer; Neurological disease	Histidine nucleotide binding protein 1 modulator	Anticancer; Neuroprotectant
459.	**Discovery	Human genome Sciences Inc	HG-1052	Neurological disease	Inositol monophosphatase 2 modulator	Neuroprotectant
460.	**Discovery	Human genome Sciences Inc	HG-1055	Cardiovascular disease; Neurological disease	Voltage gated potassium channel modulator; Cardiovascular agent	Neuroprotectant
461.	**Discovery	Human genome Sciences Inc	HG-1056	Cardiovascular disease; Neurological disease	Voltage gated potassium channel modulator; Cardiovascular agent	Neuroprotectant
462.	**Discovery	Human genome Sciences Inc	HG-1075	Neurological disease	Neuroserpin modulator	Neuroprotectant
463.	**Discovery	Human genome Sciences Inc	HG-1082	Cancer; Neurological disease	RXRg gene modulator; Retinoid X receptor gamma modulator	Anticancer; Neuroprotectant
464.	**Discovery	Human genome Sciences Inc	HG-1098	Neurological disease	Chromaffin granule amine transporter modulator	Neuroprotectant
465.	**Discovery	Human genome Sciences Inc	HG-1099	Cancer; Neurological disease	Synuclein gamma modulator	Anticancer; Neuroprotectant
466.	**Discovery	Human genome Sciences Inc	HG-1000	Cardiovascular disease; Neurological disease	Stanniocalcin 1 ligand modulator	Neuroprotectant; Cardiovascular agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
467.	**Discovery	Human genome Sciences Inc	HG-1108	Cancer; Neurological disease	Ubiquitin conjugating enzyme E2 modulator	Anticancer; Neuroprotectant
468.	**Discovery	Human genome Sciences Inc	HG-1109	Cancer; Neurological disease	Ubiquitin conjugating enzyme E2 E2 modulator	Anticancer; Neuroprotectant
469.	**Discovery	Human genome Sciences Inc	HG-1114	Immune disorder; Neurological disease	Psychosine receptor modula	Immuno-modulator; Neuroprotectant
470.	**Discovery	Human genome Sciences Inc	HG-1124	Immune disorder; Cancer; Neurological disease		Anticancer; Immuno-modulator; Neuroprotectant
471.	**Discovery	Human genome Sciences Inc	HG-1140	Bone disease; Cardiovascular disease; Neurological disease	FGF-13 ligand modulator; FGF-17 ligand modulator	Neuroprotectant; Bone modulator; Cardiovascular agent
472.	**Discovery	Human genome Sciences Inc	HG-1149	Neurological disease	Trace amine-associated receptor-5 modulator	Neuroprotectant
473.	**Discovery	Human genome Sciences Inc	HG-1155	Cancer; Neurological disease	TATA box binding protein like protein 1 modulator; TRF2 gene modulator	Anticancer; Neuroprotectant
474.	**Discovery	Human genome Sciences Inc	HG-1156	Neurological disease		Neuroprotectant
475.	**Discovery	Human genome Sciences Inc	HG-1163	Neurological disease	Superoxide dismutase modulator	Neuroprotectant
476.	**Discovery	Human genome Sciences Inc	HG-1165	Immune disorder; Cancer; Neurological disease	Tetraspanin 3 modulator; TSPAN3 gene modulator	Anticancer; Immuno-modulator; Neuroprotectant
477.	**Discovery	Human genome Sciences Inc	HG-1168	Immune disorder; Cancer; Neurological disease	G protein coupled receptor 4 modulator; P2Y5 purinoceptor modulator	Anticancer; Immuno-modulator; Neuroprotectant
478.	**Discovery	Human genome Sciences Inc	HG-1171	Immune disorder; Cancer; Neurological disease	Receptor activity modifying protein 3 inhibitor; Antiarrhythmic agent	Anticancer; Immuno-modulator; Neuroprotectant
479.	**Discovery	Human genome Sciences Inc	HG-1199	Cancer; Neurological disease	Neuregulin-3 ligand modulator	Anticancer; Neuroprotectant
480.	**Discovery	Human genome Sciences Inc	HG-1202	Immune disorder; Cancer; Neurological disease	Butyrophilin like protein 3 modulator	Anticancer; Immuno-modulator; Neuroprotectant
481.	**Discovery	Human genome Sciences Inc	HG-1217	Immune disorder; Cancer; Neurological disease	Integrin alpha 11 modulator	Anticancer; Immuno-modulator; Neuroprotectant
482.	**Discovery	Human genome Sciences Inc	HG-1224	Immune disorder; Neurological disease	Tumor necrosis factor 13C receptor modulator	Immuno-modulator; Neuroprotectant
483.	**Discovery	Human genome Sciences Inc	HG-1229	Immune disorder; Cancer; Neurological disease	Tetraspanin 16 modulator; Short 3-hydroxyacyl CoA dehydrogenase modulator	Anticancer; Immuno-modulator; Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
484.	**Discovery	Human genome Sciences Inc	HG-1230	Immune disorder; Cancer; Neurological disease	Sialic acid-binding Ig-like lectin 7 modulator; Sialic acid-binding Ig-like lectin 9 modulator	Anticancer; Immuno-modulator; Neuroprotectant
485.	**Discovery	Human genome Sciences Inc	HG-1232	Cancer; Neurological disease	Dickkopf-3 ligand modulator	Anticancer; Neuroprotectant
486.	**Discovery	Human genome Sciences Inc	HG-1234	Immune disorder; Neurological disease	IL-20 modulator	Immuno-modulator; Neuroprotectant
487.	**Discovery	Human genome Sciences Inc	HG-1249	Neurological disease	Vanilloid VR2 receptor modulator	Neuroprotectant
488.	**Discovery	Human genome Sciences Inc	HG-1251	Neurological disease		Neuroprotectant
489.	**Discovery	Human genome Sciences Inc	HG-1255	Immune disorder; Cancer; Neurological disease	G protein coupled 1 receptor modulator; G-protein coupled receptor-3 modulator	Anticancer; Immuno-modulator; Neuroprotectant
490.	**Discovery	Human genome Sciences Inc	HG-1259	Cancer; Neurological disease	Mammalian ependymin related protein 1 modulator	Anticancer; Neuroprotectant
491.	**Discovery	Human genome Sciences Inc	HG-1287	Cardiovascular disease; Neurological disease	Membrane metallo-endopeptidase-like 1 modulator	Cardiovascular agent; Neuroprotectant
492.	**Discovery	Human genome Sciences Inc	HG-1291	Immune disorder; Cancer; Neurological disease		Anticancer; Immuno-modulator; Neuroprotectant
493.	**Discovery	Human genome Sciences Inc	HG-1308	Immune disorder; Cancer; Neurological disease	Sialic acid-binding Ig-like lectin 10 modulator; Sialic acid-binding Ig-like lectin 11 modulator	Anticancer; Immuno-modulator; Neuroprotectant
494.	**Discovery	Human genome Sciences Inc	HG-1312	Cardiovascular disease; Neurological disease	Protein MAL2 modulator	Cardiovascular agent; Neuroprotectant
495.	**Discovery	Human genome Sciences Inc	HG-1336	Neurological disease	NTT4 neurotransmitter transporter modulator	Neuroprotectant
496.	**Discovery	Human genome Sciences Inc	HG-1344	Cancer; Neurological disease	Ubiquitin conjugating enzyme E2L3 modulator	Anticancer; Neuroprotectant
497.	**Discovery	Human genome Sciences Inc	HG-1345	Cancer; Neurological disease	Cysteine protease modulator; Caspase-7 modulator; MCH receptor-1 modulator	Anticancer; Neuroprotectant
498.	**Discovery	Human genome Sciences Inc	HG-1359	Immune disorder; Cancer; Neurological disease	G protein coupled 1 receptor modulator	Anticancer; Immuno-modulator; Neuroprotectant
499.	**Discovery	Human genome Sciences Inc	HG-1383	Immune disorder; Cancer; Neurological disease	Opticin modulator	Anticancer; Immuno-modulator; Neuroprotectant
500.	**Discovery	Human genome Sciences Inc	HG-1436	Cancer; Neurological disease		Anticancer; Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
501.	*No development reported (Discovery)	Curis Inc/Evotec OAI (UK)	Hh agonists	Diabetic neuropathy; Parkinsons disease; Neurological disease	Hedgehog protein agonist	Neuroprotectant; Antiparkinsonian
502.	**Discovery	Suven Life Sciences Ltd	Histamine-3 antagonists (metabolic disorders/ neurodegenerative diseases)	Schizophrenia; Metabolic disorder; Neurological disease	Histamine H3 receptor antagonist	Nootropic agent; Antipsychotic
503.	Discovery	Abbott Laboratories	Histamine H3 antagonists	Obesity; Attention deficit hyperactivity disorder; Cognitive disorder; Central nervous system disease; Pain	Histamine H3 receptor antagonist	Appetite suppressant; Nootropic agent; CNS modulator; Analgesic
504.	*No development reported (Discovery)	Pfizer Inc	Histamine H3 antagonists (cognitive disorders)	Cognitive disorder	Histamine H3 receptor antagonist	Nootropic agent
505.	Discovery	Merck & Co Inc	Histamine H3 antagonists	CNS disease; Non-insulin dependent diabetes	Histamine H3 antagonist; Non-steroidal anti-inflammatory; CNS modulator; Hypoglycemic agent	Anticonvulsant agent; Analgesic
506.	Discovery	Athersys Inc	Histamine H3 antagonists (cognitive disorders/ obesity)	Obesity; Cognitive disorder	Histamine H3 receptor antagonist	Nootropic agent
507.	Discovery	Ligand Pharmaceuticals Inc	Histamine H3 receptor inverse agonists (oral, cognitive disorder)	Cognitive disorder	Histamine H3 receptor inverse agonist; Histamine H3 receptor antagonist	Nootropic agent
508.	Phase 1	High Point Pharmaceuticals LLC	HPP-854	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta secretase 1 inhibitor	Neuroprotectant
509.	Discovery	NexGenix Pharmaceuticals LLC	Hsp 90 inhibitors (neurofibromatosis/ cancer/neurological disease)	Cancer; Neurofibromatosis; Neurological disease	Hsp 90 inhibitor	Anticancer; Neuroprotectant
510.	**Discovery	Aegera Therapeutics Inc	Hsp90 inhibitors (oral, CNS/ inflammatory/ autoimmune diseases)	Autoimmune disease; Cancer; CNS disease; Fungal infection; Inflammatory disease	Hsp 90 inhibitor	Anticancer; Immuno-modulator; Fungicide; CNS modulator; Anti-inflammatory
511.	**Phase 2	Helicon Therapeutics Inc	HT-0712	Amnesia; Cognitive disorder	PDE 4 inhibitor	Nootropic agent
512.	**Discovery	Helicon Therapeutics Inc	HT-1067	Parkinsons disease; Cognitive disorder	MAO B inhibitor	Nootropic agent; Antiparkinsonian
513.	**Phase 2	Helicon Therapeutics Inc	HT-2157	Cognitive disorder; Major depressive disorder	Galanin GAL3 receptor antagonist	Nootropic agent; Antidepressant
514.	**Discovery	Helicon Therapeutics Inc	HT-2678	Cognitive disorder	GABA inverse agonist; GABA A receptor alpha-5 subunit modulator	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
515.	**Discovery	Siena Biotech SpA	Htt-mediated toxicity inhibitors (Huntington's disease)	Huntingtons chorea	Huntingtin inhibitor	Neuroprotectant
516.	Phase 2	Global Biotech Inc	HTU-PA	Myocardial infarction; Stroke	Kallikrein modulator; Urokinase plasminogen activator stimulator	
517.	Phase 2	Stem Cell Therapeutics Corp	Human chorionic gonadotropin + erythropoietin (im, stroke/brain injury/ neurodegenerative diseases/multiple sclerosis/myocardial infarction)	Neurodegenerative disease; Stroke; Multiple sclerosis; Myocardial infarction; Brain injury	Chorionic gonadotropin ligand; Erythropoietin ligand	Neuroprotectant; Cardiac agent
518.	*No development reported (Discovery)	Keio University/ Neurologix Inc	Humanin gene therapy (Alzheimer's)	Alzheimers disease; Motor neuron disease	Gene therapy; Humanin modulator	Neuroprotectant; Nootropic agent
519.	Discovery	Probiobdrug AG	Human glutaminyl cyclase inhibitors (Alzheimer's disease)	Alzheimers disease	Amyloid protein deposition inhibitor; Glutaminyl peptide cyclotransferase inhibitor	Neuroprotectant
520.	*Phase 2 (Phase 1)	StemCells Inc	Human neural stem cell therapy	Central nervous system disease; Spinal cord injury; Retinopathy; Demyelinating disease; Jansky-Bielschowsky disease; Santavuori-Haltia disease; Alzheimers disease	Stem cell stimulator	Neuroprotectant; Nootropic agent
521.	**Discovery	FoldRx Pharmaceuticals Inc (Pfizer Inc)	Huntington's disease therapy	Huntingtons chorea	Unspecified drug target	Neuroprotectant
522.	*No development reported (Discovery)	Auril AB	Hypothermic therapy (ischemia)	Ischemia	Unspecified drug target	Protectant
523.	Phase 2	MediciNova Inc	Ibudilast (oral, neuropathic pain/ opiate dependence/ neurodegeneration)	Neurodegenerative disease; Amphetamine dependence; Opiate dependence	IL-1 beta ligand inhibitor; TNF alpha ligand inhibitor; IL-6 antagonist; TLR-4 antagonist; IL-10 modulator	Neuroprotectant; Analgesic; Anti-inflammatory
524.	Phase 2	MediciNova Inc	Ibudilast	Multiple sclerosis; Neurological disease	Leukotriene D4 antagonist; PDE 10 inhibitor; PDE 11 inhibitor; NO synthesis inhibitor; PDE 4 inhibitor; Platelet activating factor receptor antagonist; Macrophage migration inhibitory factor inhibitor	Neuroprotectant; Vasodilator

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
525.	*No development reported (Phase 2)	Mochida Pharmaceutical Co Ltd	Icosapent ethyl; former epadel	Alzheimers disease	Antihyperlipidemic agent	Neuroprotectant; Antiarterio-sclerotic
526.	Phase 2	Vanda Pharmaceuticals Inc/Novartis Pharma AG	Iloperidone depot (schizophrenia)	Schizophrenia	Dopamine D1 receptor antagonist; 5-HT 2a receptor antagonist	Antipsychotic
527.	*No development reported (Discovery)	Pfizer Inc	ILS-920	Stroke	FK506 binding protein modulator; Calcium channel modulator L-type	Cerebro-protectant
528.	Discovery	Institute of Medicinal Molecular Design Inc	IMD-4482; former IMD-4690	Alzheimers disease	Plasminogen activator inhibitor 1 inhibitor; Anti-inflammatory	Neuroprotectant
529.	Discovery	Intellect Neurosciences Inc	IN-N01	Alzheimers disease; Brain injury; Glaucoma; Age related macular degeneration	Beta amyloid antagonist; Ophthalmological agent	Neuroprotectant; Nootropic agent
530.	**Discovery	Intellect Neurosciences Inc	IN-N01-OX2	Age related macular degeneration; Glaucoma; Alzheimers disease; Cerebral amyloid angiopathy; Traumatic brain injury	Ophthalmological agent; Beta amyloid modulator; Melatonin receptor agonist; Anti-inflammatory	Neuroprotectant; Nootropic agent; Imaging agent
531.	*No development reported (Discovery)	Alseres Pharmaceuticals Inc	Inosine (neuronal regeneration)	Neurodegenerative disease; Glaucoma; Stroke; Spinal cord injury	NGF receptor agonist; Antiglaucoma agent	Neuroprotectant
532.	**Phase 1	Merck Serono SA	Interferon beta-1a (extended-release formulation)	Multiple sclerosis	Interferon beta ligand	Immuno-modulator
533.	**Discovery	Ichor Medical Systems Inc	Interferon beta gene therapy (electroporation/ TriGrid/im, multiple sclerosis)	Multiple sclerosis; Atherosclerosis	IFNB gene stimulator; Non-steroidal anti-inflammatory	Immuno-modulator; Gene therapy
534.	Phase 2	Medical College of Georgia	Intravenous minocycline (stroke)	Cerebrovascular ischemia	Tetracycline; Matrix metalloprotease inhibitor; Poly ADP ribose polymerase 1 inhibitor	Neuroprotectant
535.	Discovery	InVasc Therapeutics Inc	INV-155; former alpha lipoic acid derivative based therapeutics (hypertension/ stroke)	Stroke; Hypertension	LDL receptor modulator	Antihypertensive; Neuroprotectant
536.	**Discovery	Ono Pharmaceutical Co Ltd	Ion channel modulators (cardiovascular/ CNS/urology diseases)	Urinary tract disease; Cardiovascular disease; CNS disease	Unspecified ion channel modulator	
537.	Phase 1	Cephalon Inc	Irdabisant; former CEP-26401	Cognitive disorder	Histamine H3 receptor antagonist	Nootropic agent; Psychostimulant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
538.	Phase 1	Isis Pharmaceuticals Inc	ISIS-SOD1Rx	Motor neurone disease	Superoxide dismutase gene inhibitor; Antisense oligonucleotide inhibitor	Neuroprotectant
539.	Phase 2	AstraZeneca plc	Ispronicline	Attention deficit hyperactivity disorder; Alzheimers disease	Nicotinic ACh receptor alpha 4 subunit modulator; Nicotinic ACh receptor beta 2 subunit modulator; Nicotinic acetylcholine receptor agonist	Neuroprotectant; Nootropic agent; Psychomodulator; Antipsychotic
540.	Phase 3	Kyowa Hakko Kirin Co Ltd	Istradefylline	Parkinsons disease	Adenosine A2a antagonist	Antidepressant; Antiparkinsonian
541.	Phase 1	Jeil Pharmaceutical Co Ltd/Seoul University	JES-9501	Alzheimers disease; Cognitive disorder	Cholinesterase inhibitor; Glutamate receptor antagonist; Beta amyloid antagonist	Nootropic agent
542.	**Phase 2	Johnson & Johnson	JNJ-18038683	Major depressive disorder	5-HT 7 receptor antagonist	Antidepressant
543.	**Discovery	Johnson & Johnson	JNJ-1930942	Cognitive disorder	Nicotinic ACh receptor alpha 7 subunit modulator	Nootropic agent
544.	**Phase 2	Johnson & Johnson Pharmaceutical Research & Development LLC	JNJ-26489112	Major depressive disorder	Unspecified drug target	Antidepressant; Anticonvulsant agent
545.	**Clinical	Johnson & Johnson	JNJ-26990990	Epilepsy; CNS disease	Unspecified drug target	CNS modulator; Anticonvulsant agent
546.	**Phase 2	Johnson & Johnson	JNJ-37822681	Schizophrenia	Dopamine D2 receptor antagonist	Antipsychotic
547.	**Phase 1	Janssen Pharmaceutica NV	JNJ-39393406	Cognitive disorder	Unspecified drug target	Nootropic agent; Antipsychotic
548.	**Phase 2	Johnson & Johnson	JNJ-40411813	Anxiety disorder; Schizophrenia	Metabotropic glutamate receptor 2 modulator	Antipsychotic
549.	Discovery	Celgene Corp	JNK inhibitors	Inflammatory disease; Neurodegenerative disease; Liver disease; Ischemia; Pulmonary fibrosis; Cancer; Asthma	Jun N terminal kinase-1 inhibitor; Jun N terminal kinase-2 inhibitor; Jun N terminal kinase-3 inhibitor; Angiogenesis inhibitor; Anticancer protein kinase inhibitor	Anti-inflammatory; Anticancer; Angiogenesis inhibitor
550.	**Discovery	Eisai Co Ltd	JNK inhibitors (multiple sclerosis)	Multiple sclerosis	Jun N terminal kinase inhibitor	Neuroprotectant
551.	*No development reported (Discovery)	GlaxoSmithKline plc	JNK inhibitors (neurodegenerative disorders)	Neurodegenerative disease	Jun N terminal kinase inhibitor	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
552.	Discovery	Elan Corp plc	JNK3 inhibitors (neuronal injury/ neurodegenerative disease)	Central nervous system injury; Neurodegenerative disease	Jun N terminal kinase-3 inhibitor	Neuroprotectant
553.	Phase 2	Kwang Dong Pharmaceutical Co Ltd	KD-501	Alzheimers disease	Unspecified drug target	Nootropic agent
554.	**Discovery	Kwang Dong Pharmaceutical Co Ltd	KD-901	Alzheimers disease	Unspecified drug target	Nootropic agent
555.	**Discovery	Kyowa Hakko Kirin Co Ltd	Ki-20227	Bone metastases; Multiple sclerosis; Bone disease	CSF-1 antagonist; Protein tyrosine kinase inhibitor	Anticancer
556.	Discovery	Amnestix Inc	KIBRA pathway modulators (cognitive impairment)	Cognitive disorder	WW domain containing protein modulator	Nootropic agent
557.	Discovery	Cellceutix Corp	KM-3174	Neurological disease	Unspecified drug target	Neuroprotectant
558.	**Discovery	Cellceutix Corp	KM-362	Neurological disease	Unspecified drug target	Neuroprotectant
559.	**Discovery	Korea Institute of Science and Technology/Seoul National University/ Hanmi Pharmaceutical Co Ltd	KMS-88 series	Alzheimers disease	Beta amyloid antagonist	Neuroprotectant
560.	Phase 2	KeyNeurotek Pharmaceuticals AG	KN-38-7271	Stroke; Brain injury	Cannabinoid CB1 receptor agonist; Cannabinoid CB2 receptor agonist	Neuroprotectant; Analgesic
561.	Discovery	Kinexis Inc	KNX-Monoclonal204	Alzheimers disease	Beta amyloid modulator	Neuroprotectant
562.	Discovery	Kinexis Inc	KNX-Monoclonal205	Alzheimers disease	Beta amyloid modulator	Neuroprotectant
563.	Discovery	Kinexis Inc	KNX-Vaccine3A	Alzheimers disease	Beta amyloid antagonist; Protein subunit vaccine; Prophylactic vaccine; Therapeutic vaccine	Neuroprotectant
564.	**Discovery	Kyungpook National University	KR-31360	Nervous system inflammation	Unspecified drug target	Anti-inflammatory
565.	**Phase 2	Kyorin Pharmaceutical Co Ltd (Kyorin Holdings Inc)/Novartis AG	KRP-203	Inflammatory bowel disease; Multiple sclerosis; Cutaneous lupus erythematosus; Ulcerative colitis; Transplant rejection; Graft versus host disease	Sphingosine-1-phosphate receptor-1 agonist	Immuno-suppressant;
566.	Discovery	Kareus Therapeutics Llc/Connexios Life Sciences Pvt Ltd	KU-046; former drug combination (Alzheimer's disease)	Alzheimers disease	Unspecified drug target	Neuroprotectant
567.	**Discovery	Merck Serono SA	Kv1.3 potassium channel blockers (multiple sclerosis)	Multiple sclerosis; Autoimmune disease	KCNA voltage-gated potassium channel-3 inhibitor; Anti-inflammatory	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
568.	**Discovery	CHDI Foundation Inc (CHDI Inc)/Evotec AG	Kynurenine mono-oxygenase inhibitors (Huntington's disease)	Huntingtons chorea	Kynurenine 3-hydroxylase inhibitor	Nootropic agent
569.	*No development reported (Phase 3)	Schwarz Pharma AG	Lacosamide	Neuropathic pain; Migraine	Sodium channel modulator; Dihydropyrimidinase related protein 2	Analgesic; Anticonvulsant agent
570.	Phase 2	Avraham Pharmaceuticals Ltd	Ladostigil	Alzheimers disease; Mild cognitive impairment	Acetylcholinesterase inhibitor; MAO B inhibitor	Neuroprotectant; Nootropic agent
571.	**Phase 3	Teva Pharmaceutical Industries Ltd	Laquinimod	Multiple sclerosis; Lupus nephritis; Systemic lupus erythematosus; Crohns disease	Unspecified drug target	Neuroprotectant; Anti-inflammatory; Immuno-suppressant
572.	**Phase 1	Almirall Prodesfarma SA	LAS-186323	Multiple sclerosis; Rheumatoid arthritis	Dihydroorotate dehydrogenase inhibitor	Immuno-modulator; Anti-inflammatory
573.	**Discovery	Almirall Prodesfarma SA	LAS-189913	Multiple sclerosis	Immunomodulator	Sphingosine 1 phosphate phosphatase 1 inhibitor
574.	Phase 3	Medivation Inc/Pfizer Inc	Latrepirdine	Alzheimers disease	Energy metabolism modulator	Nootropic agent
575.	**Discovery	Biovista Inc	Latrepirdine (oral, epilepsy)	Epilepsy	Anticonvulsant agent	Neuroprotectant
576.	**Discovery	Biovista Inc	Latrepirdine (oral, multiple sclerosis)	Multiple sclerosis	Immunomodulator	Neuroprotectant; Anticonvulsant agent
577.	Phase 1	Medivation Inc/Pfizer Inc	Latrepirdine (transdermal, Alzheimer's disease/ Huntington's disease)	Alzheimers disease; Huntingtons chorea	NMDA receptor modulator; Acetylcholinesterase modulator	Neuroprotectant; Nootropic agent
578.	Discovery	Neurotez Inc	Leptin (Alzheimer's disease)	Alzheimers disease	Beta amyloid synthesis inhibitor; Leptin ligand	
579.	*No development reported (Discovery)	Spectrum Pharmaceuticals Inc	Leteprinim	Neuropathy	FGF receptor agonist; NGF receptor agonist	Neuroprotectant; Nootropic agent; Antiparkinsonian
580.	**Discovery	Sirtis Pharmaceuticals Inc (GlaxoSmithKline plc)	Leucine-rich repeat kinase 2 (LRRK2) inhibitors (Parkinson's disease)	Parkinsons disease	Leucine rich serine threonine kinase 2 inhibitor	Antiparkinsonian
581.	*Phase 3 (No development reported)	Curaxis Pharmaceutical Corp/ DURECT Corp	Leuprolide acetate implant (Alzheimer's disease)	Alzheimers disease; Cancer	GNRH agonist; Amyloid protein deposition inhibitor	Nootropic agent; Anticancer; Anti-inflammatory
582.	Phase 2	AgeneBio Inc	Levetiracetam (amnesic mild cognitive impairment)	Cognitive disorder	Synaptic vesicle glycoprotein 2A inhibitor	Nootropic agent
583.	**Phase 1	Orion Corp	Levodopa (optimized formulation, Parkinson's disease)	Parkinsons disease	Dopamine receptor agonist	Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
584.	*No development reported (Discovery)	Mazal Plant Pharmaceuticals Inc	LHM-123	Alzheimers disease	Unspecified drug target	Neuroprotectant
585.	Discovery	OXIS International Inc	Lipid soluble antioxidants	Alzheimers disease; Parkinsons disease; Cardiovascular disease; Diabetes mellitus	Antioxidant agent; Hypoglycemic agent; Unspecified drug target	Antiparkinsonian; Neuroprotectant; Cardioprotectant
586.	Discovery	La Jolla Pharmaceutical	LJP-1485 (parenteral, tissue regeneration/ pulmonary fibrosis); former GMI-1485	Bone injury; Myocardial infarction; Cartilage disease; Heart injury; Stroke; Pulmonary fibrosis	FK506 binding protein modulator	Vulnerary agent; Cardiovascular agent
587.	**Phase 1	TauRx Therapeutics Pte Ltd	LMT-X	Neurodegenerative disease	Tau aggregation inhibitor	Nootropic agent
588.	**Discovery	Link Medicine Corp	LNK-3186	Alzheimers disease		Neuroprotectant
589.	**Discovery	Link Medicine Corp	LNK-3248	Alzheimers disease		Neuroprotectant
590.	Phase 1	Link Medicine Corp	LNK-754	Alzheimers disease; Neurodegenerative disease	Ras GTPase inhibitor; Protein farnesyltransferase inhibitor	Anticancer; Nootropic agent; CNS modulator
591.	**Discovery	Hanmi Pharmaceutical Co Ltd	Long-acting interferon beta conjugate (LAPS, multiple sclerosis)	Multiple sclerosis	Interferon beta ligand	Immuno-modulator
592.	Phase 2	GlaxoSmithKline plc	Losmapimod	Chronic obstructive pulmonary disease; Neuropathic pain; Atherosclerosis; Lipid metabolism disorder; Major depressive disorder	p38 MAP kinase inhibitor; Antiarteriosclerotic; Antidepressant; Anti-inflammatory; Antihyperlipidemic agent	Analgesic
593.	**Discovery	Lipopharma Therapeutics SL	LP-205A1	Cardiovascular disease; CNS disease; Metabolic disorder	Cell cycle inhibitor; Cardiovascular agent	Neuroprotectant
594.	**Discovery	Lipopharma Therapeutics SL	LP-226A1	CNS disease	Cell cycle inhibitor; Unspecified drug target	Neuroprotectant
595.	**Discovery	Lipopharma Therapeutics SL	LPA-181	Spinal cord injury	Unspecified drug target	Neuroprotectant
596.	**Discovery	Vernalis plc/H Lundbeck A/S	LRRK2 inhibitors (Parkinson's disease)	Neurodegenerative disease; Parkinsons disease	Leucine rich serine threonine kinase 2 inhibitor	Neuroprotectant; Antiparkinsonian
597.	*No development reported (Phase 2)	H Lundbeck A/S	Lu-AA24493	Brain injury; Stroke	Angiogenesis stimulator; Cardioprotectant	Neuroprotectant; Anti-inflammatory
598.	Phase 2	H Lundbeck A/S	Lu-AE58054	Alzheimers disease	5-HT 6 receptor antagonist	Nootropic agent
599.	**Phase 2	Spectrum Pharmaceuticals Inc	Lucanthone	Brain tumor	Endonuclease inhibitor; Topoisomerase II inhibitor	Anticancer; Radiochemo-sensitizer

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
600.	*Launched (Pre-registration)	Dainippon Sumitomo Pharma Co Ltd	Lurasidone	Schizophrenia; Bipolar disorder; Major depressive disorder	Dopamine D2 receptor antagonist; 5-HT 1a receptor partial agonist; 5-HT 7 receptor antagonist; 5-HT 2a receptor antagonist; Alpha 2C adrenoceptor modulator	Antipsychotic; Antidepressant
601.	**Discovery	Dainippon Sumitomo Pharma Co Ltd	Lurasidone (extended release/injectable, schizophrenia)	Schizophrenia	Dopamine D2 receptor antagonist; 5-HT 7 receptor antagonist; 5-HT 2a receptor antagonist; Alpha 2C adrenoceptor modulator; 5-HT 1a receptor antagonist	Antipsychotic
602.	Discovery	AstraZeneca plc	LXR agonists (atherosclerosis/dyslipidemia/Alzheimer's disease)	Alzheimers disease; Atherosclerosis; Lipid metabolism disorder	Lipid metabolism modulator; Liver X receptor agonist	Antiarterio-sclerotic; Nootropic agent
603.	*Discontinued (Phase 2)	Eli Lilly & Co	LY-545694	Pain	Ionotropic glutamate receptor antagonist	Analgesic
604.	**Discovery	Eli Lilly & Co	LY-554862	Parkinsons disease	PPAR gamma agonist	Antiparkinsonian
605.	**Discovery	Acorda Therapeutics Inc/Mayo Foundation	M1 monoclonal antibodies	CNS disease	Unspecified drug target	Neuroprotectant; CNS modulator
606.	Discovery	Merck & Co Inc	M1 muscarinic acetylcholine receptor agonist (Alzheimer's disease); former BQCA	Neurological disease	Muscarinic M1 receptor agonist	Neuroprotectant; Nootropic agent
607.	Discovery	Thrombolytic Science Inc	M5	Stroke; Thrombosis	Fibrinolysis stimulator; Plasmin stimulator	
608.	*No development reported (Discovery)	Mapreg	MAP-4343	Spinal cord injury; Alzheimers disease	Microtubule associated protein 2 stimulator	Neuroprotectant
609.	*Phase 3 (Phase 2)	Novartis AG	Mavoglurant; former AFQ-056	Fragile X syndrome; Huntingtons chorea; Movement disorder	Gastrointestinal system agent; Metabotropic glutamate receptor 5 antagonist	Anxiolytic
610.	**Discovery	M's Science Corp	MC-113	CNS disease	Sigma opioid receptor agonist	CNS modulator
611.	**Discovery	M's Science Corp	MC-116	CNS disease	Opioid receptor sigma agonist 1	CNS modulator
612.	*No development reported (Discovery)	Mithridion Inc	MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia)	Alzheimers disease; Schizophrenia	Muscarinic M1 receptor agonist	Nootropic agent; Neuroprotectant; Antipsychotic
613.	*No development reported (Discovery)	Mithridion Inc	MCD-386 (high dose, Alzheimer's disease/schizophrenia)	Alzheimers disease; Schizophrenia	Muscarinic M1 receptor agonist	Nootropic agent; Neuroprotectant; Antipsychotic

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
614.	Phase 1	Mithridion Inc	MCD-386 (oral controlled release, CNS disorders)	Alzheimers disease; Schizophrenia; Progressive supranuclear palsy	Muscarinic M1 agonist	Nootropic agent
615.	Discovery	Mithridion Inc	MCD-386 (transdermal, Alzheimer's disease/schizophrenia)	Alzheimers disease; Schizophrenia	Muscarinic M1 receptor agonist	Nootropic agent; Neuroprotectant; Antipsychotic
616.	**Discovery	Lundbeck Research USA Inc (H Lundbeck A/S)	MCH-1 receptor antagonists	Psychiatric disorder	Appetite suppressant; MCH receptor-1 antagonist	Antidepressant; Anxiolytic
617.	**Discovery)	Medeia Therapeutics Ltd	MDA-107	Neurodegenerative disease	Unspecified drug target	Neuroprotectant
618.	**Discovery)	Medeia Therapeutics Ltd	MDA-107 back-up compound (neurodegenerative diseases)	Neurodegenerative disease	Unspecified drug target	Neuroprotectant
619.	*No development reported (Discovery)	Medeia Therapeutics Ltd	MDA-200C	Alzheimers disease	Cell-based therapy	Neuroprotectant; Nootropic agent
620.	**Discovery)	Medeia Therapeutics Ltd	MDA-409	Neurodegenerative disease	Unspecified drug target	Neuroprotectant
621.	Phase 2	Memory Pharmaceuticals Corp	MEM-1414	Alzheimers disease; Asthma	PDE 4 inhibitor	Nootropic agent; Neuroprotectant; Anti-inflammatory; Respiratory system agent
622.	*No development reported (Phase 2)	Memory Pharmaceuticals Corp/F Hoffmann-La Roche Ltd	MEM-3454	Schizophrenia; Cognitive disorder	Nicotinic ACh receptor alpha 7 subunit modulator; 5-HT 3 receptor antagonist; Nicotinic ACh receptor partial agonist	Nootropic agent; Antipsychotic; Neuroprotectant
623.	Phase 1	Memory Pharmaceuticals Corp/ Roche Holding AG	MEM-63908	Alzheimers disease	Nicotinic Ach receptor alpha 7 subunit stimulator; Nicotinic ACh receptor partial agonist	Nootropic agent
624.	*No development reported (Discovery)	Memory Pharmaceuticals Corp	MEM-68626	Obesity; Neurological disease	5-HT 6 receptor antagonist	Nootropic agent; CNS modulator
625.	*Registered (Phase 3)	Forest Laboratories Inc/Merz & Co GmbH	Memantine (extended release)	Alzheimers disease	NMDA receptor antagonist	Neuroprotectant; Nootropic agent
626.	**Phase 1	Adamas Pharmaceuticals Inc	Memantine + donepezil (extended release formulation, dementia)	Dementia	Acetylcholinesterase inhibitor; NMDA receptor antagonist	Nootropic agent
627.	**Discovery	Astellas Pharma Inc/ Purdue University	Memapsin 2 inhibitors (Alzheimers)	Alzheimers disease	Aspartic protease inhibitor	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
628.	**Phase 3	Raptor Pharmaceuticals Corp	Mercaptamine	Huntingtons chorea; Non-alcoholic steatohepatitis; Nephropathic cystinosis	Renal system agent; Transglutaminase inhibitor; Gastric secretion stimulator	Neuroprotectant
629.	*Phase 2 (Clinical)	Stemedica Cell Technologies Inc	Mesenchymal bone marrow-derived stem cell therapy (intravenous, stroke)	Stroke		Cerebro-protectant
630.	Discovery	Eli Lilly & Co	Metabotropic glutamate receptor agonists	Neurodegenerative disease; Anxiety disorder; Pain; Epilepsy; Schizophrenia; Drug dependence; Major depressive disorder	Metabotropic glutamate receptor 2 agonist; Metabotropic glutamate receptor 3 agonist	Anxiolytic; Analgesic; Antipsychotic; Anticonvulsant agent; Antidepressant
631.	Discovery	Addex Pharmaceuticals SA	Metabotropic glutamate receptor 2 inhibitors (depression, Alzheimers disease)	Alzheimers disease; Major depressive disorder	Metabotropic glutamate receptor 2 antagonist	Neuroprotectant; Antidepressant
632.	*No development reported (Discovery)	Taisho Pharmaceutical Co Ltd/Merck & Co Inc	Metabotropic glutamate receptor ligands	Psychotic disorder; Schizophrenia; Major depressive disorder	Metabotropic glutamate receptor modulator; Metabotropic glutamate receptor 1 antagonist	Antipsychotic; Antidepressant
633.	Discovery	Neurosciences Victoria Ltd/ University of Tasmania	Metallothionein (neurodegenerative disorder)	Brain injury; Neurodegenerative disease; Spinal cord injury	Chelating agent; Free radical scavenger; Metallothionein modulator	Neuroprotectant
634.	*Phase 1 (Discovery)	Sinapis Pharma Inc	Methamphetamine (iv, stroke/brain injury)	Brain injury; Stroke		Cerebro-protectant
635.	Discovery	To-BBB technologies BV	Methylprednisolone (PEGylated liposomal/G-technology, Neuro-inflammation); former 2B3-201	Nervous system inflammation	Glucocorticoid agonist; Anti-inflammatory	Neuroprotectant
636.	Discovery	AstraZeneca plc	mGluR1 antagonists; former Metabotropic glutamate receptor modulators (CNS disorders)	Neurological disease	Metabotropic glutamate receptor 1 antagonist; CNS modulator	Analgesic
637.	*No development reported (Discovery)	Banyu Pharmaceuticals Co Ltd	mGluR1 antagonists (neurological/ psychiatric diseases)	Psychiatric disorder; Neurological disease	Metabotropic glutamate receptor 1 antagonist	CNS modulator
638.	Discovery	Pfizer Inc	mGluR2 PAMs (CNS disorders)	CNS disease	Metabotropic glutamate receptor 2 modulator	CNS modulator
639.	**Discovery	Addex Pharmaceuticals SA	mGluR4 PAM modulators (oral, Parkinson's disease/ anxiety)	Anxiety disorder; Parkinsons disease	Metabotropic glutamate receptor 4 modulator	Anxiolytic; Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
640.	**Discovery	Evotec AG/Boehringer Ingelheim Corp	mGluR4 PAMs (Parkinsons disease)	Parkinsons disease	Metabotropic glutamate receptor 4 modulator	Antiparkinsonian
641.	**Discovery	Novartis AG	mGluR5 antagonists (anxiety)	Anxiety disorder	Metabotropic glutamate receptor 5 antagonist	Anxiolytic
642.	**Discovery	Seaside Therapeutics Inc/Vanderbilt University	mGluR5 antagonists (fragile X syndrome, autism)	Fragile X syndrome; Autism	Metabotropic glutamate receptor 5 antagonist	Nootropic agent; Antipsychotic
643.	**Discovery	Addex Pharmaceuticals SA	mGluR5 NAMs (dyskinesia/ Parkinson's disease)	Movement disorder	Metabotropic glutamate receptor 5 modulator	
644.	*No development reported (Discovery)	Merz & Co GmbH	mGluR antagonists	Pain	Metabotropic glutamate receptor antagonist	Analgesic
645.	**Discovery	Mithridion Inc	MI-08-016/35	Cognitive disorder	Muscarinic M1 receptor agonist	Nootropic agent
646.	Discovery	Mithridion Inc	MI-09018; former MCD-386 back-up compound (Alzheimer's disease/schizophrenia)	Alzheimers disease; Schizophrenia	Muscarinic M1 receptor agonist	Nootropic agent
647.	**Discovery	Mithridion Inc	MI-10-022	Alzheimers disease; Schizophrenia	Muscarinic M4 receptor agonist; Muscarinic M1 receptor agonist	Nootropic agent; Antipsychotic
648.	Phase 2	Eli Lilly & Co	Mibampator	Alzheimers disease; Neurodegenerative disease	AMPA receptor agonist	Psychosedative; Nootropic agent
649.	**Phase 3	Upsher-Smith Laboratories Inc	Midazolam (intranasal, seizures)	Epilepsy	Benzodiazepine receptor agonist	Anxiolytic; Anticonvulsant agent
650.	*Pre-registration (Phase 3)	Corcept Therapeutics Inc	Mifepristone (Cushing's syndrome/psychotic major depression)	Psychotic disorder; Major depressive disorder; Cushing's disease	Glucocorticoid antagonist; Progesterone receptor antagonist	Antidepressant; Antipsychotic; Nootropic agent
651.	Discovery	AFFiRiS AG	Mimovax	Alzheimers disease	Beta amyloid modulator; Protein subunit vaccine; Therapeutic vaccine	Nootropic agent
652.	Discovery	Northwestern University	Minokine	Neurodegenerative disease	p38 MAP kinase inhibitor; Cytokine modulator	Neuroprotectant; CNS modulator
653.	Phase 1	Meta-IQ Aps	MIQ-001	Alzheimers disease	Unspecified drug target	Neuroprotectant
654.	**Discovery	Meta-IQ Aps	MIQ-003	Multiple sclerosis	Unspecified drug target	Immuno-modulator
655.	**Discovery	Meta-IQ Aps	MIQ-004	Brain tumor	Unspecified drug target	Anticancer

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
656.	Phase 2	Antipodean Pharmaceuticals Inc	Mitoquinone/ mitoquinol redox mixture (Parkinson's and liver disease)	Parkinsons disease; Sunburn; Liver disease	An orally active mitochondria-targeted antioxidant based on Coenzyme Q10 (ubiquinone) that selectively blocks mitochondrial oxidative damage and prevents cell death	Neuroprotectant; Antiparkinsonian; Antioxidant agent; Anti-inflammatory
657.	*No development reported (Phase 1)	Merck & Co Inc	MK-0752	Alzheimers disease; Breast tumor; Cancer	CNS modulator; Gamma-secretase inhibitor; Notch antagonist	Neuroprotectant; Anticancer
658.	Phase 1	Merck & Co Inc	MK-7288	Neurological disease; Sleep disorder	Unspecified drug target	CNS modulator
659.	**Discovery	Eli Lilly & Co	Modified GDNF (drug implant, Parkinson's Disease)	Parkinsons disease	Glial cell neurotrophic factor ligand	Antiparkinsonian
660.	**Phase 2	MorphoSys AG	MOR-103	Inflammatory disease; Multiple sclerosis; Rheumatoid arthritis	GM-CSF receptor modulator	Anti-inflammatory
661.	Discovery	Addiction Therapeutix Inc	MP-100	Alzheimers disease; Anxiety disorder; Major depressive disorder	Unspecified drug target	Antidepressant; Anxiolytic
662.	Phase 1	Mitsubishi Tanabe Pharma Corp	MP-124	Stroke	PARP inhibitor	Cerebro-protectant
663.	**Discovery	Dainippon Sumitomo Pharma Co Ltd	mPGES-1 inhibitors (inflammation)	Inflammatory disease; Pain; Cardiovascular disease; Cancer; Neurological disease	Prostaglandin E synthase-1 inhibitor	Anticancer; CNS modulator; Analgesic; Non-steroidal anti-inflammatory; Cardiovascular agent
664.	**Phase 1	Merz & Co GmbH	MRZ-8456	Movement disorder	Metabotropic glutamate receptor 5 modulator	
665.	**Phase 1	Mitsubishi Tanabe Pharma Corp (Mitsubishi Chemical Holdings Corp)	MT-1303	Multiple sclerosis	Sphingosine-1-phosphate receptor-1 modulator	CNS modulator
666.	*Phase 2 (Phase 1)	Athersys Inc/ Angiotech Pharmaceuticals Inc/ Pfizer Inc	Multipotent adult progenitor cell therapy (ischemia/ cerebral palsy/AMI/ GvHD/PD/IBD)	Cerebral palsy; Myocardial infarction; Stroke; Spinal cord injury; Brain injury; Graft versus host disease; Inflammatory bowel disease; Multiple sclerosis; Parkinsons disease	Stem cell therapy; Anti-inflammatory; Angiogenesis inhibitor; Gastrointestinal system agent; Antiparkinsonian; Immunosuppressant	Cerebro-protectant; Neuroprotectant
667.	**Discovery	Seaside Therapeutics Inc/Vanderbilt University	Muscarinic acetylcholine subtype 1 receptor antagonists (fragile X syndrome/autism)	Fragile X syndrome; Autism	Muscarinic M1 receptor antagonist	Nootropic agent; Antipsychotic

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
668.	*No development reported (Discovery)	Mithridion Inc	Muscarinic agonists (cognitive disorders)	Cognitive disorder	Muscarinic receptor agonist	Nootropic agent
669.	**Discovery	Heptares Therapeutics Ltd	Muscarinic M1 agonists (Alzheimer's disease/schizophrenia)	Alzheimers disease; Schizophrenia	Neuroprotectant; Antipsychotic	Muscarinic M1 receptor agonist
670.	**Discovery	Vanderbilt University	Muscarinic receptor modulators (nervous system disorders)	CNS disease	Muscarinic receptor modulator	CNS modulator
671.	*No development reported (Discovery)	MIGENIX Inc	MX-4565	Glaucoma; Retinitis pigmentosa; Neurodegenerative disease	Apoptosis inhibitor; Estradiol agonist	Neuroprotectant; Antiglaucoma agent; Antiparkinsonian
672.	Phase 2	NoNO Inc/Arbor Vita Corp	NA-1	Stroke	NMDA receptor antagonist; Discs large homolog 4 inhibitor; Neuronal nitric oxide synthase inhibitor	Neuroprotectant
673.	**Discovery	PsychoGenics Inc	NAAG peptidase inhibitors (brain injury, schizophrenia, pain)	Schizophrenia; Brain injury; Pain	Glutamate carboxypeptidase II inhibitor	Neuroprotectant; Antipsychotic; Analgesic
674.	Discovery	Pfizer Inc/Siena Biotech SpA	nAChR alpha 7 agonists (schizophrenia/Alzheimer's disease)	Schizophrenia; Alzheimers disease; Cognitive disorder	Nicotinic ACh receptor alpha 7 subunit stimulator; Nicotinic acetylcholine receptor agonist	Nootropic agent; Antipsychotic
675.	Discovery	Galantos Pharma GmbH	nAChR alpha 7 APLs (Alzheimer's disease)	Alzheimers disease	Nicotinic ACh receptor modulator; Apoptosis inhibitor	Nootropic agent
676.	Discovery	Galantos Pharma GmbH	nAChR APLs (Alzheimer's disease)	Alzheimers disease	Nicotinic ACh receptor modulator; Apoptosis inhibitor	Nootropic agent
677.	**Phase 2	Proximagen Group plc	Naluzotan	Epilepsy; Parkinsons disease	5-HT 1a receptor agonist	Antidepressant; Anxiolytic; Antiparkinsonian; Anticonvulsant agent
678.	Discovery	Ablynx NV/Boehringer Ingelheim Corp	Nanobody therapeutics (Alzheimer's disease)	Alzheimers disease	Antibody fragment; Unspecified drug target	CNS modulator
679.	Phase 3	Britannia Pharmaceuticals Ltd	Nasal Apomorphine (Lyonase, erectile dysfunction/Parkinson's disease)	Erectile dysfunction; Parkinsons disease	Dopamine D2 receptor agonist	Antiparkinsonian; Apomorphine modulator
680.	**Discovery	Neurocrine Biosciences Inc	NBI-138183	Epilepsy; Pain; Tremor	Unspecified GPCR antagonist	Analgesic; Anticonvulsant agent
681.	Discovery	NeoCytex Biopharma Inc	NBI-18	Neurodegenerative disease; Cerebrovascular disease	Stem cell stimulator	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
682.	Phase 2	BIAL Group	Nebicapone	Parkinsons disease	Catechol O-methyltransferase inhibitor	Antiparkinsonian
683.	*No development reported (Discovery)	Neuro Bioscience Inc/ RLI Ltd	NEBO-176	Parkinsons disease	Dopamine receptor agonist; Stem cell therapy	Antiparkinsonian
684.	Phase 2	Rottapharm Madaus/ Xytis Inc	Neboglamine	Schizophrenia; Cocaine addiction	NMDA receptor modulator; Norepinephrine uptake inhibitor	Antidepressant; Anxiolytic; Antipsychotic
685.	**Discovery	LG Life Sciences Ltd	Necrosis inhibitors (oral)	Liver disease; Neurodegenerative disease; Ischemia	High mobility group protein B1 inhibitor	Antioxidant agent; Protectant
686.	Phase 2	Neuren Pharmaceuticals Ltd	Nefiracetam	Psychiatric disorder	Acetylcholine receptor agonist; Neurotransmitter release stimulator; ACAT stimulator; Calcium channel stimulator	Nootropic agent; Antipsychotic
687.	**Discovery	Alseras Pharmaceuticals Inc/ Children's Hospital Boston	NEP1-40 + inosine (stroke)	Stroke	NGF receptor agonist; Nogo receptor antagonist	Neuroprotectant
688.	Phase 2	Biotie Therapies Holding AG	Nepicastat	Cocaine addiction; Post traumatic stress disorder	Dopamine beta hydroxylase inhibitor	Antiparkinsonian; Cardioprotectant
689.	Phase 3	Merz & Co GmbH/ Kyorin Pharmaceutical Co Ltd	Neramexane	Tinnitus; Nystagmus	NMDA receptor antagonist; Nicotinic acetylcholine receptor antagonist	Neuroprotectant; Analgesic; Antiparkinsonian
690.	**Discovery	Raptor Pharmaceuticals Corp	Nerve growth factor conjugated RAP peptide (NeuroTrans, neurodegenerative disease)	Neurodegenerative disease	NGF receptor agonist	CNS modulator
601.	Phase 1	GNT Pharma Co Ltd/ AmKor Pharma Inc/ Simcere Pharmaceutical Group/ Hengdian Group Ltd/ JW Pharmaceutical Corp	Neu-2000	Stroke; Cardiac arrest; Neurological disease; Spinal cord injury; Myocardial infarction; Skin burns	Free radical scavenger; NMDA receptor epsilon 2 subunit inhibitor; Noncompetitive NMDA antagonist; Antiarrhythmic agent; Coagulation inhibitor	Neuroprotectant; Vulnerary agent; Antioxidant agent
692.	Phase 1	Biogen Idec Inc/Biogen Inc	Neublastin	Nervous system injury; Neuropathic pain; Sciatica	Ret tyrosine kinase receptor stimulator	Analgesic
693.	*No development reported (Discovery)	Acorda Therapeutics Inc	Neuregulin-2	Heart disease; Neurological disease	EGFR family tyrosine kinase receptor modulator; Neuregulin-2 ligand	Neuroprotectant; Cardioprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
694.	Discovery	University of Minnesota	Neuroimmunophilin ligands (alopecia)	Alopecia	FK506 binding protein-12 inhibitor	Chemoprotectant; Neuroprotectant; Antiparkinsonian; Dermatological agent
695.	Discovery	Abbott Laboratories	Neurological therapeutics	Neurological disease	CNS modulator; Unspecified drug target	
696.	Discovery	Abbott Laboratories	Neuronal nAChR modulators	Alzheimers disease; Neurodegenerative disease; Pain; Nicotine dependence; Anxiety disorder; Schizophrenia; Major depressive disorder	Nicotinic ACh receptor alpha 4 subunit modulator; Nicotinic ACh receptor alpha 7 subunit stimulator; Nicotinic ACh receptor beta 2 subunit modulator; Nicotinic ACh receptor agonist	Anxiolytic; Antipsychotic; Analgesic; Nootropic agent; Antidepressant; Neuroprotectant
697.	**Discovery	GlaxoSmithKline plc	Neuropeptide S antagonist (neurological diseases)	Neurological disease	Neuropeptide receptor S antagonist	
698.	**Discovery	TauRx Therapeutics Pte Ltd	Neuroprotectants	Neurodegenerative disease		Neuroprotectant
699.	Discovery	Trophos SA	Neuroprotectants (Huntington's disease)	Huntingtons chorea	Unspecified drug target	Neuroprotectant
700.	**Phase 1	Acino Holding AG	Neuroprotectant (transdermal therapeutic system, Alzheimers disease)	Alzheimers disease	Unspecified drug target	Neuroprotectant
701.	*Phase 1; Discovery	Medipost Co Ltd	Neurostem-AD	Central nervous system disease; Alzheimers disease	Beta amyloid modulator; Stem cell therapy	CNS modulator
702.	*No development reported (Discovery)	GNT Pharma Co Ltd/ AmKor Pharma Inc	NG-2006	Alzheimers disease; Gastrointestinal disease	Beta amyloid antagonist; Gastrointestinal system agent	Anti-inflammatory; Antioxidant agent
703.	Phase 2	NeuroGeneration Inc	NGN-9076	Parkinsons disease	Cell line	Antiparkinsonian
704.	**Discovery	NeuroGeneration Inc	NGN-9078	Stroke		Neuroprotectant
705.	**Discovery	NeuroGeneration Inc	NGN-9079	Alzheimers disease		Neuroprotectant; Nootropic agent
706.	**Discovery	NeuroGeneration Inc	NGN-9080	Spinal cord injury	Bone synthesis modulator	
707.	*No development reported (Phase 1)	Raptor Pharmaceuticals Corp	NGX-426	Neuropathic pain; Migraine	Kainate receptor antagonist; AMPA receptor antagonist; Glutamate receptor antagonist	Analgesic
708.	*Phase 1 (Discovery)	Neurimmune Therapeutics AG/ Biogen Idec Inc	NI-101; former Monoclonal antibodies (Alzheimer's disease)	Alzheimers disease	Beta amyloid antagonist	Neuroprotectant
709.	**Discovery	Novartis Institutes for BioMedical Research Inc (Novartis AG)	NIBR-785	Multiple sclerosis	Sphingosine-1-phosphate receptor-1 agonist	Immuno-suppressant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
710.	**Discovery	Targacept Inc	Nicotinic ACh agonists (Parkinsons disease)	Parkinsons disease	Nicotinic ACh receptor alpha 4 subunit stimulator; Nicotinic ACh receptor alpha 6 subunit inhibitor; Nicotinic ACh receptor alpha 7 subunit stimulator; Nicotinic ACh receptor beta 2 subunit stimulator; Nicotinic acetylcholine receptor agonist	Neuroprotectant; Antiparkinsonian
711.	**Discovery	Servier	Nicotinic ACh ligands (cognitive disorders)	Cognitive disorder	Nicotinic acetylcholine receptor modulator; Nicotinic ACh receptor alpha 4 subunit modulator; Nicotinic ACh receptor beta 2 subunit modulator	Nootropic agent
712.	Phase 1	Archer Pharmaceuticals	Nilvadipine derivative (Alzheimer's disease)	Alzheimers disease	Amyloid protein deposition inhibitor	Neuroprotectant
713.	**Phase 1	Archer Pharmaceuticals	Nivaldipine derivative (sustained release, Alzheimer's disease)	Alzheimers disease	Amyloid protein deposition inhibitor	Neuroprotectant
714.	**Discovery	GlaxoSmithKline plc	NK-3 antagonists	CNS disease	NK3 receptor antagonist	CNS modulator; Anti-inflammatory
715.	**Discovery	Neurologix Inc	NLX-E201	Epilepsy	Neuropeptide Y receptor agonist; Adeno-associated virus based gene therapy	Anticonvulsant agent
716.	**Phase 2	Neurologix Inc	NLX-P101	Parkinsons disease	Adeno-associated virus based gene therapy; Glutamate decarboxylase stimulator	Antiparkinsonian
717.	Discovery	Merck Sharp & Dohme Research Laboratories	NMDA receptor antagonists (NR2B subtype-selective)	Neuropathic pain; Parkinsons disease; Stroke; Epilepsy	NMDA receptor epsilon 2 subunit inhibitor	Neuroprotectant; Analgesic; Antiparkinsonian; Anticonvulsant agent
718.	Discovery	Neuronascent Inc	NNI-AD; former NNI-362	Alzheimers disease	Neuron formation stimulant	Nootropic agent; Neuroprotectant
719	Phase 2	Neuren Pharmaceuticals Ltd	NNZ-2566 (intravenous, brain injury/stroke)	Neurological disease; Brain injury	Apoptosis inhibitor; Anti-inflammatory; Cytokine receptor antagonist	Neuroprotectant
720.	Discovery	Neuren Pharmaceuticals Ltd	NNZ-2566 (oral, neurodegeneration/injury)	Neurodegenerative disease; Brain injury; Rett syndrome	Unspecified drug target	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
721.	Discovery	Neuren Pharmaceuticals Ltd	NNZ-2591	Neurodegenerative disease	Unspecified drug target	Neuroprotectant; Antiparkinsonian
722.	**Discovery	University of California Los Angeles	Non-aminoglycoside stop codon suppressors (Duchenne muscular dystrophy)	Ataxia telangiectasia; Duchenne dystrophy	Dystrophin stimulator	Muscle system agent; Neuroprotectant
723.	*No development reported (Phase 1)	PharmAthene Inc	non-PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure)	Alzheimers disease	Cholinesterase stimulator	Neuroprotectant
724.	**Discovery	Noscira SA	NP-0336	Cognitive disorder	Cholinesterase inhibitor	Nootropic agent
725.	Discovery	Noscira SA	NP-103	Alzheimers disease	Glycogen synthase kinase-3 inhibitor	Neuroprotectant
726.	Discovery	Noscira SA	NP-17	Alzheimers disease	Alpha-secretase stimulator	Neuroprotectant
727	Discovery	Noscira SA	NP-34	Alzheimers disease	Acetylcholinesterase inhibitor; Calcium channel inhibitor	Neuroprotectant
728.	Phase 1	Noscira SA	NP-61	Alzheimers disease	Acetylcholinesterase inhibitor; Amyloid protein deposition inhibitor; Beta amyloid antagonist	Neuroprotectant; Nootropic agent
729.	Discovery	NPS Pharmaceuticals Inc	NPS-P156	Central nervous system disease; Epilepsy; Neuropathic pain	NMDA receptor agonist; CNS modulator	Analgesic; Anticonvulsant agent
730.	Phase 1	Bellus Health Inc	NRM-8499	Alzheimers disease	Amyloid protein deposition inhibitor	Neuroprotectant; Nootropic agent
731.	*No development reported (Phase 1)	Pfizer Inc	NSA-789	Alzheimers disease; Schizophrenia; Cognitive disorder	Unspecified drug target	Nootropic agent; Psychomodulator
732.	Phase 1	NsGene A/S	NsG-0202	Alzheimers disease	NGF receptor agonist	Nootropic agent
733.	Discovery	NsGene A/S	NsG-0501	Epilepsy	Galanin ligand	Anticonvulsant agent
734.	Phase 1	Neuralstem Inc	NSI-566RSC; former Neural stem cell therapy (ALS, spinal cord injury, paraplegia, stroke)	Spinal cord injury; Huntingtons chorea; Motor neurone disease; Paraplegia; Stroke; Alzheimers disease; Brain tumor; Major depressive disorder	Stem cell therapy; Anticancer; Antidepressant	Neuroprotectant; Cerebro-protectant
735.	Discovery	Neuron Biopharma SA	NST-0021	Brain disease	HMG CoA reductase inhibitor; Anticonvulsant agent; Antioxidant agent	Neuroprotectant; Nootropic agent
736.	Discovery	Neuron Biopharma SA	NST-0037	Alzheimers disease	HMG CoA reductase inhibitor; Anticonvulsant agent; Antioxidant agent	Neuroprotectant
737.	Discovery	Neuron Biopharma SA	NST-005	Brain disease	HMG CoA reductase inhibitor; Anticonvulsant agent	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
738.	**Discovery	Neurotez Inc	NT-1	Alzheimers disease	Presenilin modulator; Beta amyloid synthesis inhibitor; CAP Gly domain linker protein 1 modulator	Neuroprotectant
739.	**Discovery	Neurotez Inc	NT-2	Alzheimers disease	Presenilin modulator; Beta amyloid synthesis inhibitor; CAP Gly domain linker protein 1 modulator	Neuroprotectant
740.	Discovery	Mayo Foundation	NT-69-L	Alzheimers disease; Pain; Parkinsons disease; Nicotine dependence; Schizophrenia; Cognitive disorder; Alcoholism	Neurotensin receptor agonist	Antipsychotic; Analgesic; Antiparkinsonian; Nootropic agent
741.	**Phase 2	Stem Cell Therapeutics Corp	NTx-488	Multiple sclerosis	Prolactin ligand	Neuroprotectant
742.	Discovery	Neuromed Pharmaceuticals Inc/ Zalicus Inc	N-type calcium channel blockers (pain)	Pain	Calcium channel inhibitor N-type	Analgesic
743.	**Discovery	NeuroVive Pharmaceutical AB/to-BBB technologies BV	NVP-014	Stroke; Neurological disease	Peptidyl-prolyl cis-trans isomerase D inhibitor	Neuroprotectant
744.	**Discovery	NeuroVive Pharmaceutical AB	NVP-015	Obesity; Mitochondrial disease; Cardiovascular disease; Neurological disease	Peptidylprolyl isomerase inhibitor	Neuroprotectant
745.	**Discovery	NeuroVive Pharmaceutical AB	NVP-016	Mitochondrial disease; Neurological disease	Peptidylprolyl isomerase inhibitor	Neuroprotectant
746.	**Discovery	NeuroVive Pharmaceutical AB	NVP-017	Epilepsy	Unspecified drug target	Neuroprotectant
747.	**Phase 2	Nexgenix Pharmaceuticals Inc	NX-101	Neurofibromatosis	Vascular damaging agent	Anticancer
748.	Phase 1	Garnet BioTherapeutics Inc	NX-CP105	Myocardial infarction; Stroke	Cytokine synthesis stimulator; Unspecified growth factor receptor modulator	Cardioprotectant
749.	Discovery	Nymox Pharmaceutical Corp	NXD-9062	Alzheimers disease	Unspecified drug target	Neuroprotectant
750.	**Phase 3	Genentech Inc/Roche Holding AG	Ocrelizumab	Multiple sclerosis	B-lymphocyte antigen CD20 inhibitor; Anticancer monoclonal antibody	Anticancer; Anti-inflammatory
751.	*No development reported (Phase 2)	ThromboGenics NV	Ocriplasmin (injected, stroke)	Stroke	Fibrinolysis stimulator; Plasmin stimulator; Alpha-2 antiplasmin inhibitor	Neuroprotectant
752.	Phase 3	Trophos SA	Olesoxime	Motor neurone disease; Parkinsons disease; Spinal muscular atrophy; Multiple sclerosis; Peripheral neuropathy	Apoptosis inhibitor	Neuroprotectant; Analgesic; Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
753.	**Discovery	Noscira SA	Olfactory ensheathing glia cell therapy (spinal cord injury)	Spinal cord injury		Neuroprotectant
754.	*Phase 1 (Discovery)	Santhera Pharmaceuticals AG	Omigapil	Muscular dystrophy	Apoptosis inhibitor; Triosephosphate dehydrogenase modulator	Neuroprotectant; Nootropic agent; Antiparkinsonian
755.	**Phase 2	Ono Pharmaceutical Co Ltd/Merck KGaA	ONO-4641	Multiple sclerosis	Sphingosine-1-phosphate receptor-1 agonist	Immuno-modulator
756.	**Phase 3	Portela & Ca SA	Opicapone	Parkinsons disease	Catechol O-methyltransferase inhibitor	Antiparkinsonian
757.	*Phase 2 (Phase 1)	Orion Corp	ORM-12741	Alzheimers disease; Psychiatric disorder; Raynauds disease	Alpha 2C adrenoceptor antagonist	CNS modulator; Psychomodulator
758.	**Phase 2	Osmotica Pharmaceutical Corp	OS-320	Parkinsons disease	Unspecified drug target	CNS modulator
759.	**Discovery	Osmotica Pharmaceutical Corp	OS-440	Muscle hypertonia	Unspecified drug target	CNS modulator
760.	**Discovery	Intellect Neurosciences Inc	OX-2	Neurodegenerative disease		Neuroprotectant
761.	*Discontinued (Phase 1)	Intellect Neurosciences Inc/New York University	OX1; former OXIGON	Alzheimers disease; Huntingtons chorea; Parkinsons disease	Beta amyloid antagonist; Antioxidant agent; Cooper metabolism modulator	Neuroprotectant; Nootropic agent; Antiparkinsonian
762.	**Phase 3	Daewoong Pharmaceutical Co Ltd/Supernus Pharmaceuticals Inc	Oxcarbazepine (once-daily, oral extended release, epilepsy)	Epilepsy	Sodium channel inhibitor	Anticonvulsant agent
763.	Phase 2	Oxygen Biotherapeutics Inc	Oxycyte	Anemia; Blood transfusion; Stroke; Brain injury; Spinal cord injury; Decompression sickness; Poison intoxication	Blood substitute	Blood system agent; Vulnerary agent; Neuroprotectant
764.	Discovery	Afraxis Inc	p21-activated kinase inhibitor (central nervous system disorders/cancer)	Central nervous system disease; Cancer	PAK protein kinase inhibitor; Anticancer protein kinase inhibitor	Neuroprotectant; Nootropic agent
765.	**Discovery	Nexgenix Pharmaceuticals Inc	p21 activated kinase inhibitors (type 2 neurofibromatosis, fragile X syndrome/autism)	Fragile X syndrome; Neurofibromatosis; Autism	PAK protein kinase inhibitor; Anticancer protein kinase inhibitor	Neuroprotectant
766.	**Discovery	Affectis Pharmaceuticals AG/ Merck Serono SA	P2X7 antagonists (oral, neuroinflammation)	Nervous system inflammation	Cytokine release inhibitor; Anti-inflammatory; P2X7 purinoceptor antagonist	CNS modulator

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
767.	**Discovery	Affectis Pharmaceuticals AG	P2X7 purinoreceptor antagonists (neuropathic pain/multiple sclerosis)	Neuropathic pain; Multiple sclerosis	Cytokine release inhibitor; P2X7 purinoceptor antagonist	Analgesic; Anti-inflammatory; Immuno-suppressant
768.	**Phase 2	Geron Corp	Paclitaxel/AngioPep-2 conjugate	Glioma; Brain tumor	LDL receptor related protein modulator; Microtubule stabilizer	Anticancer
769.	Discovery	Panacea Pharmaceuticals Inc	PAN-811	Alzheimers disease; Ischemia	Ribonucleotide reductase inhibitor; Chelating agent; Free radical scavenger; Bcl-2 gene stimulator	Neuroprotectant; Antioxidant agent
770.	**Discovery	Cephalon Inc	Pan-MLK inhibitors (Alzheimer's disease)	Alzheimers disease	Mixed lineage kinase inhibitor	Neuroprotectant
771.	Phase 3	Abbott Laboratories	Pardoprunox	Parkinsons disease	Dopamine D2 receptor partial agonist; Adrenoceptor agonist; 5-HT 1a receptor agonist	Neuroprotectant; Antidepressant; Anxiolytic; Antiparkinsonian
772.	**Discovery	Elan Corp plc	Parkin modulators (Parkinson's disease)	Parkinsons disease	Parkin modulator	Antiparkinsonian
773.	Discovery	Panacea Pharmaceuticals Inc	Parkinsons therapeutic peptides	Parkinsons disease	Synuclein alpha inhibitor	Antiparkinsonian
774.	**Discovery	Angion Biomedica Corp	PARP-1 inhibitors (acute pancreatitis/stroke)	Pancreatitis; Stroke	Anti-inflammatory; Poly ADP ribose polymerase 1 inhibitor	Neuroprotectant
775.	Discovery	Jeil Pharmaceutical Co Ltd	PARP-1 inhibitors (cancer/stroke)	Stroke; Cancer	Poly ADP ribose polymerase 1 inhibitor	Anticancer; Neuroprotectant
776.	Discovery	Crimson Pharmaceutical (Hong Kong) Ltd	PARP inhibitors	HIV infection; Stroke; Cancer	PARP inhibitor	Anticancer; Neuroprotectant; Anti-inflammatory; Antiviral
777.	Phase 2	Prana Biotechnology Ltd	PBT-2	Alzheimers disease; Huntingtons chorea	Chelating agent; Tau protein modulator; Amyloid protein deposition inhibitor	Nootropic agent; CNS modulator
778.	**Discovery	Prana Biotechnology Ltd	PBT-3	Alzheimers disease	Unspecified drug target	Neuroprotectant
779.	**Discovery	Prana Biotechnology Ltd	PBT-4	Age related macular degeneration; Alzheimers disease; Huntingtons chorea; Parkinsons disease	Chelating agent; Ocular antineovascularisation agent	Neuroprotectant; Nootropic agent
780.	**Discovery	Prana Biotechnology Ltd	PBT-434	Parkinsons disease	Synuclein alpha modulator; Protein DJ1 modulator	Neuroprotectant; Antiparkinsonian
781.	**Discovery	AFFiRIS AG	PD-01	Parkinsons disease	Synuclein alpha inhibitor; Therapeutic vaccine	Antiparkinsonian
782.	**Discovery	Bioarctic Neuroscience AB	PD-0805	Parkinsons disease; Lewy body dementia	Synuclein alpha modulator	Nootropic agent; Antiparkinsonian
783.	**Discovery	Takeda Pharmaceutical Co Ltd	PDE1 inhibitors (oral, cognitive disorders)	Cognitive disorder	PDE 1 inhibitor	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
784.	*Discontinued (Discovery)	Pfizer Inc	PDE10A inhibitors (psychosis)	Psychiatric disorder; Neurodegenerative disease	PDE 10 inhibitor	Antipsychotic; Neuroprotectant
785.	**Discovery	Biocrea GmbH	PDE 10 inhibitors (CNS disorders)	Schizophrenia; Central nervous system disease	PDE 10 inhibitor	Antipsychotic
786.	**Discovery	Biocrea GmbH	PDE 2 inhibitors (mild cognitive impairment)	Mild cognitive impairment	PDE 2 inhibitor	Neuroprotectant
787.	Phase 1	University of Auckland/Cornell University	PD gene therapy	Parkinson disease	Adenovirus based gene therapy; Unspecified drug target	Antiparkinsonian
788.	*Phase 2 (Phase 1)	Halozyne Therapeutics Inc	PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer)	Pancreas tumor; Stroke; Solid tumor	Hyaluronidase stimulator	Anticancer
789.	**Phase 3	Biogen Idec Inc	PEGylated IFN beta 1-a (multiple sclerosis)	Multiple sclerosis	Interferon beta ligand	Immuno-modulator
790.	Discovery	CoDa Therapeutics (NZ) Ltd	Peptagon	Stroke	Gap junction pathway modulator	Neuroprotectant
791.	**Discovery	ProteoTech Inc	Pepticlere	Alzheimers disease	Amyloid protein deposition inhibitor; Laminin modulator	Neuroprotectant
792.	*Pre-registration (Phase 3)	Eisai Co Ltd	Perampanel	Epilepsy; Multiple sclerosis; Migraine; Diabetic neuropathy; Neuropathic pain; Postherpetic neuralgia	AMPA receptor antagonist	Neuroprotectant; Anticonvulsant agent; Analgesic; Antiparkinsonian
793.	Phase 2	Cerevast Therapeutics Inc	Perfluoropropane gas-filled nanobubbles (SonoLysis)	Stroke; Thrombosis	Unspecified drug target	Coagulation inhibitor
794.	*Phase 3 (Phase 2)	Proneuron Biotechnologies Inc	Personalized macrophage cell therapy (acute complete spinal cord injury)	Spinal cord injury	Macrophage modulator	Neuroprotectant
795.	**Discovery	AC Immune SA	PET imaging agent (Alzheimer's disease)	Alzheimers disease	PET contrast agent	Radiodiagnostic; CNS diagnostic agent
796.	**Phase 1	Janssen Alzheimer Immunotherapy/Pfizer Inc	PF-05236812	Alzheimers disease	Beta amyloid modulator	Neuroprotectant
797.	*Phase 2 (Phase 1)	Pfizer Inc/EnVivo Pharmaceuticals Inc	PF-2545920	Schizophrenia; Huntingtons chorea	PDE 10 inhibitor	Antipsychotic; Nootropic agent
798.	*Discontinued (Phase 2)	Pfizer Inc	PF-3654746	Alzheimers disease; Schizophrenia; Cognitive disorder; Narcolepsy	Histamine H3 receptor antagonist; Anti-inflammatory	Nootropic agent; Psychomodulator; CNS modulator
799.	Discovery	Pfizer Inc	PF-4181366	Cognitive disorder	PDE 9a inhibitor	Nootropic agent
800.	*Discontinued (Phase 2)	Pfizer Inc	PF-4447943	Alzheimers disease; Cognitive disorder	PDE 9a inhibitor	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
801.	Phase 2	Pfizer Inc	PF-4494700	Diabetic nephropathy; Alzheimers disease	Advanced glycosylation product receptor antagonist	Nootropic agent
802.	Discovery	Amicus Therapeutics Inc	Pharmacological chaperones (oral, Alzheimer's disease)	Alzheimers disease	Unspecified drug target	
803.	Discovery	Sanguine Corp	PHER-O2	Fungal infection; Bacterial infection; Cardiac failure; Stroke; Cancer	Oxygen carrier; Unspecified drug target	Anticancer; Antibacterial; Fungicide; Cardiovascular agent
804.	Discovery	Signum Biosciences Inc/ Princeton University	Phosphoprotein 2A modulators (CNS disease, diabetes)	Central nervous system disease; Diabetes mellitus; Alzheimers disease; Parkinsons disease	Hypoglycemic agent; Protein phosphatase 2A modulator; Tau aggregation inhibitor	Neuroprotectant; Antiparkinsonian
805.	Phase 2	Asubio Pharma Co Ltd	Piclozotan	Parkinsons disease; Stroke	5-HT 1a receptor agonist	Neuroprotectant; Antiparkinsonian
806.	Phase 3	ACADIA Pharmaceuticals Inc	Pimavanserin	Psychotic disorder; Movement disorder	5-HT 2a inverse agonist	Antipsychotic
807.	Discovery	Geymonat SpA	Placental growth factor (ischemic stroke)	Stroke	Placenta growth factor ligand	Angiogenesis stimulator
808.	*Phase 2 (Phase 1)	Talecris Biotherapeutics Holdings Corp	Plasmin (plasma-derived, peripheral arterial occlusion/ ischemic stroke)	Stroke; Peripheral arterial occlusive disease	Fibrinolysis stimulator; Plasmin modulator; Coagulation inhibitor	Neuroprotectant
809.	**Discovery	Helicon Therapeutics Inc	Plasticity modulators (CNS diseases)	CNS disease	Unspecified gene inhibitor	Neuroprotectant; Nootropic agent
810.	**Discovery	Scripps Research Institute/Massachusetts Institute of Technology	PME-1 inhibitors (neurodegenerative disorders/cancer)	Neurodegenerative disease; Cancer	Protein phosphatase methylesterase 1 inhibitor	Anticancer; Neuroprotectant
811.	Discovery	Proneuron Biotechnologies Inc	PN-277	Spinal cord injury; Neurodegenerative disease; Glaucoma; Stroke; Parkinsons disease	An immunomodulating oligopeptide with neuroprotectant activity	Neuroprotectant; Immuno-modulator; Antiglaucoma agent; Antiparkinsonian
812.	**Discovery	Wellstat Therapeutics Corp (Wellstat Management Company LLC)	PN-403	Alzheimers disease; Mitochondrial disease	Unspecified drug target	Nootropic agent
813.	**Discovery	Elan Corp plc	Polo-like kinase 2 modulator (Parkinson's disease)	Parkinsons disease	Polo-like kinase 2 modulator	Antiparkinsonian
814.	*Phase 3 (Phase 2)	Eli Lilly & Co	Pomaglumetad methionil; former LY-2140023	Schizophrenia	Metabotropic glutamate receptor 2 agonist; Metabotropic glutamate receptor 3 agonist	Antipsychotic
815.	**Phase 2	Actelion Ltd	Ponesimod	Multiple sclerosis; Psoriasis; Autoimmune disease	Systemic antipsoriatic product; Sphingosine-1-phosphate receptor-1 agonist	Immuno-modulator; Anti-inflammatory
816.	*Discontinued (Phase 2)	Pfizer Inc	Ponezumab	Alzheimers disease	Beta amyloid antagonist	Neuroprotectant; Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
817.	Discovery	University of Kuopio/ Finncover Oy	POP inhibitor (Alzheimers)	Alzheimers disease	Prolylendopeptidase inhibitor	Neuroprotectant
818.	Phase 2	QR Pharma Inc	Posiphen	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta- secretase inhibitor; Acetylcholinesterase inhibitor	Nootropic agent; Neuroprotectant
819.	**Discovery	Vanderbilt University	Positive allosteric mGluR4 modulators (Parkinson's disease)	Parkinsons disease	Metabotropic glutamate receptor 4 modulator	Antiparkinsonian
820.	Phase 2	Abbott Laboratories	Pozanicline	Attention deficit hyperactivity disorder; Nicotine dependence	Nicotinic ACh receptor alpha 4 subunit stimulator; Nicotinic ACh receptor beta 2 subunit stimulator; Nicotinic ACh receptor partial agonist	Antipsychotic; Nootropic agent
821.	**Discovery	GlaxoSmithKline plc	PPAR gamma agonists	Multiple sclerosis; Atherosclerosis; Non- insulin dependent diabetes	Insulin sensitizer; PPAR gamma agonist	Hypoglycemic agent
822.	**Phase 1	Probiobdrug AG	PQ-912	Alzheimers disease	Glutaminy peptide cyclotransferase inhibitor; Amyloid protein deposition inhibitor	Neuroprotectant
823.	Phase 1	NeuroScience Pharmaceuticals Inc	Pregnenolone (schizophrenia)	Schizophrenia	Steroid hormone antagonist	Antipsychotic
824.	*Phase 3 (Phase 2)	Merck & Co Inc	Preladenant	Parkinsons disease	Adenosine A2a receptor antagonist	Antiparkinsonian; Antidepressant
825.	**Discovery	UCB Pharma SA/ University of North Carolina	Primary amino acid derivatives (anticonvulsant and neuropathic pain)	Epilepsy; Neuropathic pain	Unspecified drug target	Analgesic; Anticonvulsant agent
826.	*No development reported (Discovery)	Samaritan Pharmaceuticals Inc/ Pharmaplatz Ltd	Procaine hydrochloride	Alzheimers disease; HIV infection; Cushings disease	Corticosteroid antagonist; HIV uptake inhibitor; Anticancer hormone antagonist	Anticancer; Immuno- modulator; Nootropic agent
827.	Discovery	Endogenous Stem Cells Activators Inc	Propentofylline	Alzheimers disease	PDE inhibitor; Stem cell modulator	Antiarterio- sclerotic
828.	*Discontinued (Discovery)	Vyrex Corp	Propofol phosphate	Anesthesia; Neurological disease	A water-soluble prodrug of the anesthetic propofol that has demonstrated antioxidant and anti- inflammatory properties	Anesthetic; Anxiolytic; Hypnotic; Anti- inflammatory; Antioxidant agent
829.	**Phase 2	Oxford BioMedica plc	ProSavin	Parkinsons disease	Dopamine synthesis stimulant; Retrovirus based gene therapy; GTP cyclohydrolase-I stimulator; Tyrosine hydroxylase stimulator; Dopa decarboxylase stimulator	Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
830.	Discovery	Cambria Pharmaceuticals Inc	Protein misfolding therapies (ALS)	Motor neurone disease	Unspecified drug target	Neuroprotectant
831.	Discovery	Siena Biotech SpA	Protein-protein inhibitors (Alzheimer's disease)	Alzheimers disease		Neuroprotectant; Nootropic agent
832.	*No development reported (Phase 1)	PharmAthene Inc	Protexia; former PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure)	Alzheimers disease; Toxicity	Cholinesterase stimulator	Neuroprotectant; Antidote
833.	Discovery	Upsher-Smith Laboratories Inc	PRX-1	Parkinsons disease	Dopamine receptor agonist	Antiparkinsonian
834.	Phase 2	Nanotherapeutics Inc	PRX-3140	Alzheimers disease; Post traumatic stress disorder	5-HT 4 receptor agonist; Acetylcholine release stimulator; Brain derived neurotrophic factor ligand	Nootropic agent
835.	*No development reported (Discovery)	Proximagen Group plc	PRX-5 program (cognitive decline/ parkinsons disease)	Cognitive disorder; Parkinsons disease	Dopamine D1 receptor agonist	Nootropic agent; Antiparkinsonian
836.	**Discovery	Proximagen Group plc	PRX-6 gene therapy (Parkinson's disease)	Parkinsons disease	Apoptosis inhibitor; Gene therapy; Unspecified drug target	Neuroprotectant; Antiparkinsonian
837.	Discovery	Protagenic Therapeutics Inc	PT-00114	Anxiety disorder; Neurological disease; Injury; Major depressive disorder	Neuropeptide agonist	Neuroprotectant; Antidepressant; Anxiolytic
838.	Discovery	Protagenic Therapeutics Inc/ University of Toronto	PT-00121	Anxiety disorder; Major depressive disorder	Unspecified drug target	Antidepressant; Anxiolytic
839.	Discovery	Protagenic Therapeutics Inc	PT-00311	Neurological disease; Injury	Neuropeptide agonist	Neuroprotectant
840.	*Phase 1 (Discovery)	Memorial Sloan-Kettering Cancer Center	PU-H71; former Hsp90 inhibitors	Alzheimers disease; Cancer; Multiple sclerosis	Hsp 90 inhibitor	Anticancer; Neuroprotectant; Anti-inflammatory
841.	Phase 1	Phytopharm plc	PYM-50018	Motor neurone disease; Neuromuscular disease; Glaucoma	Adrenergic modulator	Neuroprotectant; Cardioprotectant
842.	Phase 2	Phytopharm plc	PYM-50028	Alzheimers disease; Parkinsons disease; Motor neurone disease; Glaucoma	Dopamine modulator; Neuronal growth factor receptor agonist; Muscarinic M1 receptor modulator; Glial cell neurotrophic factor ligand modulator; Brain derived neurotrophic factor ligand modulator	Neuroprotectant; Nootropic agent; Antiparkinsonian
843.	Phase 2	Quigley Pharma Inc	QR-333	Diabetic neuropathy	Aldose reductase inhibitor	Neuroprotectant; Antioxidant agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
844.	*No development reported (Phase 2)	Gedeon Richter Ltd/ Forest Laboratories Inc	Radiprodil	Neuropathic pain; Pain	NMDA receptor antagonist	Analgesic
845.	Phase 3	Newron Pharmaceuticals SpA	Ralfinamide	Neuropathic Pain; Pain; Psychiatric disorder	Sodium channel inhibitor; Calcium channel inhibitor N-type; NMDA receptor antagonist	Analgesic; Antipsychotic
846.	**Discovery	Syntaxin Ltd/Ipsen	Recombinant botulinum toxin targeted secretion inhibitors (neurological disorder)	Neurological disease	Acetylcholine receptor antagonist; Neuromuscular blocking agent	
847.	*No development reported (Discovery)	Shanghai Wanxing Bio-Pharmaceutical Co Ltd	Recombinant human kallikrein (rhK1) (ischemia/ thrombosis)	Thrombosis; Peripheral vascular disease; Stroke	Coagulation inhibitor; Kallikrein stimulator	
848.	*Phase 1 (Discovery)	ReNeuron Group plc	ReN-001	Stroke	Stem cell modulator	Neuroprotectant
849.	Discovery	ReNeuron Group plc	ReN-004	Alzheimers disease; Parkinsons disease	Stem cell therapy	Neuroprotectant; Nootropic agent; Antiparkinsonian
850.	Discovery	ReNeuron Group plc	ReN-005	Huntingtons chorea	Stem cell therapy	Neuroprotectant
851.	**Discovery	Biovista Inc	Repositioned compounds (neurological diseases/depression)	Neurological disease; Major depressive disorder	Unspecified drug target	Nootropic agent; Antidepressant; Antiparkinsonian; Anticonvulsant agent
852.	Discovery	reMYND NV/Roche Holding AG	ReS9-S7	Parkinsons disease	Synuclein alpha modulator; Vesicular transporter modulator	Antiparkinsonian
853.	*Discontinued (Phase 2)	Sirtris Pharmaceuticals Inc	Resveratrol (metabolic disorder)	Huntingtons chorea; Neurodegenerative disease; Obesity; MELAS syndrome; Cancer; Non-insulin dependent diabetes; Diabetes mellitus	NAD-dependent deacetylase sirtuin-1 stimulator; Lipid metabolism stimulator; Hypoglycemic agent	Anticancer; Neuroprotectant; Nootropic agent
854.	*Launched (Phase 3)	Valeant Pharmaceuticals International/ GlaxoSmithKline plc	Retigabine	Postherpetic neuralgia; Epilepsy	GABA A agonist; Potassium channel activator	Anticonvulsant agent; Vasodilator
855.	Phase 1	Valeant Pharmaceuticals International/ GlaxoSmithKline plc	Retigabine (sustained release)	Epilepsy	GABA A agonist; Potassium channel stimulator	Anticonvulsant agent; Vasodilator
856.	Phase 1	Trigen GmbH/ Corimmun GmbH	Revacept; former PR-15	Coronary thrombosis; Atherosclerosis; Stroke	Platelet aggregation inhibitor; Unspecified drug target	Coagulation inhibitor
857.	**Phase 2	Glenmark Pharmaceuticals Ltd	Revamilast	Inflammatory disease; Multiple sclerosis; Rheumatoid arthritis; Asthma	PDE 4 inhibitor	Anti-inflammatory

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
858.	**Phase 1	Roche Holding AG	RG-1577	Alzheimers disease	MAO B inhibitor	Neuroprotectant; Nootropic agent; Antiparkinsonian
859.	Phase 1	Hoffmann-La Roche AG	RG-1578; former R-1578	Major depressive disorder	Metabotropic glutamate receptor 2 antagonist	Nootropic agent; Antidepressant
860.	Phase 1	Roche Holding AG	RG-1662	Cognitive disorder; Down syndrome	GABA A receptor alpha-5 subunit modulator; GABA A receptor inverse agonist	Nootropic agent
861.	**Discovery	Repligen Corp	RG-2833	Friedreich ataxia	FXN gene stimulator; Histone deacetylase-1 inhibitor	Neuroprotectant
862.	**Phase 1	Repligen Corp	RG-3039	Spinal muscular atrophy	SMN1 gene stimulator; mRNA decapping enzyme inhibitor	
863.	**Phase 2	Chungai Pharmaceuticals Co Ltd/ F Hoffmann-La Roche Ltd	RG-7090	Major depressive disorder; Fragile X syndrome	Metabotropic glutamate receptor 5 antagonist	Nootropic agent; Antidepressant
864.	**Phase 1	Roche Holding AG	RG-7129	Alzheimers disease	Beta amyloid synthesis inhibitor; Beta secretase inhibitor	Neuroprotectant
865.	*No development reported (Discovery)	BioAxone Therapeutique Inc	Rho kinase inhibitors (neurodegenerative disorders)	Neurodegenerative disease	Rho associated protein kinase inhibitor	Neuroprotectant
866.	**Phase 2	GlaxoSmithKline plc	Rilapladib	Alzheimers disease; Atherosclerosis	Antiartherosclerotic; Phospholipase A2 inhibitor	Nootropic agent
867.	Discovery	Targeted Genetics Corp	RNAi therapy (Huntington's disease)	Huntingtons chorea	Huntington modulator; siRNA agent	Neuroprotectant
868.	**Discovery	Roche Holding	RO-4491533	Cognitive disorder	Metabotropic glutamate receptor 2 antagonist; Metabotropic glutamate receptor 3 antagonist	Nootropic agent
869.	**Phase 1	F Hoffmann-La Roche Ltd	RO-5508887	Alzheimers disease		Nootropic agent
870.	*No development reported (Phase 2)	UCB SA	Rotigotine (nasal spray)	Parkinsons disease; Restless leg syndrome	Dopamine D2 receptor agonist	Antiparkinsonian
871.	Discovery	Reviva Pharmaceuticals Inc	RP-4000	Alzheimers disease		Nootropic agent; Neuroprotectant
872.	*Phase 1	Reviva Pharmaceuticals Inc	RP-5000	Schizophrenia		Antidepressant; Antipsychotic
873.	**Discovery	Reviva Pharmaceuticals Inc	RP-6000	Major depressive disorder		Antidepressant
874.	*No development reported (Discovery)	Reata Pharmaceuticals Inc	RTA-404	Alzheimers disease; Multiple sclerosis; Parkinsons disease; Brain tumor	Unspecified cytokine receptor antagonist	Anticancer; Neuroprotectant; Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
875.	**Discovery	Reata Pharmaceuticals Inc	RTA-801	Motor neurone disease	Superoxide dismutase modulator	Neuroprotectant
876.	Phase 1	RaQualia Pharma Inc	RQ-00000009	Alzheimers disease	5-HT 4 receptor partial agonist; Beta amyloid synthesis inhibitor; Acetylcholine release stimulator	Neuroprotectant; Nootropic agent
877.	Phase 1	Resverlogix Corp	RVX-208 (Alzheimer's disease)	Alzheimers disease	HDL cholesterol enhancer; Apolipoprotein gene stimulator; Amyloid protein deposition inhibitor	Antiartherio-sclerotic
878.	**Discovery	Resverlogix Corp	RVX-297	Multiple sclerosis	IL-17 release inhibitor; IL-6 release inhibitor	Neuroprotectant; Anti-inflammatory
879.	*No development reported (Phase 2)	Shionogi & Co Ltd	S-0139	Stroke	Endothelin ET-A antagonist	Cerebro-protectant
880	**Discovery	Servier	S-24795	Alzheimers disease	Nicotinic ACh receptor alpha 7 subunit modulator; Beta amyloid antagonist	Neuroprotectant
881.	*No development reported (Phase 2)	Servier	S-33138	Schizophrenia	Dopamine D3 antagonist	Antipsychotic
882.	*Phase 2 (Discovery)	Servier	S-38093; former histamine H3 antagonists (sleep/cognitive disorders)	Alzheimers disease; Sleep disorder; Cognitive disorder	Histamine H3 receptor antagonist	Nootropic agent
883.	**Phase 1	Servier	S-47445	Cognitive disorder	AMPA receptor modulator	Neuroprotectant; Nootropic agent
884.	Phase 2	Proximagen Group plc/BrainCells Inc	Sabcomeline	Schizophrenia; Non-insulin dependent diabetes	Muscarinic M1 modulator; Muscarinic receptor partial agonist	Nootropic agent; Antipsychotic; Antidepressant
885.	Phase 3	Merck Serono SA	Safinamide	Parkinsons disease	Calcium channel modulator; Dopamine uptake inhibitor; MAO B inhibitor; Sodium channel inhibitor; Glutamate release inhibitor	Neuroprotectant; Antiparkinsonian; Anticonvulsant agent
886.	*Discontinued (Phase 2)	Pfizer Inc	SAM-531	Alzheimers disease	5-HT 6 receptor antagonist	Nootropic agent; Neuroprotectant; Antipsychotic
887.	**Phase 1	Pfizer Inc	SAM-760	Alzheimers disease	5-HT 6 receptor antagonist	Nootropic agent
888.	**Discovery	Sanomune Inc	SAN-161	Alzheimers disease	Glycogen synthase kinase-3 beta inhibitor; Beta amyloid antagonist; Natural product	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
889.	**Phase 1	Sanofi	SAR-104772	Stroke	Thrombin-active fibrinolysis inhibitor inhibitor	Coagulation inhibitor
890.	*Phase 2 (Phase 1)	Sanofi	SAR-110894	Alzheimers disease; Cognitive disorder	Histamine H3 receptor antagonist	Nootropic agent
891.	**Phase 1	Sanofi	SAR-126119	Stroke	Thrombin-active fibrinolysis inhibitor inhibitor	Coagulation inhibitor
892.	**Phase 1	Glenmark Pharmaceuticals Ltd/ Sanofi	SAR-339658	Inflammatory bowel disease; Multiple sclerosis; Crohns disease	Integrin antagonist; CD49b antagonist	Anti-inflammatory
893.	*Discontinued (Discovery)	GlaxoSmithKline plc	SB-277011	Drug dependence	Dopamine D3 antagonist	Antipsychotic
894.	*Phase 2 (Discovery)	Sanbio Inc/Teijin Ltd	SB-623; former bone marrow-derived mesenchymal stem cell therapy (intravenous, stroke)	Stroke; Neurological disease		Neuroprotectant; Cerebro-protectant
895.	Phase 2	GlaxoSmithKline plc	SB-742457	Alzheimers disease	5-HT 6 antagonist; 5-HT 2a receptor antagonist	Antipsychotic; Nootropic agent
896.	**Discovery	Icogenex Corp	SBIM therapeutics (Huntington's disease)	Huntingtons chorea	Huntingtin inhibitor	Neuroprotectant
897.	*No development reported (Phase 2)	Merck & Co Inc	SCH-900435	Alcoholism; Panic disorder; Schizophrenia	Glycine transporter-1 inhibitor	Antipsychotic
898.	**Discovery	Acure Pharma AB/ AnaMar Medical AB	SCI program	Spinal cord injury	Melanocortin agonist	Neuroprotectant; Anti-inflammatory
899.	Phase 1	Scios Inc	SCIO-323	Myelodysplastic syndrome; Multiple myeloma; Rheumatoid arthritis; Stroke; Diabetes mellitus	p38 MAP kinase inhibitor; TNF alpha synthesis inhibitor	Anti-inflammatory; Anticancer
900.	Discovery	Taisho Pharmaceutical Co Ltd	SEA-0400	Stroke	Na+ Ca2+ ion exchange inhibitor	Neuroprotectant
901.	**Discovery	Kareus Therapeutics SA	Second generation DMAD project (Alzheimer's disease)	Alzheimers disease	Unspecified drug target	Neuroprotectant
902.	Discovery	ALSP Inc	Secretase inhibitors (Alzheimers disease)	Alzheimers disease	Cathepsin B inhibitor; Secretase inhibitor	
903.	**Phase 3	Novartis AG	Secukinumab	Psoriatic arthritis; Multiple myeloma; Multiple sclerosis; Psoriasis; Polymyalgia rheumatica; Rheumatoid arthritis; Xerophthalmia; Uveitis; Ankylosing spondylitis; Crohns disease	IL-17 antagonist	Systemic antipsoriatic product; Anticancer; Anti-inflammatory
904.	**Discovery	Selvita Life Sciences Solutions/Orion Corp	SEL-103	Alzheimers disease	Unspecified drug target	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
905.	Discovery	ExonHit Therapeutics Inc	Selective Rac1/1b GTPase nucleotide binding inhibitors (cancer/Alzheimer's disease)	Alzheimers disease; Cancer	Anticancer; RAC1 GTPase inhibitor	Neuroprotectant; Nootropic agent
906.	Discovery	University of Manchester	SEM-606	Neurological disease	Beta amyloid synthesis inhibitor	Neuroprotectant
907.	*Discontinued (Phase 3)	Eli Lilly & Co	Semagacestat	Alzheimers disease	Beta amyloid synthesis inhibitor; Gamma-secretase inhibitor	Neuroprotectant; Nootropic agent
908.	**Discovery	Senexis Ltd	SEN-1176	Alzheimers disease	Interleukin-1 beta ligand inhibitor; Beta amyloid modulator; NO synthesis inhibitor; Anti-inflammatory; TNF alpha ligand inhibitor; IL-6 antagonist	Neuroprotectant; Nootropic agent
909.	*Phase 2 (Phase 1)	Siena Biotech SpA	SEN-196	Huntingtons chorea	NAD-dependent deacetylase sirtuin-1 inhibitor	Neuroprotectant; Nootropic agent
910.	Discovery	DNAVEC Corp	SeV-amyloid beta RNA vaccine (intranasal, Alzheimer's disease)	Alzheimers disease	Recombinant viral vector vaccine; Therapeutic vaccine; RNA vaccine; Beta amyloid antagonist	Nootropic agent
911.	**Discovery	DNAVEC Corp	SeV gene vaccine (virus recombinant, Parkinson's disease)	Parkinsons disease	Recombinant viral vector vaccine; RNA vaccine	
912.	**Discovery	UCB SA	Sigma-1 ligands (cognitive disorders)	Cognitive disorder	Opioid receptor sigma modulator 1	Nootropic agent
913.	Discovery	Silamed Inc	Silicon-modified indomethacin (cancer)	Alzheimers disease; Arthritis; Cancer	Non-steroidal anti-inflammatory; Cyclooxygenase 2 inhibitor	Anticancer; Neuroprotectant
914.	**Discovery	Simcere Pharmaceutical Group	SIM-071201	Cerebrovascular disease	Unspecified drug target	Cerebro-protectant; Vascular agent
915.	**Discovery	SK biopharmaceuticals	SKL-A4R	Alzheimers disease	Unspecified drug target	Nootropic agent
916.	**Phase 2	SK biopharmaceuticals/ Shionogi & Co Ltd	SKL-N05	Narcolepsy; Cocaine addiction; Major depressive disorder	Antidepressant; Analgesic	Sigma opioid receptor modulator; CNS modulator
917.	**Discovery	SK biopharmaceuticals	SKL-PD	Parkinsons disease; CNS disease	MAO B inhibitor; Antiparkinsonian	Neuroprotectant
918.	*Phase 3 (Discovery)	SK Chemicals Life Science	SK-PC-B70M	Alzheimers disease	Beta amyloid modulator	Neuroprotectant; Nootropic agent
919.	Phase 1	Abbott Laboratories	SLV-338	Cardiovascular disease; Metabolic disorder; Neurological disease	Neutral endopeptidase inhibitor; Endothelin converting enzyme inhibitor	Neuroprotectant; Cardiovascular agent
920.	**Phase 1	Abbott Laboratories	SLV-354	Neurological disease	Unspecified drug target	CNS modulator

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
921.	**Discovery	Cognosci Inc	Small molecule protein phosphatase 2A stimulators (Alzheimers disease)	Alzheimers disease	Protein phosphatase 2A stimulator	Neuroprotectant
922.	**Discovery	Genzyme Corp (Sanofi)/Isis Pharmaceuticals Inc	SMN promoter activators (spinal muscular atrophy)	Spinal muscular atrophy	SMN1 gene stimulator; Antisense oligonucleotide inhibitor	Neuroprotectant
923.	Discovery	Yantai University	SMND-309	Myocardial infarction; Stroke	Unspecified drug target	Neuroprotectant; Cardioprotectant
924.	Phase 2	NeuroNova AB	sNN-0029	Motor neurone disease; Central nervous system disease	VEGF ligand	Neuroprotectant
925.	Phase 2	NeuroNova AB	sNN-0031	Parkinsons disease	PDGF receptor agonist	Neuroprotectant; Antiparkinsonian
926.	Discovery	Amorfix Life Sciences Ltd/Pan-Provincial Vaccine Enterprise Inc	SOD1-targeting antibody (injection; Alzheimer's disease/ ALS)	Alzheimers disease; Motor neurone disease	Superoxide dismutase modulator; Vaccine	Neuroprotectant
927.	Phase 2	Abbott Laboratories	Sofinicine	Attention deficit hyperactivity disorder; CNS disease; Nicotine dependence	Nicotinic ACh receptor alpha 4 subunit modulator; Nicotinic ACh receptor beta 2 subunit modulator; Nicotinic ACh receptor agonist	Psychomodulator; Analgesic
928.	Phase 3	Eli Lilly & Co	Solanezumab	Alzheimers disease	Beta amyloid modulator	Neuroprotectant
929.	Phase 1	PAION AG	Solulin	Nervous system injury; Lung embolism; Stroke; Radiation sickness; Hemophilia	Factor IIa antagonist; Thrombomodulin modulator; Coagulation inhibitor	Neuroprotectant; Radioprotectant
930.	Discovery	Samaritan Pharmaceuticals Inc	SP-004	Alzheimers disease	Acetylcholinesterase inhibitor; Opioid receptor sigma antagonist 1	Neuroprotectant
931.	Discovery	Samaritan Pharmaceuticals Inc	SP-08	Alzheimers disease	Amyloid protein deposition inhibitor; Beta amyloid antagonist	Neuroprotectant
932.	Discovery	Samaritan Pharmaceuticals Inc	SP-233	Alzheimers disease	Amyloid protein deposition inhibitor; Beta amyloid antagonist	Neuroprotectant; Nootropic agent; Antiparkinsonian
933.	**Discovery	Nymox Pharmaceutical Corp	Spheron-based therapeutics (Alzheimers)	Alzheimers disease	Unspecified drug target	Neuroprotectant
934.	Discovery	Satori Pharmaceuticals Inc	SPI-014	Alzheimers disease	Amyloid protein deposition inhibitor; Gamma-secretase modulator	Neuroprotectant
935.	Phase 1	Sucampo Group	SPI-017 (intravenous, peripheral arterial and vascular disease/ stroke)	Peripheral vascular disease; Stroke	Ion modulator	Vascular agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
936.	Discovery	Sucampo Group	SPI-017 (oral, Alzheimer's disease)	Alzheimers disease	Ion modulator	
937.	Phase 1	EndogenX Inc/ Spectrum Pharmaceuticals Inc	SPI-1620	Brain injury; Stroke; Cancer	Diuretic agent; Anticancer chemosensitizer; Endothelin ET-B agonist	
938.	**Discovery	Sucampo Pharmaceuticals Inc (Sucampo Group)	SPI-3608	Spinal stenosis	Unspecified ion channel modulator	
939.	Discovery	AstraZeneca plc	Spirofuropyridine alpha-7 neuronal nicotinic receptor agonists (cognitive disorder)	Cognitive disorder	Nicotinic Ach receptor alpha 7 subunit modulator	Nootropic agent
940.	**Discovery	Scripps Research Institute	SR-1001	Multiple sclerosis	IL-17 release inhibitor; T-lymphocyte inhibitor	Anti-inflammatory; Immuno-suppressant
941.	Phase 2	Sonexa Therapeutics/ Zenyaku Kogyo Co Ltd	ST-101; former ZSET-1446	Cognitive disorder; Major depressive disorder; Alzheimers disease; Tremor	Acetylcholine release stimulator; CAM kinase kinase beta stimulator	Neuroprotectant; Nootropic agent; Antidepressant
942.	**Discovery	University of California San Diego (University of California)/Life Technologies Corp/ The Salk Institute for Biological Studies	Stem cell-derived astrocytes (ALS)	Motor neurone disease	Astrocyte modulator	Neuroprotectant
943.	Discovery	Samaritan Pharmaceuticals Inc	Stem cell therapeutics (non-embryonic, Alzheimer's disease/ neurodegeneration)	Alzheimers disease; Neurodegenerative disease	Neuronal stem cell differentiation therapy drugs, including the naturally occurring compounds SP-sc4 and SP-sc7, to induce stem cell differentiation	Nootropic agent; Neuroprotectant
944.	**Discovery	Medipost Co Ltd/ Genexine Co Ltd	Stem cell therapy (spinal cord injury)	Spinal cord injury	BDNF gene stimulator	Gene therapy; Stem cell stimulator
945.	**Clinical	Stemedica Cell Technologies Inc	Stem cell therapy (vascular dementia/ Alzheimer's disease)	Alzheimers disease; Vascular dementia		Nootropic agent
946.	*No development reported (Discovery)	University of Miami	Stilbazulenyl nitron	Stroke; Brain injury; Ischemic heart disease	Azulenyl nitron-based antioxidant	Neuroprotectant; Antioxidant agent; Cardioprotectant
947.	Discovery	Dong Wha Pharmaceutical Industry Co Ltd	Stroke program	Stroke	Unspecified drug target	Neuroprotectant
948.	**Discovery	NuvOx Pharma LLC	Stroke program	Stroke		Cerebro-protectant
949.	Phase 1	Seaside Therapeutics LLC	STX-107	Fragile X syndrome; Autism	Metabotropic glutamate receptor 5 antagonist	Nootropic agent; Antipsychotic

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
950.	Phase 1	Cecoura Therapeutics Inc	SUN-N8075	Stroke	Calcium channel inhibitor T-type; Na+ Ca2+ ion exchange inhibitor; Sodium channel inhibitor	Neuroprotectant; Vasodilator; Antioxidant agent
951.	**Discovery	Daewoong Pharmaceutical Co Ltd	Sustained release incrementally modified drug (Alzheimers disease)	Alzheimers disease	Unspecified drug target	Nootropic agent
952.	Phase 1	Suven Life Sciences Ltd	SUVN-502	Alzheimers disease; Neurological disease	5-HT 6 receptor antagonist	Nootropic agent
953.	Discovery	Suven Life Sciences Ltd	SUVN-507	Neurological disease; Schizophrenia	5-HT 6 receptor antagonist	Nootropic agent; Neuroprotectant; Antipsychotic
954.	*No development reported (Discovery)	Aida Pharmaceuticals Inc	SY-02	Stroke	Coagulation inhibitor; Unspecified drug target	Cerebro-protectant
955.	Discovery	SYGNIS Pharma AG	SY-300	Neurodegenerative disease	Apoptosis inhibitor; Unspecified drug target	Neuroprotectant
956.	Phase 1	Biotie Therapies Holding AG	SYN-114	Cognitive disorder	5-HT 6 antagonist	Nootropic agent
957.	*No development reported (Phase 1)	Biotie Therapies Holding AG	SYN-116	Pain	Prostacyclin antagonist; IP prostanoid receptor antagonist	Analgesic
958.	*No development reported (Discovery)	Biotie Therapies Holding AG	SYN-119	Drug dependence	Metabotropic glutamate receptor 1 agonist	
959.	Phase 1	Biotie Therapies Holding AG	SYN-120	Cognitive disorder	5-HT 6 receptor antagonist	Nootropic agent
960.	**Discovery	ProteoTech Inc	Synucleure	Parkinsons disease	Synuclein alpha inhibitor	Neuroprotectant; Antiparkinsonian
961.	Phase 2	Taro Pharmaceutical Industries Ltd	T-2000	Tremor; Myoclonus	Non-sedating barbiturate; Unspecified drug target	Anticonvulsant agent; Cerebro-protectant
962.	*No development reported (Discovery)	Taro Pharmaceutical Industries Ltd	T-2001	Stroke	Neuroprotective barbiturate	Neuroprotectant; Cerebro-protectant
963.	Phase 1	Taro Pharmaceutical Industries Ltd	T-2007	Epilepsy	GABA A receptor agonist	Anticonvulsant agent
964.	Phase 2	Toyama Chemical Co Ltd	T-817MA	Alzheimers disease	Benzothiophene derivatives; Unspecified drug target	Neuroprotectant; Nootropic agent
965.	Discovery	Universitat Autònoma de Barcelona	Tacrine-huperzine A hybrids (huprines) (Alzheimer's disease)	Alzheimers disease	Acetylcholinesterase inhibitor; Muscarinic M1 receptor agonist; Nicotinic acetylcholine receptor agonist	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
966.	*Pre-registration (Phase 3)	FoldRx Pharmaceuticals Inc	Tafamidis	Amyloid polyneuropathy; Myocardial disease	Transthyretin modulator; Amyloid protein deposition inhibitor	
967.	*No development reported (Discovery)	Berlex Biosciences	TAFI inhibitors (thrombosis/ myocardial infarction/stroke); former TAFI inhibitors	Thrombosis; Coronary thrombosis; Myocardial infarction; Cerebrovascular ischemia	Thrombin-active fibrinolysis inhibitor; Fibrinolysis stimulator; Plasmin modulator	
968.	*Discontinued (Phase 1)	Takeda Pharmaceutical Co Ltd	TAK-065	Alzheimers disease; Parkinsons disease	Unspecified drug target	Neuroprotectant; Antiparkinsonian; Nootropic agent
969.	*No development reported (Phase 2)	Teva Pharmaceutical Industries Ltd	Talampanel	Motor neurone disease; Glioblastoma; Glioma	AMPA receptor agonist	Neuroprotectant; Antiparkinsonian; Anticonvulsant agent; Anticancer
970.	**Discovery	Siemens Medical Solutions Molecular Imaging (Siemens AG)	Tau-binding PET tracer (Alzheimer disease)	Alzheimers disease	Tau protein modulator	PET contrast agent; CNS diagnostic agent
971.	Discovery	AC Immune SA	Tau monoclonal antibodies (SupraAntigen, Alzheimer's disease)	Alzheimers disease	Tau aggregation inhibitor; Vaccine	Neuroprotectant
972.	**Discovery	Biogen Idec Inc	Tau protein modulator (neurodegenerative disease)	Neurodegenerative disease	Tau protein modulator	Neuroprotectant
973.	**Discovery	Neotope Biosciences Ltd (Elan Corp plc)	Tau-targeted antibody therapy (Alzheimer's disease)	Alzheimers disease	Tau protein modulator	Neuroprotectant
974.	Discovery	AC Immune SA	Tau vaccine (SupraAntigen, Alzheimer's disease)	Alzheimers disease	Tau aggregation inhibitor; Therapeutic vaccine	Neuroprotectant
975.	Phase 2	ThrombGenics NV/ BioInvent International AB	TB-402	Heart arrhythmia; Phlebothrombosis; Stroke; Atrial fibrillation	Factor VIII antagonist; Coagulation inhibitor	Antiarrhythmic agent
976.	*No development reported (Discovery)	Targecept Inc	TC-2429	CNS disease	Nicotinic ACh agonist	Nootropic agent; Antiparkinsonian
977.	Phase 2	Targecept Inc	TC-5619	Attention deficit hyperactivity disorder; Major depressive disorder; Alzheimers disease	Nicotinic ACh receptor alpha 7 subunit stimulator; Anti-inflammatory	Nootropic agent; Neuroprotectant; Antipsychotic; Anti-inflammatory
978.	**Discovery	SK biopharmaceuticals/ Mayo Foundation	TDP-43 inhibitors (amyotrophic lateral sclerosis)	Motor neurone disease	TAR DNA binding protein 43 inhibitor	Neuroprotectant
979.	**Discovery	Biogen Idec Inc	TDP-43 modulator (neurodegenerative disease)	Motor neurone disease	TAR DNA binding protein 43 inhibitor	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
980.	**Phase 3	Servier	Terutroban	Cerebrovascular disease; Arterial occlusive disease	Platelet aggregation inhibitor; Thromboxane A2 antagonist	Antiartherosclerotic; Coagulation inhibitor
981.	**Discovery	University of California Irvine/ NeuroRepair Inc	TGF alpha (neurological damage)	Stroke; Neurological disease	TGF alpha ligand	
982.	*Phase 2 (Phase 1)	Thrombotech technologies Ltd	THR-18	Asthma; Stroke; Chronic obstructive pulmonary disease; Myocardial infarction	Fibrinolysis stimulator; Plasminogen activator inhibitor 1 inhibitor	
983.	Phase 1	RegeneRx Biopharmaceuticals Inc/Defiante Farmaceutica Lda	Thymosin beta-4 (iv, cardiovascular disease/stroke/MS/ brain injury)	Brain injury; Cardiovascular disease; Stroke; Multiple sclerosis; Myocardial infarction	Matrix metalloprotease modulator; Keratinocyte stimulator; Thymosin beta 4 ligand; Nuclear factor kappa B inhibitor; Anti-inflammatory; Collagen modulator; Angiogenesis stimulator; Actin modulator; GDF agonist	Cardiac agent
984.	Phase 2	Noscira SA	Tideglusib; former NP-12	Alzheimers disease; CNS disease; Progressive supranuclear palsy	Tau kinase inhibitor; Amyloid protein deposition inhibitor; Glycogen synthase kinase-3 beta inhibitor	Neuroprotectant; Nootropic agent;
985.	*No development reported (Discovery)	EUSA Pharma Inc	TKP-1001	Alzheimers disease	Beta amyloid modulator	Neuroprotectant; Nootropic agent
986.	**Discovery	Addex Pharmaceuticals SA	TNFR1 negative allosteric modulators	Alzheimers disease; Multiple sclerosis; Psoriasis; Rheumatoid arthritis	Systemic antipsoriatic product; Type I TNF receptor modulator	Neuroprotectant; Anti-inflammatory
987.	*Phase 1 (Phase 2)	Proximagen Group plc/ Upsher-Smith Laboratories Inc	Tonabersat	Epilepsy	Gap junction pathway modulator	Analgesic; Anticonvulsant agent
988.	**Phase 3	Upsher-Smith Laboratories Inc	Topiramate (extended-release, epilepsy)	Epilepsy	GABA receptor agonist; NMDA receptor antagonist; Sodium channel inhibitor	Anticonvulsant agent
989.	**Phase 1	CyDex Pharmaceuticals Inc (Ligand Pharmaceuticals Inc)	Topiramate (intravenous/ Captisol, epilepsy)	Epilepsy	GABA receptor agonist; NMDA receptor antagonist; Sodium channel inhibitor	Anticonvulsant agent
990.	**Phase 2	Supernus Pharmaceuticals Inc	Topiramate (once-daily, epilepsy)	Epilepsy	GABA receptor agonist; NMDA receptor antagonist; Sodium channel inhibitor	Anticonvulsant agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
991.	Phase 2	Biotie Therapies Holding AG	Tozadenant; former SYN-115	Parkinsons disease	Adenosine A2a receptor antagonist	Antiparkinsonian; Anxiolytic; Nootropic agent
992.	**Discovery	CHDI Foundation Inc (CHDI Inc)/Evotec AG	Transglutaminase 2 inhibitors (Huntington's disease)	Huntingtons chorea	Tissue transglutaminase inhibitor	Nootropic agent
993.	**Discovery	Digna Biotech SL/ Flamel Technologies SA	Transmethylator inhibitor (oral controlled release/ Micropump, multiple sclerosis)	Multiple sclerosis	Methyltransferase inhibitor	Anti-inflammatory
994.	**Discovery	Digna Biotech SL	Transmethylator inhibitor (oral, MS/ transplant rejection)	Multiple sclerosis; Transplant rejection	Methyltransferase inhibitor	Anti-inflammatory
995.	Phase 2	Diffusion Pharmaceuticals LLC	Trans sodium crocetinate	Hemorrhagic shock; Peripheral arterial occlusive disease; Brain tumor; Ischemia	Blood substitute; Vitamin A agonist	Radiosensitizer; Anticancer
996.	**Discovery	Bristol-Myers Squibb Co/Albany Molecular Research Inc	Triple reuptake inhibitors (depression/CNS disease)	CNS disease	Dopamine uptake inhibitor; Monoamine uptake inhibitor; Norepinephrine uptake inhibitor; 5-HT uptake inhibitor	Antidepressant
997.	**Discovery	Addex Pharmaceuticals SA	TrkB negative allosteric modulators (neurodegenerative diseases)	Neurodegenerative disease	TrkB receptor modulator	Neuroprotectant
998.	*Phase 2 (Discovery)	Trophos SA	TRO-40303	Reperfusion injury	Translocator protein modulator	Neuroprotectant; Cardioprotectant
999.	Phase 2	TauRx Therapeutics Pte Ltd	TRx-0014	Dementia	Tau aggregation inhibitor	Nootropic agent
1000.	**Phase 1	TauRx Therapeutics Pte Ltd	TRx-0037	Alzheimers disease	Unspecified drug target	Nootropic agent
1001.	Phase 1	Taisho Pharmaceutical Co Ltd	TS-011	Cerebral infarction	Arachidonic acid metabolism inhibitor	Cerebro-protectant; Anti-inflammatory
1002.	*Phase 1 (Discovery)	Transition Therapeutics Inc	TT-301; former anti-neuroinflammatories (Alzheimer's disease)	CNS disease; Arthritis	Interleukin-1 beta ligand inhibitor; Monocyte chemotactic protein 1 ligand inhibitor; TNF alpha synthesis inhibitor; IL-6 antagonist; RANTES ligand inhibitor; Cytokine synthesis inhibitor	Neuroprotectant; Anti-inflammatory ; CNS modulator
1003.	Discovery	Transition Therapeutics Inc	TT-302; former MW01-5-188WH	CNS disease; Arthritis	Monocyte chemotactic protein 1 ligand inhibitor; TNF alpha ligand inhibitor; IL-6 antagonist; RANTES ligand inhibitor; Cytokine synthesis inhibitor	Neuroprotectant; CNS modulator; Anti-inflammatory

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
1004.	*Phase 1 (Discovery)	Pfizer Inc	TTP-4000	Diabetic nephropathy; Alzheimers disease	Advanced glycosylation product receptor modulator	Renal system agent
1005.	*No development reported (Discovery)	VM Discovery Inc	T-type calcium channel modulators (cancer/pain/neurological disease/cardiovascular disease)	Pain; Cardiovascular disease; Cancer; Neurological disease	Calcium channel modulator T-type; Cardiac agent	Anticancer; Neuroprotectant; Analgesic
1006.	**Phase 1	Teva Pharmaceutical Industries Ltd	TV-1390	Multiple sclerosis	Interferon beta ligand	Neuroprotectant
1007.	**Phase 1	UCB SA	UCB-0942	Epilepsy	Unspecified drug target	Anticonvulsant agent
1008.	**Discovery	Heptares Therapeutics Ltd	Undisclosed GPCR modulators (Alzheimer's disease/schizophrenia/anxiety)	Alzheimers disease; Anxiety disorder; Schizophrenia	Unspecified GPCR modulator	Neuroprotectant; Anxiolytic
1009.	*Suspended (Phase 2)	Repligen Corp	Uridine (oral)	Neurodegenerative disease; Bipolar disorder	Uracil metabolism modulator	Antidepressant
1010.	Phase 3	Wellstat Therapeutics Corp/BTG plc	Uridine triacetate	Leukopenia, drug induced; Neurodegenerative disease; Toxicity; Mitochondrial disease	Uracil metabolism modulator	Chemo-protectant; Neuroprotectant
1011.	Phase 2	Pierre Fabre SA	V-0191	Cognitive disorder	Unspecified drug target	Nootropic agent
1012.	*Phase 1 (Phase 2)	Vernalis plc	V-81444; former Vipadenant	Parkinsons disease	Adenosine A2a antagonist	Antiparkinsonian; Antidepressant; Anxiolytic
1013.	Phase 1	Merck & Co Inc	V-950	Alzheimers disease	Therapeutic vaccine; Amyloid protein deposition inhibitor	Immuno-modulator
1014.	*Phase 1 (Phase 2)	Pfizer Inc	Vabicaserin	Schizophrenia	5-HT 2c agonist; 5-HT 2b antagonist	Antidepressant; Antipsychotic
1015.	**Clinical	Neurocrine Biosciences Inc	Valnoctamide stereoisomers (epilepsy/bipolar disorder/neuropathic pain)	Epilepsy; Neuropathic pain; Bipolar disorder	Unspecified drug target	CNS modulator; Analgesic; Anticonvulsant agent
1016.	Phase 2	Pfizer Inc/Janssen Alzheimer Immunotherapy	Vanutide cridificar	Alzheimers disease	Therapeutic vaccine; Amyloid protein deposition inhibitor; Beta amyloid modulator	Nootropic agent
1017.	**Discovery	Proximagen Group plc	VAP-1	Inflammatory disease; CNS disease	Membrane copper amine oxidase modulator	Anti-inflammatory
1018.	**Discovery	Varinel Inc	VAR-10200	Age related macular degeneration; Neurodegenerative disease	MAO B inhibitor; Iron chelator	Ophthalmological agent; Neuroprotectant; Free radical scavenger; Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
1019.	Discovery	Technion Research & Development Foundation Ltd/ Weizmann Institute of Science/Varinel Inc	VAR-10300	Neurodegenerative disease	Iron chelator; MAO inhibitor; Apoptosis inhibitor	Nootropic agent; Antiparkinsonian; Antioxidant agent
1020.	**Discovery	Critical Outcome Technologies Inc	VEGFR/PDGFR kinase inhibitors (multiple sclerosis)	Multiple sclerosis	VEGF receptor antagonist; PDGF receptor antagonist	
1021.	Discovery	Oxford BioMedica plc	VEGF-targeting gene therapy (ALS, LentiVector)	Motor neuron disease	VEGF receptor agonist; Retrovirus based gene therapy	Neuroprotectant
1022.	Phase 2	Theravance Inc	Velusetrag	Alzheimers disease; Functional bowel disorder	5-HT 4 receptor agonist	Neuroprotectant; Laxative; Nootropic agent
1023.	Phase 2	GlaxoSmithKline plc/ Neurocrine Biosciences Inc	Verucerfont	Anxiety disorder; Major depressive disorder; Post traumatic stress disorder; Alcoholism; Irritable bowel syndrome	CRF-1 receptor antagonist	Antidepressant; Anxiolytic
1024.	**Discovery	Vanderbilt University	VU-0364770	Parkinsons disease	Metabotropic glutamate receptor 4 modulator	Antiparkinsonian
1025.	Phase 2	Vertex Pharmaceuticals Inc	VX-765	Epilepsy	Systemic antipsoriatic product; Anti-inflammatory; Anticonvulsant agent; Interleukin-1 converting enzyme inhibitor	Neuroprotectant; Cardioprotectant
1026.	Discovery	Xel Pharmaceuticals Inc	XEL-001HG	Alzheimers disease	Acetylcholinesterase inhibitor; Beta amyloid modulator; NMDA receptor antagonist	Neuroprotectant; Nootropic agent; Antioxidant agent
1027.	Phase 1	Xel Pharmaceuticals Inc	XEL-001HP; former Huperzine A (transdermal patch, Alzheimer's disease)	Alzheimers disease	Acetylcholinesterase inhibitor; Beta amyloid modulator; NMDA receptor antagonist	Neuroprotectant; Antioxidant agent
1028.	Phase 2	Auris Medical AG/ Xigen SA	XG-102	Inner ear disease; Alzheimers disease; Myocardial infarction; Stroke; Hearing disorder; Inflammatory disease	Apoptosis inhibitor; Beta amyloid synthesis inhibitor; Jun N terminal kinase inhibitor	Neuroprotectant; Cardioprotectant; Anti-inflammatory
1029.	**Discovery	Neurologix Inc	XIAP gene therapy (AAV vector, Huntington's disease)	Huntingtons chorea	X-linked inhibitor of apoptosis protein stimulator; Apoptosis inhibitor; Adeno-associated virus based gene therapy	Neuroprotectant
1030.	**Phase 2	XenoPort Inc	XP-21279	Parkinsons disease	Dopamine receptor agonist	Antiparkinsonian
1031.	**Discovery	XenoPort Inc	XP-23829	Multiple sclerosis	Anti-inflammatory	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
1032.	**Discovery	Korea Research Institute of Chemical Technology/Yungjin Pharmaceutical Co Ltd	YJP-60107	Neurodegenerative disease	Caspase inhibitor	Neuroprotectant
1033.	**Phase 1	SK biopharmaceuticals	YKP-10461	CNS disease		Neuroprotectant
1034.	**Phase 2	SK biopharmaceuticals	YKP-3089	Epilepsy; Neuropathic pain; Anxiety disorder	Unspecified drug target	Anxiolytic; Analgesic; Anticonvulsant agent
1035.	Discovery	Zalicus Inc	Z-944; former T-type calcium channel blockers (pain/hypertension/epilepsy)	Pain; Hypertension; Epilepsy	Calcium channel inhibitor T-type; Class IV antiarrhythmic agent	Antihypertensive; Analgesic; Hypoglycemic agent; Anticonvulsant agent
1036.	**Discovery	Sangamo BioSciences Inc	ZFP TF gene therapy (Parkinson's disease)	Parkinsons disease	FGF-9 ligand; Adeno-associated virus based gene therapy; Glial cell neurotrophic factor ligand modulator; Zinc finger protein transcription factor agonist	Neuroprotectant; Antiparkinsonian
1037.	**Discovery	Sangamo BioSciences Inc/CHDI Foundation Inc	ZFP TFs (Huntington's disease)	Huntingtons chorea	Huntingtin inhibitor; Gene therapy; Zinc finger protein transcription factor agonist	Neuroprotectant
1038.	**Discovery	Sangamo BioSciences Inc	ZFP TFs (VEGF-A upregulators, spinal cord/brain injury/stroke/CNS trauma)	Spinal cord injury; Central nervous system injury; Stroke; Brain injury	VEGF gene stimulator; Adeno-associated virus based gene therapy; Zinc finger protein transcription factor agonist; Nuclease stimulator	Neuroprotectant
1039.	Phase 2	Sciencom Ltd	Zolpidem (brain injury)	Brain injury	Benzodiazepine receptor agonist	

Glossary

No Development Reported: No evidence of continuing development has been reported for the past 18 months.

Discontinued: Confirmation from the company source that in-house development has been terminated.

Discovery: Late research stage, preparation for human testing; adaptation of research chemical synthesis (mg) to larger scale (kg), selection of salt form, selection of galenical form, design of clinical proof of concept studies, definition of endpoints, selection of biomarkers for clinical testing, additional safety testing, IND (investigational new drug) filing, clinical ethical review boards.

Phase 1: Clinical testing; tolerance in humans, repeated dosing, some escalation; proof of therapeutic concept or mechanism using scientific evaluation methods in a limited number of volunteers or patients.

Phase 2: Dose-finding studies, statistics, double blind studies.

Phase 3: Proof of efficacy, comparison to standard therapy, statistics, double blind studies with up to thousands of patients; final phase of testing before registration and license to market.

Source

'Investigational Drugs database, Copyright 2011 Thomson Reuters, <http://partnering.thomson-pharma.com/>.'

This source was amended whenever the author found more accurate information on the websites of the companies.

Disclaimer

The author does not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of the information in the article. It is not the intention of the author to provide medical advice or to promote or endorse any medical practice, test or program, but rather to provide readers with information to better understand neurodegenerative diseases. The author is not responsible for errors in or omissions of information contained in the article or any actions resulting from the use of such information. Readers are encouraged to confirm the information in the article with other reliable sources.